The GENVABO study – genetic variants as biomarkers of jaw osteonecrosis associated with bisphosphonates: a large, multicentre genome-wide association study and detailed analyses of clinical phenotype by Fung, PL
1 
 
 
 
 
 
The GENVABO study  
– genetic variants as biomarkers of jaw 
osteonecrosis associated with 
bisphosphonates: a large, multicentre 
genome-wide association study and 
detailed analyses of clinical phenotype 
 
Pok Lam Fung 
BDS (Hons) HKU, MSc Oral Medicine (Distinction) UCL 
 
 
Thesis submitted for the Degree of Doctor of Philosophy,  
University College London  
 
 
Oral Medicine Unit 
UCL Eastman Dental Institute 
2015 
 
              
 
UCL EASTMAN DENTAL INSTITUTE 
ORAL MEDICINE UNIT 
 
2 
 
 
 
DECLARATION 
 
I, Pok Lam Fung, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this 
has been indicated in the thesis. 
 
 
Pok Lam Fung 
 
 
Oral Medicine Unit 
UCL Eastman Dental Institute 
2015 
  
3 
 
ABSTRACT 
Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of 
bisphosphonates. It can cause persistent pain and infection to the jawbones, and is 
currently considered incurable. ONJ occurs in a subset of individuals exposed to 
bisphosphonates (≤7%). Although a number of clinical risk factors, such as 
dentoalveolar surgery and dental infection, can increase the risk of ONJ development, 
there remains a number of patients who do not present with these clinical risk factors. 
Therefore, a genetic predisposition has been proposed. 
Genome-wide association studies (GWAS), widely performed in pharmacogenomics 
and successful in other drug side effects, have also been attempted in 
bisphosphonates-associated ONJ. However, possibly due to small cohort sizes (≤30 
cases), these studies failed to detect any significant genetic risk factors. 
The aim of this thesis is to present the results of a large, multicentre GWAS, coupled 
with detailed analyses of clinical phenotype.  
393 ONJ cases were recruited from 23 clinical centres worldwide. All cases were 
thoroughly phenotyped and adjudicated by specialist multidisciplinary teams. 
Random effects logistic regressions (Stata v12.1) were used for clinical risk factor 
analyses. All samples were genotyped using Illumina® Human1M Omni Express 
Beadchip (1,072,820 probes) and were compared with 2,554 genetically-matched 
population controls from publicly available sources. Genotype statistical analysis was 
performed in PLINK.  
Risk factors including advanced age, longer bisphosphonates duration, other cancers 
and use of steroids were found statistically significant (p<0.05). With extreme 
phenotyping, i.e. non-surgery triggered ONJ cases versus the population controls, for 
the first time, a genome-wide significant single nucleotide polymorphism was 
identified: rs12440268 at TJP1 gene (p=1.21E-8). Individuals positive for this marker 
were nearly three times more likely to develop ONJ than those negative for it 
(OR=2.66). TJP1 encodes protein at the tight junctions, which maintain epithelial 
integrity. Its polymorphism may contribute to ONJ pathogenesis through impaired 
mucosal healing.  
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Public engagement 
Phossy jaw research artwork exhibition. 
Worked with postgraduates at Courtauld Institute of Art, designed and printed image. 
 Online exhibition, Out of Our Heads, Art in medicine online, since Oct 2014. 
http://www.outofourheads.net/oooh/handler.php?id=724 
 Exhibited at UK Universities Week, Jun 2014; Natural History Museum, London, 
UK. 
 UCL Graduate School research images competition/exhibition 2013, Selected as 
1 of 28 exhibits out of 330 entrants; UCL South Cloister, London, UK. 
Phossy jaw research blog, http://phossyjaw.wordpress.com/ 
 Worked with historians and archivists, researched at British Library, Museum of 
London, RCS, Royal Society of Chemistry, UCL/UCLH archives  
 Designed blog, wrote 22 posts  
 >5,000 views by ~2,500 viewers from ~80 countries 
 
Figure 1. Public engagement 
  
From left to right: Phossy jaw research artwork exhibition at UK Universities Week, Natural 
History Museum. Exhibition at UCL South Cloister. Phossy jaw research blog.  
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1.1 Overview of jaw osteonecrosis 
1.1.1 Introduction 
Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of 
bisphosphonate medications affecting the jawbones. Bisphosphonates are 
commonly used in managing bone diseases including osteoporosis, multiple 
myeloma and bone metastases from solid cancers. 
Since its first report in 2003 (Marx, 2003), thousands of bisphosphonate-
associated ONJ cases have been reported worldwide (Filleul et al., 2010). The 
disease is often painful and has a wide range of clinical features, which can 
lead to eating difficulties, speech impairment, facial disfigurement and overall 
significantly reduced quality of life (Miksad et al., 2011). To seek compensation 
for their drug side-effect, patients have attempted to bring pharmaceutical 
companies to court and the largest successful verdict to date involved USD 
10.45 million (Barbara Davids and Helene Deutsch v. Novartis 
Pharmaceuticals Corporation, No. 06 431, U.S. District Court, Eastern District 
of New York, 11 July 2012).  
Currently, there remains no consensus regarding the terminology and 
definition of ONJ, and little is known regarding its pathogenesis and the most 
effective management. In severe cases, patients may require jaw resection 
and reconstruction under general anaesthesia, in which surgical complications 
including death have been reported in some cases (Bedogni et al., 2011; de 
Boer et al., 2012). It is therefore a serious adverse drug reaction (ADR), 
defined as “an undesirable experience concerned with a particular drug and 
that leads to any of the following: death or life-threatening event, 
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hospitalisation, disability or permanent damage, congenital abnormality or 
birth defect” (Daly, 2012). 
In the late 19th century, there was a similar disease known as the “phossy jaw”, 
or phosphorus necrosis. It was an occupational disease amongst match 
factory workers who were exposed to toxic white phosphorus vapour. Once 
inhaled, white phosphorus reacts with water to form pyrophosphate, then it 
becomes bisphosphonate through combining with carbonic acid and amino 
acid. Therefore, “phossy jaw” and ONJ are similar diseases, both related to 
bisphosphonates, and they also share very similar clinical features (Marx, 
2008).          
1.1.2 Clinical features 
1.1.2.1 Signs 
ONJ affects the mandible in approximately 60% of cases, whereas about 30% 
develops in the maxilla. Few individuals, about 10%, have ONJ affecting both 
jaws  (Woo et al., 2006).  
It typically presents with brown or grey necrotic bone, exposed through the 
oral mucosa, gingiva or facial skin (Filleul et al., 2010). Some individuals 
present with the non-exposed ONJ variant, i.e. there is no frank bone exposure, 
but with the presence of unexplained jaw bone pain, fistula tract, bone or 
gingival swelling, not caused by dental or other bone diseases  (Fedele et al., 
2010) (Figure 2). The non-exposed variant had been neglected for some years 
until its first report by Junquera and Gallego, 2008. In 2015, Fedele et al., 
reported by far the largest case series of 192 patients with the non-exposed 
variant, representing one-fourth of all ONJ cases in their study cohort.  
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Both exposed and non-exposed ONJ are associated with a wide range of 
clinical manifestations including intra- and extra-oral fistulae, tooth mobility, 
maxillary sinusitis and pathological fracture of mandible; infection is common 
and is associated with soft tissue manifestations including erythema, bleeding, 
swelling and suppuration (Filleul et al., 2010). 
1.1.2.2 Symptoms 
ONJ can be asymptomatic but pain is common – about 80% of patients report 
pain during the course of ONJ (Filleul et al., 2010; Otto et al., 2012). Patients 
may also complain of mobile teeth, gingival swelling, pus discharge, bad 
breath and paraesthesia (Vescovi et al., 2012).  
1.1.2.3 Disease onset 
There is a large variability in the time to onset of ONJ. It can vary according to 
the type of bisphosphonates. Studies reported that the average time from the 
start of bisphosphonates therapy to ONJ development is approximately 1.8 
years for zoledronate and 4.6 years for alendronate (Palaska et al., 2009). As 
for ONJ onset event, about 60% were surgically-triggered, mainly dental 
extractions, while the rest were non-surgically-triggered (Vescovi et al., 2011).  
Figure 2. Exposed and non-exposed ONJ 
   
Left: Exposed ONJ of the left mandible, extensive exposure of brown or grey necrotic bone. 
Right: Non-exposed ONJ of the right maxilla, a small sinus tract detected clinically by a 
periodontal probe. 
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1.1.3 Diagnosis, definition and disease staging  
Diagnosis of ONJ is usually made through history-taking and clinical 
examination (Ruggiero and Mehrotra, 2009; McLeod et al., 2012; Khan et al., 
2015). Biopsy is not mandatory but can be useful for excluding other jawbone 
disorders, such as metastasis (Khosla et al., 2007; Arrain and Masud, 2011; 
Bhatt et al., 2014). Although there is no specific imaging features for ONJ, it 
remains helpful in differential diagnosis and disease staging (Khan et al., 2015). 
Before 2014, ONJ case definition proposed in 2009 by the American 
Association of Oral and Maxillofacial Surgeons (AAOMS) had been most 
widely accepted (Ruggiero et al., 2009; McLeod et al., 2011, 2012). There 
were also the American Society for Bone and Mineral Research (ASBMR) 
definition, the British Dental Association and the Scottish Dental Clinical 
Effectiveness Programme definitions, all very similar to the one by AAOMS 
2009 (Arrain and Masud, 2011) (Table 1).  
However, the 2009 definition only included the exposed variant of ONJ. An 
increasing number of authors have been calling for its revision to include the 
non-exposed variant (Colella et al., 2009; Yarom et al., 2010; Bedogni et al., 
2012; Fedele et al., 2015). In 2014, the AAOMS definition was revised and 
“bone that can be probed through a fistula” was finally included (Ruggiero et 
al., 2014). 
A number of ONJ staging systems have been introduced and the AAOMS 
2009 staging system had also been widely used (McLeod et al., 2012) (Table 
2). However, it failed to classify, for instance, non-exposed ONJ cases with 
jaw fracture or extraoral fistula (Bagan et al., 2012). In the new AAOMS 2014 
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staging system, non-exposed cases were also properly incorporated 
(Ruggiero et al., 2014) (Table 3).  
Table 1. ONJ definitions 
Year Organisation Definition  Reference 
2007,  
2009 
AAOMS 
 Current or previous treatment with a 
bisphosphonate 
 Exposed, necrotic bone in the 
maxillofacial region that has persisted 
for more than 8 weeks 
 No history of radiation therapy to the 
jaws 
(AAOMS 
2007), 
(Ruggiero et 
al., 2009) 
2006 
Australian and New 
Zealand Bone and 
Mineral Society, 
Osteoporosis 
Australia, Medical 
Oncology Group of 
Australia, and the 
Australian Dental 
Association 
An area of exposed bone that persists for 
more than 6 weeks 
(Sambrook 
et al., 2006) 
2007 ASBMR 
 Confirmed case: same as AAOMS 
2007/09 
 Suspected case: same as AAOMS 
2007/09 except exposed bone has been 
present for less than 8 weeks 
(Khosla et 
al., 2007) 
2012 
Expert Panel of the 
Italian Society for 
Maxillofacial 
Surgery (SICMF) 
and the Italian 
Society of Oral 
Pathology and 
Medicine (SIPMO) 
on 
Bisphosphonate-
Related 
Osteonecrosis of 
the Jaws 
An adverse drug reaction described as the 
progressive destruction and death of bone 
that affects the mandible or maxilla of 
patients exposed to the treatment with 
nitrogen-containing bisphosphonates, in 
the absence of a previous radiation 
treatment 
(Bedogni et 
al., 2012) 
2014 AAOMS 
 Current or previous treatment with 
antiresorptive or antiangiogenic agents 
 Exposed bone or bone that can be 
probed through an intraoral or extraoral 
fistula(e) in the maxillofacial region that 
has persisted for more than 8 weeks 
 No history of radiation therapy to the 
jaws or obvious metastatic disease to 
the jaws 
(Ruggiero et 
al., 2014) 
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Table 2. ONJ staging systems 
Year Organisation 
Staging system 
Reference 
Diagnosis 
No. of 
stages 
Inclusion 
of non-
exposed 
ONJ 
2006 AAOMS Clinical examination 3 No (AAOMS 2007) 
2007 / 
Clinical examination, 
radiographs, 
computed 
tomography (CT), 
magnetic resonance 
imaging (MRI), 
biopsy 
6 Yes 
(McMahon et 
al., 2007) 
2009 AAOMS 
Clinical examination; 
radiographs for non-
exposed variant 
4 Yes 
(Ruggiero et al., 
2009) 
2012 
SICMF and 
SIPMO on ONJ 
Clinical examination, 
CT 
3 Yes 
(Bedogni et al., 
2012) 
2014 AAOMS 
Clinical and 
radiographic 
examinations 
4 Yes 
(Ruggiero et al., 
2014) 
 
 
Table 3. AAOMS staging (Ruggiero et al., 2014) 
Stage Description 
At Risk 
Category 
No apparent necrotic bone in patients who have been treated with either 
oral or IV bisphosphonates 
Stage 0 
No clinical evidence of necrotic bone, but non-specific clinical findings, 
radiographic changes and symptoms 
Stage 1 
Exposed and necrotic bone, or fistulae that probes to bone, in patients 
who are asymptomatic and have no evidence of infection 
Stage 2 
Exposed and necrotic bone, or fistulae that probes to bone, associated 
with infection as evidenced by pain and erythema in the region of the 
exposed bone with or without purulent drainage 
Stage 3 
Exposed and necrotic bone or a fistula that probes to bone in patients 
with pain, infection, and one or more of the following: exposed and 
necrotic bone extending beyond the region of alveolar bone,(i.e., inferior 
border and ramus in the mandible, maxillary sinus and zygoma in the 
maxilla) resulting in pathologic fracture, extra-oral fistula, oral antral/oral 
nasal communication, or osteolysis extending to the inferior border of 
the mandible of sinus floor 
Underlined: updates in 2014 as compared to 2009 staging  
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1.1.4 Risk reduction and management 
The objectives of most risk reduction strategies are to improve dental hygiene 
and minimise surgical trauma from tooth extraction and implant surgery (Khan 
et al., 2015). However, these strategies are mostly based on expert opinion 
and are not supported by robust evidence (Fedele et al., 2009).   
Regarding treatment, ONJ is considered incurable as bone necrosis cannot 
be reversed (Landis et al., 2006). In addition, bisphosphonates have a very 
long half-life and remain in the jawbone for many years (Kimmel, 2007). Most 
management strategies aim at pain and infection control, consisting mainly of 
symptomatic treatment and minimally invasive surgery (McLeod et al., 2011). 
AAOMS and the Canadian Association of Oral and Maxillofacial Surgeons 
recommended treatment according to ONJ staging, ranging from optimal oral 
hygiene, topical antibiotic rinse and systemic antibiotics, to debridement and 
major resection and reconstruction surgery (Khan et al., 2015); similar 
recommendation has also been suggested by the ASBMR (Khosla et al., 2007).  
1.1.5 Epidemiology 
Data on ONJ epidemiology remain unclear, mainly due to small cohorts and 
heterogeneous study designs (Ruggiero, 2011; Campisi et al., 2014). In 2012, 
Kühl et al. reviewed nearly 700 publications and reported a wide incidence 
range of 0.0 to 27.5%. The average incidence amongst patients who were on 
intravenous bisphosphonates was 7% and that amongst oral bisphosphonates 
patients was 0.01%. 
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1.2 Causes of ONJ in association with bisphosphonates 
1.2.1 Introduction 
There is little doubt that individuals exposed to bisphosphonates are at risk of 
developing ONJ (Abrahamsen, 2010; Barasch et al., 2011; Pautke et al., 2012). 
Currently, ONJ is recognised as one of the major ADR of bisphosphonates by 
drug agencies around the world, including the European Medicines Agency 
(EMA), Medicines and Healthcare products Regulatory Agency (MHRA), 
British National Formulary (BNF) and the US Food and Drug Administration 
(FDA).  
1.2.2 Bisphosphonates 
1.2.2.1 Biochemistry 
Bisphosphonates (BPs) are pyrophosphate analogues and all have a strong 
P-C-P bond in its core, making BPs resistant to enzymatic reaction; the 
phosphate groups and side chains enable BPs to bind with hydroxyapatite 
crystals, which explains its high affinity for bone (Russell, 2011). BPs refer to 
a group of drugs, which can be classified by chemical structure or route of 
administration (Table 4). Nitrogen-containing and non-nitrogen-containing 
BPs differ in their chemical structure and mechanism of action. In general, 
nitrogen-containing BPs are of higher potency (Fleisch, 1998).     
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Table 4. Classification of BPs 
Chemical structure Route of administration 
Nitrogen-
containing 
Non-nitrogen- 
containing 
Intravenous Oral 
Alendronate 
Risedronate 
Ibandronate 
Pamidronate 
Zoledronate 
Clodronate 
Etidronate 
Tiludronate 
Ibandronate 
(Bondronat, 
Bonviva) 
Disodium 
Pamidronate  
(Aredia) 
Zoledronate 
(Aclasta, Zometa) 
Alendronate  
(Fosamax, 
Fosavance) 
Sodium 
Clodronate 
(Bonefos, Loron) 
Disodium 
Etidronate 
(Didronel, Didronel 
PMO) 
Ibandronate 
(Bondronat, 
Bonviva) 
Risedronate 
Sodium      
(Actonel, Actonel 
Once a Week) 
Disodium 
Tiludronate (Skelid) 
 
1.2.2.2 Pharmacology and mechanism of action 
Bioavailability of oral BPs is poor, about 0.7%. Subsequent to absorption at 
the gastrointestinal tract, BPs are then taken up primarily by bone tissue and 
retained for a long time, and ultimately excreted unchanged in urine (Rodan et 
al., 2004; Cremers and Papapoulos, 2011). After binding to bone, BPs are 
internalised into osteoclast by endocytosis. Nitrogen-containing BPs inhibit 
farnesyl pyrophosphate synthase (FPPS), a key enzyme of the mevalonate 
pathway; this (i) prevents prenylation of GTPase proteins which are essential 
for osteoclast function and survival, and (ii) causes accumulation of 
isopentenyl diphosphate which can induce osteoclast apoptosis. Non-
nitrogen-containing BPs are incorporated into ATP analogue, which can also 
induce osteoclast apoptosis (Kavanagh et al., 2006; Rondeau et al., 2006; 
Thompson et al., 2006; Rogers et al., 2011) (Figure 3). 
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Figure 3. Mechanism of action of BPs; Courtesy: Russell 2011. 
 
In summary, BPs act mainly by inhibiting osteoclast and bone resorption; they 
may also have effects on other cells such as osteoblast, osteoclast precursor, 
tumour cell and macrophage (Russell et al. 2007).  
1.2.2.3 Indications 
Given their antiresorptive property, BPs are widely used in managing bone 
malignancy, osteoporosis and other bone diseases.  
BPs are helpful in managing multiple myeloma and metastatic bone diseases 
(Lipton et al., 2003; Rosen et al., 2004; Saad et al., 2004; Coleman and 
McCloskey, 2011). The 2012 Cochrane review concluded that BPs prevent 
pathological vertebral fractures, skeletal-related events and pain, and improve 
overall survival of multiple myeloma (Mhaskar et al., 2012). According to two 
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other Cochrane reviews, BPs also reduce skeletal-related events and pain of 
metastatic breast and prostate cancers (Yuen et al., 2006; Wong et al., 2012). 
In the UK, the National Institute for Health and Clinical Excellence (NICE) 
recommends the use of alendronate, etidronate and risedronate as first-line 
drugs for preventing fragility fracture in postmenopausal osteoporosis women.  
In the US, as many as one in seven postmenopausal women have been 
treated with BPs and over 150 million prescriptions were dispensed between 
2005 and 2009 (Black et al., 2012; Whitaker et al., 2012). 
Evidence also suggests that BPs can control Paget’s disease of bone, the 
second most common metabolic bone disease after osteoporosis (Reid and 
Hosking, 2011). Another Cochrane report concluded that BPs increase bone 
mineral density in osteogenesis imperfecta patients (Dwan et al., 2014). BPs 
can also manage other bone disorders including periprosthetic bone loss, 
fibrous dysplasia and calcinosis in juvenile dermatomyositis (Silverman, 2011).     
1.2.2.4 Adverse effects 
In addition to ONJ, other adverse effects of BPs include oesophageal 
ulceration, renal toxicity, atrial fibrillation and atypical femoral fracture, 
according to MHRA’s safety information. Acute-phase reaction is common and 
occurs in about 40% of patients on nitrogen-containing BPs (Olson and Van 
Poznak, 2007). Other reported adverse effects include oesophageal cancer, 
ocular inflammation and musculoskeletal pain (Pazianas and Abrahamsen, 
2011). 
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1.2.3 ONJ pathogenesis 
To date, the exact pathogenesis of BPs-associated ONJ remains largely 
unknown. However, several hypotheses have been proposed and ONJ is 
considered a multifactorial disease (Landesberg et al., 2011; Kumar and Sinha, 
2013).  
1.2.3.1 Infection 
Infection is common in ONJ (Katsarelis et al., 2015). Histopathologically, 
inflammatory infiltrate and bacterial colonisation were found in about 80% of 
the necrotic bone samples, with Actinomyces, Streptococcus being the most 
frequently reported (Hinson et al., 2014). Therefore, topical antibiotic rinse and 
systemic antibiotics are often prescribed in managing ONJ (Khan et al., 2015). 
However, it remains unclear whether infection initiates ONJ or it occurs as a 
secondary event after ONJ develops. 
1.2.3.2 Impaired wound healing 
Clinical studies reported that BPs can delay healing and its discontinuation 
can result in faster resolution of ONJ symptoms (Hasegawa et al., 2013; 
Hinson et al., 2015). In vitro studies also showed that BPs are toxic to soft 
tissue and inhibit oral mucosal cell proliferation and wound healing 
(Landesberg et al., 2008; Kumar and Sinha, 2013). However, this hypothesis 
is mainly relevant to cases presenting with an open wound, mostly caused by 
an invasive procedure, such as tooth extraction and implant surgery. As for 
cases with no history of dentoalveolar surgery, also known as spontaneous 
ONJ, the same hypothesis fails to explain their ONJ development. 
Spontaneous ONJ cases, first reported 10 years ago (Marx et al., 2005), are 
not uncommon and have been suggested to account for nearly 40% of all 
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cases in a large study of more than 500 ONJ cases (Vescovi et al., 2011). 
1.2.3.3 Impaired angiogenesis 
It is suggested that BPs can reduce angiogenesis through inhibition of vascular 
endothelial growth factor (VEGF) (Wood et al., 2002; Kobayashi et al., 2010; 
Vincenzi et al., 2012). A reduction in the number of blood vessels (Aguirre et 
al., 2010, 2012), as well as reduction in their quality including thin-walled, 
dilated, less connected and less ordered vessels, in association with BPs, 
have been reported (Favia et al., 2009; Guevarra et al., 2015). However, ONJ 
cases with intact and normal vascularity in both the alveolar bone (Hellstein 
and Marek, 2005) and the overlaying soft tissue have also been reported 
(Scheller et al., 2011; Wehrhan et al., 2011). Therefore, whether or not 
impaired angiogenesis contributes to ONJ development remains unclear. 
1.2.3.4 Suppressed bone turnover 
Most cases of osteonecrosis develop in the maxilla and/or the mandible. 
However, a handful of osteonecrosis cases in the auditory canal have also 
been reported (Salzman et al., 2013; Thorsteinsson et al., 2014). Allen, 2011 
suggested that the jawbones are more likely to be affected because, compared 
to other skeleton sites, they have a relatively high remodelling rate, hence 
more susceptible to BPs’ osteoclast inhibition and bone turnover suppression. 
1.2.4 Clinical risk factors 
1.2.4.1 BPs-related factors 
Studies in beagle dogs confirmed the association of the degree of bone 
turnover suppression with BPs potency, binding affinity and cumulative dose 
(Allen and Burr, 2008; Allen et al., 2010). Clinical findings do agree with these 
experimental results as ONJ incidence and the number of cases are both 
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higher amongst patients exposed to high potency BPs, such as zoledronate, 
than in patients treated with alendronate, which is about 10-100 times less 
potent (Filleul et al., 2010; Kühl et al., 2012). Moreover, BPs duration and 
cumulative dose seem to be consistent and important risk factors for ONJ 
development (Fehm et al., 2009; Then et al., 2012; Campisi et al., 2014). 
1.2.4.2 Systemic factors 
1.2.4.2.1 Diabetes 
The relationship between diabetes and ONJ has been inconclusive. There 
were studies reporting higher ONJ incidence amongst diabetic patients 
(Thumbigere-Math et al., 2012; Watters et al., 2012). In contrast, similar ONJ 
occurrence, regardless of the presence or absence of diabetes, has also been 
observed (Iwamoto et al., 2011). On the other hand, studies on the effect of 
diabetes phenotype upon ONJ development, such as diabetes severity or 
disease duration remain uncommon. Although it has been suggested that 
diabetes is associated with microvascular ischemia, reduced bone remodelling, 
increased inflammation and risk of infection, the exact pathogenesis of how 
diabetes induces ONJ remains unclear (Peer and Khamaisi, 2015).  
1.2.4.2.2 Smoking 
Whether or not smoking increases ONJ risk is unclear. A positive association 
of ONJ with smoking has been supported by the following studies: Wessel et 
al., 2008; Katz et al., 2011; Thumbigere-Math et al., 2012; Watters et al., 2012, 
but not supported by Kyrgidis et al., 2008, Vahtsevanos et al., 2009, a case-
control study of over 1,600 patients, and Tsao et al., 2013. 
1.2.4.2.3 Concomitant medications 
It has been suggested that the concomitant use of antiangiogenic agents 
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constitutes an ONJ risk factor (Troeltzsch et al., 2012). There were also ONJ  
cases associated with bevacizumab and sunitinib per se, in the absence of 
BPs therapy (Estilo et al., 2008; Greuter et al., 2008; Serra et al., 2009; Koch 
et al., 2011; Bettini et al., 2012; Brunamonti Binello et al., 2012; Dişel et al., 
2012; Fleissig et al., 2012; Hopp et al., 2012; Nicolatou-Galitis et al., 2012; 
Santos-Silva et al., 2013; Sivolella et al., 2013). However, whether or not these 
agents increase ONJ risk amongst BPs users remains controversial (Aragon-
Ching et al., 2009; Christodoulou et al., 2009; Lazarovici et al., 2009; Guarneri 
et al., 2010; Francini et al., 2011). 
Thalidomide, another commonly prescribed medication with antiangiogenic 
effects, has never been reported to cause ONJ in the absence of BPs therapy; 
evidence that concomitant thalidomide increases ONJ risk amongst BPs users 
is also weak (Zervas et al., 2006; Boonyapakorn et al., 2008).  
It also remains unclear whether corticosteroids, another commonly prescribed 
concomitant medication in the BPs population, increase the risk of ONJ 
development (Lazarovici et al., 2009; Kos et al., 2010; Otto et al., 2012; Taylor 
et al., 2013). 
Of note, bevacizumab and sunitinib are the only concomitant medications that 
are suggested to increase the risk on ONJ by the MHRA and BNF. 
1.2.4.3 Local factors 
Dentoalveolar surgery has always been considered a strong risk factor for ONJ, 
which seems to be supported by sound and consistent data (Campisi et al., 
2014). However, a recent review concluded that the prevalence of ONJ 
amongst cancer patients following dental extraction was only 3.25% (Utreja et 
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al., 2013).  
Periodontal disease has also been suggested to be an ONJ risk factor 
(Campisi et al., 2014). However, diagnosis of periodontal disease can be 
complicated in non-dental settings, as it requires probing depth, bleeding and 
plaque indices assessment. This has therefore only been supported by a 
limited number of small-scale studies (Thumbigere-Math et al., 2013).  
1.2.5 Genetic variants 
The occurrence of ONJ in a subset of individuals exposed to BPs suggests 
that its development may be related to genetic predispositions. In the past 
seven years, there have been a number of small pharmacogenetic studies on 
ONJ (Sarasquete et al., 2008; English et al., 2010; Katz et al., 2011; Arduino 
et al., 2011; Di Martino et al., 2011; Marini et al., 2011; Such et al., 2011; 
Nicoletti et al., 2012; La Ferla et al., 2012; Balla et al., 2012; Stockmann et al., 
2013). By definition, pharmacogenetics is the study of how genetic differences 
influence the variability in patients' responses to drugs, including toxicity 
(Roses, 2000). It comprises mainly genome-wide association studies (GWAS) 
and candidate gene studies (Daly, 2010).  
1.2.5.1 GWAS on ONJ 
GWAS is a comprehensive research approach that is useful for investigating 
both complex disease and drug response including ADR. Typically, a GWAS 
screens millions of single nucleotide polymorphisms (SNPs) across the entire 
genome, in which a SNP refers to a single-base difference in DNA sequence 
in at least 1% of the general population (Daly, 2012). Most GWAS is of case-
control design and a SNP is identified as a risk factor when its minor allele 
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frequency amongst the cases is significantly higher than in the controls.  
Because GWAS tests millions of SNPs, it is possible that some variants have 
high frequency and small p-values simply by chance. To avoid any false 
positives, a stringent statistical correction for multiple comparisons is 
commonly required, which is known as Bonferroni correction. Instead of the 
usual p<0.05, the significance level for GWAS is calculated as 0.05 divided by 
roughly 1 million SNPs, i.e. p<5E-08 (Daly, 2012). 
To date, two GWAS have been conducted on BPs-associated ONJ and 
relevant results are summarised in Table 5. The first GWAS, also the first 
pharmacogenetic study on ONJ, was published in 2008 by a Spanish team 
(Sarasquete et al., 2008). They studied 87 pamidronate-treated multiple 
myeloma patients, who were of Spanish descent, of whom 22 had developed 
ONJ. These cases were compared with 65 drug-exposed controls who had not 
developed ONJ after a median follow-up of 64 months. A total of 500,568 
SNPs were screened and rs1934951 in CYP2C8 was found to be most 
significant, although it did not reach genome-wide threshold of significance 
(OR=12.75, 95% CI 3.7 to 43.5, p=1.07E-06). This study suggested that 
individuals with this SNP had nearly 13 times greater odds of developing ONJ 
than those without it. Though not directly affecting BPs’ metabolism, CYP2C8 
is known to be involved in osteoclast inhibition, osteoblast differentiation, and 
regulation of vascular tone, which may contribute to ONJ development 
(Sarasquete et al., 2009). 
The second GWAS was published in 2012 and compared 30 zoledronate-
treated breast cancer patients who developed ONJ with 17 drug-exposed 
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controls and 1,726 population controls (Nicoletti et al., 2012). The participants 
were of European descent. Compared to the previous GWAS, 731,442 SNPs 
were screened. Standard imputation was performed to enrich the genotype 
dataset, and an imputed SNP, rs17024608 in RBMS3, was found to be 
associated with ONJ, with borderline genome-wide significance (OR=5.8, 95% 
CI 3.0 to 11.0, p=7.47E-08). The rs17024608 carriers have approximately six 
times higher odds of developing ONJ than the non-carriers. RBMS3 is a gene 
involved in bone turnover and has been found to associate with decreased 
bone mass and osteoporotic fracture (Nicoletti et al., 2012). Of note, CYP2C8 
was not found a significant risk factor for ONJ in this cohort of breast cancer 
patients. 
1.2.5.2 Candidate gene studies on ONJ 
Similar to GWAS, candidate gene studies often have a case-control design 
(Daly and Day, 2001). In general they focus on potentially biologically relevant 
genes. For ADR, most of the established and high risk genetic risk factors are 
relevant to drug metabolism or transporters genes (Daly, 2013). In contrast to 
GWAS, candidate gene studies screen much fewer variants and do not 
represent a hypothesis-free approach (Tabor et al., 2002). They are also prone 
to methodological weaknesses as they typically have small cohort size, no 
Bonferroni correction for the p-value, and often do not correct for the ethnicity 
of the cohort. Therefore, it has been suggested that candidate gene design is 
more suitable for replication studies (Kraft et al., 2009).  
A total of nine candidate gene studies on BPs-associated ONJ were published 
between 2010 and 2013, including both replication and discovery gene studies, 
summarised in Table 6 and Table 7 . 
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1.2.5.2.1 Replication candidate gene studies 
Four candidate gene studies attempted to replicate the results of the Spanish 
GWAS amongst pamidronate-treated multiple myeloma patients (Sarasquete 
et al., 2008), through investigating the possible association between 
rs1934951 in CYP2C8 and ONJ in their respective independent cohorts (Table 
6). All studies failed to confirm that this variant is significant (p>0.05). 
Paradoxically, English et al., 2010 and Katz et al., 2011 reported a protective 
OR for this variant. These contradicting results are likely to be related to the 
design of the replication studies, which failed to investigate populations 
ethnically and phenotypically similar to that of the original discovery study.  
In contrast to the first GWAS, none of the four studies included individuals of 
Spanish descent, although their cohorts consisted mainly of White or 
Caucasian participants; African Americans were also inappropriately included 
(Arduino et al., 2011; Katz et al., 2011). Also, all four cohorts were 
predominantly exposed to zoledronate instead of pamidronate. Furthermore, 
only two replication studies focused on multiple myeloma patients (Katz et al., 
2011; Such et al., 2011) whereas one recruited individuals with metastatic 
prostate cancer (English et al., 2010), and another included individuals with 
osteoporosis and a wide range of malignant disorders (Balla et al., 2012).  
A recent meta-analysis attempted data pooling from the four candidate gene 
replication studies and the discovery Spanish GWAS (Zhong et al., 2013). 
They reported that rs1934951 in CYP2C8 is not associated with ONJ across 
the entire merged population (OR=2.05, 95% CI 0.67 to 6.29, p=0.2). 
However, it might still be associated with ONJ development in multiple 
myeloma patients (OR=5.77, 95% CI 1.21 to 27.63, p=0.03).  
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Of note, there remains no published replication of rs17024608 in RBMS3 
identified in Nicoletti et al., 2012. 
1.2.5.2.2 Discovery candidate gene studies 
Six discovery candidate gene studies investigated variants in genes other than 
CYP2C8 and are summarised in Table 7. These studies analysed the separate 
and combined effects of variants located in several genes, which had been 
chosen as they may relate to BPs metabolism and/or ONJ pathogenesis, e.g. 
bone turnover. Most of them screened only a small number of variants, and 
had relatively small cohorts, and are therefore susceptible to methodological 
limitations such as inadequate power. Of note, none of the SNPs tested 
reached the genome-wide significance level of p<5E-08.  
The largest discovery candidate gene study in the literature compared 94 ONJ 
cases with 110 ethnicity matched BPs-exposed controls (Stockmann et al., 
2013). The cohort included individuals with malignant disorders, including 
multiple myeloma, breast and prostate cancer, who were exposed mainly to 
zoledronate or pamidronate. The study hypothesis was that ONJ susceptibility 
might be linked to the major histocompatibility complex (MHC) class II system, 
which encodes HLA class II alleles. HLA alleles are major genetic risk factors 
for ADRs and are also associated with the adaptive immune system and 
infection, which in the case of ONJ may be related to the antigen-presenting 
function of osteoclasts and increased infection and/or inflammation 
(Landesberg et al., 2011). According to the significance threshold set by the 
study, two independent HLA haplotypes, DRB1*01/DRB1*15 and 
DQB1*05:01/DQB1*06:02, were found significant (OR>2, uncorrected p≤
0.05). Moreover, the association appeared to be stronger when more than one 
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haplotype were considered together (OR=3, corrected p=0.0003) (Stockmann 
et al., 2013).  
An Italian study by Arduino et al., recruited 30 women with breast cancer or 
multiple myeloma who developed zoledronate-induced ONJ cases, 30 drug, 
gender, disease and ethnicity-matched controls without ONJ, as well as 125 
healthy controls. Candidate gene of this study was VEGF, which had been 
previously reported to be associated with avascular osteonecrosis at the 
femoral head (Kim et al., 2008; Lee et al., 2012). No statistically significant 
association was found for any of the three studied SNPs, -634 G>C, +936 
C>T, and -2578 C>A (p>0.05). However, the haplotype determined by 
rs2010963 and rs699947 was found to be significant (corrected p=0.02) 
(Arduino et al., 2011).  
Another Italian study by La Ferla et al., studied 30 zoledronate-induced ONJ 
cases and 53 zoledronate-exposed controls with multiple myeloma, breast and 
prostate cancer. Participants were tested for polymorphisms in aromatase and 
oestrogen receptor, which were selected because of their reported effects 
upon bone mineral density and remodelling. Results showed that rs10046 
(g.132810C>T), a polymorphism in gene CYP19A1, was more prevalent 
amongst ONJ cases (OR=2.83, p=0.04) (La Ferla et al., 2012).  
Marini et al., recruited 64 Italian patients with multiple myeloma, breast and 
prostate cancer who received zoledronate, 34 of whom developed ONJ. They 
studied polymorphism rs2297480 in gene FDPS (farnesyl pyrophosphate 
synthase, a key enzyme of the mevalonate pathway of osteoclasts), which was 
found to be significantly associated with ONJ, although not genome-wide 
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significant (p=0.03). This study represents the first attempt to investigate a 
candidate gene directly involved in BPs mechanism of action (Marini et al., 
2011).  
Katz et al., recruited multiple myeloma patients only, including 12 ONJ cases 
and 66 controls, who were managed with zoledronate and/or pamidronate. In 
addition to gene CYP2C8, six other candidate genes were studied based on 
their potential roles in osteoclast genesis and differentiation, bone resorption 
and bone mineral density. The results showed that all candidate genes per se 
had no effects on ONJ, although a combined genotype of COL1A1, RANK, 
MMP2, OPG and OPN was significantly associated with ONJ development 
(OR=1.2, 95% CI 1.8 to 69.9, p=0.0097) (Katz et al., 2011). 
Di Martino et al., studied 1,936 SNPs relevant to 225 genes associated with 
drug metabolism, disposition and transport in nine multiple myeloma 
zoledronate-treated patients with ONJ and 10 matched controls. The authors 
claimed that using a platform that interrogates only highly selective SNPs has 
the advantage of avoiding any extremely high number of comparisons, and 
therefore the need for statistical corrections and large patient cohorts. As a 
consequence, the study adopted an uncorrected significance level of p<0.05 
and reported that variants in four genes, PPARG, ABP1, CHST11 and CROT, 
were statistically significant. However, since nearly 2,000 SNPs were 
screened, Bonferroni correction was required and the significance threshold 
should be approximately 2.5E-5 instead, i.e. 0.05 divided by 1,936 (Rice et al., 
2008). This would mean that, in fact, no SNPs reached the corrected 
significance threshold. Nonetheless, on the basis of uncorrected results, 
patients with rs1152003, top SNP in PPARG, had over 30 times higher odds 
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of developing ONJ (OR=31.5, 95% CI 2.35 to 422.32, p=0.0055). Of note, 
PPARG has also been associated with bone remodelling, bone mass density, 
as well as angiogenesis (Di Martino et al., 2011). 
1.3 Summary 
Little robust information is available regarding the aetiopathogenesis of BPs-
associated ONJ and it is unclear why it develops in a subset of patients. A 
number of clinical risk factors have been suggested; however, relevant 
literature lacks robustness and consistency, and in most instances ONJ 
remains an unpredictable ADR. 
There is likely a genetic predisposition for ONJ; however, previous 
pharmacogenetic studies on ONJ were of small cohort sizes and no genome-
wide significant variants have been identified.  
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Table 5. Summary of GWAS on ONJ 
Year Population 
Underlying 
disease 
BPs type 
Case 
n 
Control 
n 
Genotyping SNP Gene Chr p-value OR [95% CI] Ref 
2008 Spanish 
Multiple 
myeloma 
Majority on 
Pamidronate 
 
Zoledronate 
22 
65 BPs 
controls 
Affymetrix 
GeneChip 
Mapping 
500K set 
 
500,568 
SNPs 
screened 
rs1934951 CYP2C8 10 1.07E-06 12.75 [3.7-43.5] 
(Sarasquete 
et al., 2008) 
rs1934980 CYP2C8 10 4.23E-06 13.88 [4.0-46.7] 
rs1341162 CYP2C8 10 6.22E-06 13.27 [3.5-49.9] 
rs17110453 CYP2C8 10 2.15E-05 10.2 [3.2-32.1] 
2012 
North-
western, 
southern, 
eastern 
European 
descent 
Osteoporosis 
 
Breast 
cancer 
Majority on 
Zoledronate 
30 
17 BPs 
controls 
 
1,726 
population 
controls 
Illumina 
Human 
Omni 
Express 
12v1.0 chip 
 
731, 442 
SNPs 
analysed 
rs17024608 RBMS3 3 7.47E-08 5.8 [3.0-11.0] 
(Nicoletti et 
al., 2012) 
rs5768434 FAM19A5 22 1.17E-07 12.6 [4.9-32.2] 
rs11064477 PHB2 12 5.16E-07 21.7 [6.5-71.9] 
12–7016684 C1S 12 5.85E-07 21.1 [6.4-69.8] 
8–58133986 IMPAD1 8 3.10E-06 7.3 [3.1-16.9] 
rs1886629 KCNT2 1 5.53E-06 3.6 [2.1-6.5] 
rs7588295 CSRNP3 2 6.24E-06 8.6 [3.3-22.17] 
rs4431170 MARCH1 4 7.28E-06 5.1 [2.5-10.6] 
rs7740004 C6orf170 6 7.87E-06 5.9 [2.7-13.0] 
rs11189381 SFRP5 10 8.17E-06 6.8 [2.9-15.8] 
rs12903202 ALDH1A2 15 9.15E-06 4.0 [2.1-7.4] 
rs17751934 MEX3C 18 9.16E-06 5.0 [2.4-10.1] 
11–
23990403 
LUZP2 11 9.94E-06 12.7 [4.0-36.8] 
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Table 6. Summary of candidate gene studies on CYP2C8 on ONJ 
Year Population 
Underlying 
disease 
BPs type 
Case 
n 
Control 
n 
Genotyping SNP Gene Chr p-value OR [95% CI] Ref 
2010 
80% 
Caucasian 
10% 
African 
American 
Prostate 
cancer 
Zoledronate 
 
Combination 
of BPs 
17 
83 BPs 
controls 
Big Dye 
Terminator 
Cycle 
Sequencing 
Ready Reaction 
kit V3.1 
rs1934951 CYP2C8 10 >0.47 0.63 [0.17-2.42] 
(English 
et al., 
2010) 
2011 
68% White 
24% 
African 
American 
Multiple 
myeloma 
Zoledronate 
and/or 
Pamidronate 
12 
66 BPs 
controls 
Taqman® 
Pyrosequencing 
rs1934951 CYP2C8 10 0.63 0.68 [0.14-3.22] 
(Katz et 
al., 2011) 
rs1934980 CYP2C8 10 0.66 0.70 [0.15-3.36] 
2011 Caucasian 
Multiple 
myeloma 
Zoledronate 42 
37 BPs 
controls 
 
45 
population 
controls 
Taqman® rs1934951 CYP2C8 10 0.13 / 
(Such et 
al., 2011) 
2012 Hungarian 
Breast 
cancer 
 
Osteoporosis 
 
Multiple 
myeloma 
 
Prostate 
cancer 
Zoledronate 
 
Ibandronate 
 
Pamidronate 
46 
224 
population 
controls 
Taqman® rs1934951 CYP2C8 10 >0.05 / 
(Balla et 
al., 2012) 
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Table 7. Summary of discovery candidate gene studies on ONJ 
Year Population 
Underlying 
disease 
BPs type 
Case 
n 
Control 
n 
Genotyping SNP Gene Chr p-value OR [95% CI] Ref 
2011 
68% White 
24% 
African 
American 
Multiple 
myeloma 
Zoledronate 
and/or 
Pamidronate 
12 
66 BPs 
controls 
Taqman® 
 
Pyrosequencing 
rs1800012 COL1A1 17 0.55 1.69 [0.30-9.70] 
(Katz et 
al., 2011) 
rs12458117 RANK 18 0.38 2.14 [0.39-11.71] 
rs243865 MMP2 16 0.11 3.49 [0.75-16.18] 
rs2073618 OPG 8 0.38 2.16 [0.38-12.23] 
rs3102735 OPG 8 0.75 0.79 [0.19-3.34] 
rs11730582 OPN 4 0.21 2.97 [0.53-16.55] 
rs28357094 OPN 4 0.41 0.51 [0.10-2.59] 
rs1800629 TNF 6 0.67 0.68 [0.12-3.95] 
2011 Italian 
Breast 
cancer 
 
Multiple 
myeloma 
Zoledronate 30 
30 BPs 
controls 
 
125 
population 
controls 
Taqman® 
rs3025039 
VEGF 6 
0.40 0.57 [0.21-1.54] 
(Arduino 
et al., 
2011) 
rs699947 0.78 0.99 [0.31-3.18] 
rs2010963 0.86 0.96 [0.37-2.53] 
2011 N/A 
Multiple 
myeloma 
Zoledronate 9 
10 BPs 
controls 
Affymetrix 
DMETTM plus 
platform 
 
1,936 SNPs 
analysed 
rs1152003 PPARG 3 0.0055 
/ 
(Di 
Martino et 
al., 2011) 
rs10893 
ABP1 7 
0.023 
0.023 
0.023 
rs4725373 
rs1049793 
rs2463437 
CHST11 12 
0.0198 
0.0198 
0.0198 
rs903247 
rs2468110 
rs2097937 CROT 7 0.0198 
2011 Caucasian 
Breast 
cancer 
 
Multiple 
myeloma 
 
Prostate 
cancer 
Zoledronate 34 
34 BPs 
controls 
GoTaq® rs2297480 FDPS 1 0.03 / 
(Marini et 
al., 2011) 
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Table 7 continued. 
Year Population 
Underlying 
disease 
BPs type 
Case 
n 
Control 
n 
Genotyping SNP Gene Chr p-value OR [95% CI] Ref 
2012 Caucasian 
Breast 
cancer 
 
Multiple 
myeloma 
 
Prostate 
cancer 
Zoledronate 30 
53 BPs 
controls 
Taqman® 
rs2234693 ESR1 6 >0.05 
/ 
(La Ferla et 
al., 2012) 
rs9340799 ESR1 6 >0.05 
/ 
rs10046 CYP19A1 15 0.0439 
2.83 
2013 White 
Breast 
cancer 
 
Multiple 
myeloma 
 
Prostate 
cancer 
Zoledronate 
 
Pamidronate 
 
Combination 
of BP 
94 
110 BPs 
controls 
LABType single 
strand 
oligonucleotide 
typing kit 
DRB1*01 
MHC 6 
0.049 2.0 [0.99-4.1] 
(Stockmann 
et al., 2013) 
DRB1*15 0.014 2.3 [1.2-4.4] 
DQB1*05:01 0.050 2.0 [0.99-4.0] 
DQB1*06:02 0.014 2.3 [1.2-4.6] 
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AIMS & OBJECTIVES 
The aims of this study were to 
 Validate ONJ cases and BPs-exposed controls in supporting the 
following analyses  
 Identify potential clinical risk factors associated with BPs-associated 
ONJ development in a series of case-control analyses  
 Identify potential genetic variants associated with BPs-associated ONJ 
development in a large, multicentre GWAS 
The objective of case validation was to test whether the non-exposed ONJ 
cases are comparable to the exposed, so as to substantiate the inclusion of 
the non-exposed type in GENVABO analysis. 
The objective of control validation was to test whether the controls had been 
adequately reviewed prior to recruitment to the GENVABO study.   
As for clinical and genetic risk factor analyses, the objectives were to identify 
potential factors associated with the risk of ONJ development. 
The STREGA (strengthening the reporting of genetic association studies) and 
STROBE (strengthening the reporting of observational studies in epidemiology) 
recommendations were followed in reporting the methods, results and 
discussion of the current study (von Elm et al., 2008; Little et al., 2009).  
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Phenotyping and genotyping 
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2.1 Overview 
The current study represents part of GENVABO, “GENetic VAriants as 
Biomarkers of jaw Osteonecrosis associated with bisphosphonates”, a large, 
ongoing, international collaborative study led by the UCL/UCLH Eastman 
Dental Institute and Hospital. 
The GENVABO Consortium was multidisciplinary and consisted of a clinical 
team and a genetic team. The clinical team was responsible for the following: 
application to the Ethical Committee, arrangement of collaboration agreement 
and “Material Transfer Agreement” with clinical centres, recruitment of study 
participants, collection of clinical data, blood and saliva samples, data entry, 
sample storage and management, as well as detailed clinical phenotyping and 
all related analyses. 
The genetic team worked closely with the clinical team. It consisted of iSAEC, 
the international Serious Adverse Event Consortium, Dr Paola Nicoletti and Dr 
Yufeng Shen from the Columbia University Center for Computational Biology 
and Bioinformatics, and the University of Liverpool Wolfson Centre for 
Personalised Medicine. The team arranged DNA extraction from the biological 
samples, genotyping, and related association analyses.  
2.2 Participant recruitment and clinical phenotyping 
2.2.1 Participating clinical centres 
This is a large, multicentre study with a total of 27 clinical centres from Europe 
and Asia (Table 8 and Table 9). In the discovery cohort, there were 23 centres, 
mostly from Italy, Spain and the UK. In this cohort, 393 BPs-associated ONJ 
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cases and 276 BPs-exposed controls were recruited. As for the replication 
cohort, 130 ONJ cases from seven European centres were recruited. 
2.2.2 Participants inclusion criteria 
Patients referred to the participating centres since January 2004 were eligible 
and the inclusion and exclusion criteria for both ONJ cases and BPs-exposed 
controls were detailed in Table 10.  
The most updated ONJ definition at the beginning of the study, i.e. the AAOMS 
2009 definition, which included the exposed type ONJ only, was adopted 
(Ruggiero et al., 2009). In addition, non-exposed cases were also recruited 
using the criteria suggested by Fedele et al., 2010. In fact, with the inclusion 
of the non-exposed, the GENVABO criteria was comparable to the most recent 
AAOMS 2014 definition (Ruggiero et al., 2014).  
Of note, all participants had a head and neck examination performed by a 
clinician with experience and expertise in diseases of the mouth and jawbone. 
All ONJ cases were diagnosed and adjudicated by multidisciplinary teams of 
specialists in Oral Medicine, Oral and Maxillofacial Surgery, Oncology, 
Haematology, Rheumatology and Radiology. 
2.2.3 Clinical phenotyping 
Participants, including both cases and controls, required only a single visit for 
collection of clinical data and a blood or saliva sample for DNA extraction in 
the GWAS. The study was explained according to the participant information 
sheet (Appendix 8.1), and all participants gave informed consent (Appendix 
8.2). 
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2.2.3.1 Case report form 
A standardised Case Report Form (CRF) was used to gather clinical data for 
all study participants (Appendix 8.3). Information including demographics, 
primary underlying disease, BPs history, medical and dental history, were 
collected. These data were selected with reference to previous ONJ studies 
as discussed in Chapter 1 and were used for detailed analyses in Chapters 3, 
4, 5 and 6.  
As for ONJ cases, information regarding their ONJ features were also 
collected, including the site of the lesion, i.e. mandible and/or maxilla, ONJ 
type, i.e. exposed or non-exposed, dimension of the lesion, referring to the 
total length of exposed bone in millimetres, and lastly pain intensity, rated on 
a visual analogue scale (VAS 0-100mm) by the participant. 
2.2.3.2 Data management 
Data collection was performed between October 2008 and January 2015. The 
CRFs were stored in secured facilities at the UCL/UCLH Eastman Dental 
Institute and Hospital. Data were first transferred into electronic spreadsheets 
by two independent researchers via double entry process and were then 
reviewed by a central study panel, followed by data checking and verification. 
2.2.3.3 Discovery GWAS cases 
393 ONJ cases were recruited and their demographics, medical and dental 
history can be found in Table 11. Majority of the participants were female and 
the top three underlying diseases managed with BPs were osteoporosis, 
multiple myeloma and metastatic breast cancer. Therefore, over 80% were 
managed with zoledronate or alendronate. Regarding the prevalence of the 
potential risk factors amongst these cases, about 50% had history of 
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dentoalveolar surgery, i.e. tooth extraction and/or implant surgery, followed by 
use of steroids and smoking in about 20% of patients respectively. 
Table 12 summarises ONJ features of the cases. About 60% of the lesions 
were in the mandible and 25% in the maxilla. ONJ was dominated by the 
exposed type and about 10% was the non-exposed. The two types were 
compared and will be reported in the next Chapter. The median of jawbone 
exposure was about 1cm, while the pain intensity median was about 2-3 out 
of 10. 
As mentioned in Chapter 1, genetic variants are ethnicity-specific. Therefore, 
for the moment, only Caucasian cases were analysed and the 358 Caucasian 
cases, out of the overall cohort of 393 cases, were matched with 2,554 
Caucasian population controls so as to achieve an approximately 1:10 case-
control ratio in the discovery GWAS.  
Population controls refer to individuals not exposed to BPs whose anonymous 
genotype data had been collected in previous studies and their database was 
made available for research purpose (Table 13). The GENVABO population 
controls data had been selected by the genetic team and were age-, gender- 
and ethnicity-matched with cases recruited by the clinical team.  
2.2.3.4 Replication cases 
As discussed in Chapter 1, the replication study is to confirm the discovery 
GWAS results and should be carried out in an independent cohort, which is 
ethnically and phenotypically similar to the discovery cohort. In GENVABO, in 
addition to the 393 cases in the discovery cohort, 130 new cases have been 
recruited since October 2013 for the ongoing replication study.  
51 
 
Ethnically, the current replication cases were all recruited in European clinical 
centres and 127 out of 130, i.e. 97.7%, were Caucasians (Table 8 and Table 
9). Phenotypically, similar to the discovery case cohort, over 70% were female 
and about 70% were managed with zoledronate or alendronate, with similar 
BPs duration (Table 14). However, the replication cohort had a smaller 
proportion of multiple myeloma patients, and also fewer surgically-induced 
cases, as well as fewer exposed ONJ cases.  
Further comparison between the discovery and the replication cohort cases 
was performed by the clinical team and will be reported in Chapter 6. 
2.2.3.5 BPs-exposed controls 
BPs-exposed controls were also recruited by the GENVABO clinical team 
during the same period when the 393 discovery cohort cases were recruited.  
There were altogether 276 thoroughly phenotyped drug-exposed controls and 
their demographics, medical and dental history were reported in Table 11. 
They shared similar average age and gender proportion with the cases, the 
same top three underlying diseases managed with BPs, but different BPs 
history with regard to type and duration. Their comparison with the discovery 
cohort cases, so as to investigate the ONJ clinical risk factors, will be reported 
in Chapter 5. 
Moreover, novel validation of these controls through comparing their follow-up 
time with the cases’ time to ONJ onset was also carried out by the GENVABO 
clinical team and will be discussed in Chapter 4. 
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Table 8. List of participating clinical centres 
Country 
Centres in 
discovery 
GWAS, n 
Cases in 
discovery 
GWAS, n 
Drug-
exposed 
controls, n 
Centres in 
replication, 
n 
Cases in 
replication, 
n 
Italy 12 247 258 4 70 
Spain 4 61 12 / / 
Hungary / / / 1 50 
United Kingdom 3 29 0 2 10 
Japan 1 19 0 / / 
Sweden 1 17 1 / / 
Austria 1 13 4 / / 
China, Hong Kong 1 7 1 / / 
Total 23 393 276 7 130 
 
 
Table 9. Full list of clinical centres 
Discovery GWAS 
Italy 
1) Centro di Riferimento Oncologico della 
Basilicata, Istituto di Ricovero e Cura a 
Carattere Scientifico, Rionero in Vulture 
2) Ospedale Civile di Alessandria, Alessandria 
3) Sapienza University of Rome, Rome 
4) Second University of Naples, Naples 
5) University of Naples Federico II, Naples 
6) University of Milan, Milan 
7) University of Padua, Padua 
8) University of Palermo, Palermo 
9) University of Parma, Parma 
10) University of Turin, Turin 
11) University of Turin, Lingotto 
12) University of Verona, Verona 
Spain 
1) Complexo Hospitalario Universitario de 
Coruña (CHUAC), La Coruña 
2) Complexo Hospitalario Universitario de 
Santiago de Compostela (CHUS), A García 
3) Policlínico Vigo S.A. (POVISA), Vigo 
4) University of Valencia, Valencia 
United Kingdom 
1) Aintree University Hospital, Liverpool 
2) UCL/UCLH Eastman Dental Institute and 
Hospital, London 
3) University of Liverpool, Liverpool 
Japan 
Hyogo College of Medicine, Hyogo 
Sweden 
Uppsala University, Uppsala 
Austria 
Medical University of Graz, Graz 
China, Hong Kong 
University of Hong Kong 
Replication study 
Italy 
1) Chirurgia Maxillo-Facciale, AOU Sassari 
2) University of Palermo, Palermo 
3) University of Parma, Parma 
4) Ospedale S. Francesco, Nuoro 
Hungary 
Semmelweis University, Budapest 
United Kingdom 
1) King's College Hospital, London 
2) UCL/UCLH Eastman Dental Institute and Hospital, London 
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Table 10. Inclusion and exclusion criteria 
Inclusion criteria for all participants 
 Age over 18 
 Capable of understanding the purpose of the trial and giving informed consent 
 On BPs medications 
Inclusion criteria for ONJ cases Inclusion criteria for BPs-exposed controls 
Exposed ONJ 
AAOMS definition 2009 
(Ruggiero et al., 2009) 
 Chronic non-healing exposure of one or 
more areas of the jawbones through the 
oral cavity and/or facial skin (longer than 8 
weeks) 
 Chronic pain, infection, purulent discharge, 
abscess, fistulas 
Non-exposed ONJ 
(Fedele et al., 2010) 
 Unexplained jaw bone pain, fistula tract, 
bone or gingival swelling, not caused by 
dental or other bone disease 
 No signs or symptoms of ONJ diagnosed 
on the basis of currently accepted criteria 
Exclusion criteria for all participants  
 Age under 18 
 Incapable of understanding the purpose of the trial and giving informed consent 
 Not on BPs medications 
Exclusion criteria for ONJ cases Exclusion criteria for BPs-exposed controls 
 History of radiation therapy to the head 
and neck region 
 No ONJ 
/ 
 
 
Table 11. Discovery GWAS cases and BPs-exposed controls 
 
Cases  
N = 393 
Controls 
N = 276 
n % n % 
Age, decade Mean, median 
SD 
Range 
6.9, 7.0  
0.9 
3.7 to 8.9   
6.6, 6.6 
1.1 
3.5 to 8.8   
Gender Female 
Male 
278 
115 
70.7% 
29.3% 
168 
101 
60.9% 
36.6% 
Primary 
underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
103 
137 
89 
37 
27 
26.2% 
34.9% 
22.6% 
9.4% 
6.9% 
107 
49 
63 
38 
14 
38.8% 
17.8% 
22.8% 
13.8% 
5.1% 
BPs with longest 
duration 
Zoledronate 
Alendronate 
230 
109 
58.5% 
27.7% 
204 
31 
73.9% 
11.2% 
BPs duration, 
year 
Mean, median 
SD 
Range 
3.7, 2.8 
3.1 
0.1 to 19.9 
2.6, 1.7 
2.8 
0.1 to 20.4 
Systemic factor Diabetes 
Smoking 
Steroids 
Antiangiogenics 
36 
81 
82 
57 
9.2% 
20.6% 
20.9% 
14.5% 
19 
47 
42 
94 
6.9% 
17.0% 
15.2% 
34.1% 
History of dentoalveolar surgery 196 49.9% / 
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Table 12. ONJ features of discovery GWAS cases 
ONJ feature 
N = 393 
n % 
Site Maxilla 
Mandible 
Both jaws 
97 
242 
36 
24.7% 
61.6% 
2.3% 
Type Exposed 
Non-exposed 
344 
39 
87.5% 
9.9% 
Total dimension of 
jawbone exposure, mm 
Mean, median 
SD 
Range 
18, 10 
17 
0 to 105 
Pain intensity,  
VAS 0-100mm 
Mean, median 
SD 
Range 
32, 25 
33 
0 to 100 
 
Table 13. Population controls in discovery GWAS 
Database Ethnicity n Chip 
POPRES Caucasian 643 1M Illumina 
HYPERGENE Italian 901 1M Illumina 
Penicillin Drug exposed CTLs Italian 161 HumanOmniExpress BeadChip 
TSI Italian 99 1M Illumina 
JAVIER-SP Spanish 380 1M Illumina 
Controls SPANISH Spanish 200 1M Illumina 
WTCCC British 200 1M Illumina 
SW CONTROLS Swedish 250 1M Illumina 
 
Table 14. Replication cases  
 
Cases  
N = 130 
n % 
Age, decade Mean, median 
SD 
Range 
6.9, 7.0 
1.0 
4.3 to 8.8 
Gender Female 
Male 
99 
31 
76.2% 
23.8% 
Primary underlying disease Metastatic breast cancer 
Osteoporosis 
Metastatic prostate cancer 
Multiple myeloma 
Other cancers 
43 
42 
18 
15 
12 
33.1% 
32.3% 
13.8% 
11.5% 
9.2% 
BPs with longest duration Zoledronate 
Alendronate 
66 
27 
50.8% 
20.8% 
BPs duration, year Mean, median 
SD 
Range 
3.6, 2.8 
3.0 
0.2 to 15.1 
History of dentoalveolar surgery 42 32.3% 
ONJ onset time, year Mean, median 
SD 
Range 
4.2, 3.2 
3.4 
0.2 to 15.9   
ONJ type Exposed 
Non-exposed 
101 
28 
77.7% 
21.5% 
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2.3 Sample management and GWAS analysis 
2.3.1 Biological samples 
Blood samples from 393 discovery cohort cases, 122 replication cohort cases 
and 276 BPs-exposed controls were collected. Venepuncture using EDTA 
vacutainer tubes was performed to collect 6mL of blood.  
Transfer of samples in dry ice from clinical centres to the UCL/UCLH Eastman 
Dental Institute and Hospital was done via a professional logistic company, 
BIOCAIR®. All samples were then stored at -80℃. 
Eight replication cases donated saliva samples through a DNA collection kit, 
DNA Genotek®. Two millilitres of saliva was collected and was processed 
according to the kit’s instruction. Processed samples were then stored at the 
Eastman Dental Institute and Hospital at -20℃. 
All blood and saliva samples had been labelled with standardised coding. 
2.3.2 DNA extraction and genotyping 
Genomic DNA isolation was carried out amongst the 393 discovery cohort 
cases and 276 BPs-exposed controls. Recruitment of the replication cases is 
still in progress and their DNA extraction will be arranged in the near future. 
DNA extraction for the cases was performed using the QIAamp® DNA Blood 
Mini Kit by Expression Analysis® in the United States, while DNA of the 
controls was extracted with the chemagen Magnetic Separation Module I, in 
the Wolfson Centre for Personalised Medicine, University of Liverpool, UK.  
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Extracted DNA quantity was assessed using the NanoDropTM 
spectrophotometer, followed by normalisation to a fixed concentration. All 
samples were bar-coded and stored at -80℃. 
At present, only the discovery GWAS cases have been genotyped, using high-
throughput Illumina® Human1M Omni Express Beadchip. This platform 
contained 1,072,820 probes for SNPs and Copy Number Variations (CNVs) 
typing. Genotyping of the replication cases and the BPs-exposed controls is 
to be arranged. 
2.3.3 GWAS analysis 
As said, the 358 discovery GWAS cases were age-, gender- and ethnicity-
matched with 2,554 population controls. Associations between genetic 
variants and ONJ were tested using logistic regression and Fisher’s Exact test 
through PLINK, a statistical software for GWAS; performed by the genetic 
team. The main results will be presented in Chapter 6. 
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Figure 4. DNA extraction and genotyping 
   
    
First row, left to right: EDTA vacutainer tube. Genotek® DNA collection kit. chemagen 
Magnetic Separation Module I automated genomic DNA extraction. 
Second row. NanoDropTM spectrophotometer. Illumina® Human1M Omni Express.  
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3 Case Cohort Validation 
 
 
 
CHAPTER 3 
Case Cohort Validation 
 
Exposed type versus non-exposed type 
ONJ 
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3.1 Introduction 
3.1.1 Literature review  
When ONJ was first reported, it was widely believed that its most characteristic 
feature was exposed necrotic jawbone, which has largely defined ONJ in the 
past decade (Sambrook et al., 2006; Khosla et al., 2007; Ruggiero et al., 2009).  
Since 2008, non-exposed ONJ cases, who may represent up to one-third of 
all ONJ cases, has been increasingly reported (Junquera and Gallego, 2008; 
Mawardi et al., 2009; Woo et al., 2009; Fedele et al., 2010; Hutchinson et al., 
2010; Truong et al., 2010; Kang et al., 2011b; Bagan et al., 2012; Patel et al., 
2012; Wigler et al., 2013; Schiodt et al., 2014; Fedele et al., 2015). This was 
followed by numerous suggestions urging the inclusion of the non-exposed 
type into the definition and staging of ONJ (Colella et al., 2009; Mawardi et al., 
2009; Yarom et al., 2010; Bedogni et al., 2012; Campisi et al., 2014). In 2014, 
“bone that can be probed through an intraoral or extraoral fistula(e)”, i.e. the 
non-exposed type, was finally included into the AAOMS definition (Ruggiero 
et al., 2014). 
Therefore, for the first time, non-exposed type cases were considered for 
analysis in the current GWAS. This was further supported by early evidence 
indicating that the two types were similar, with regard to demographics, 
underlying diseases, medical history and clinical features (Schiodt et al., 2014; 
Fedele et al., 2015).  
However, whether or not the same applies to the current case cohort remained 
unknown.   
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3.1.2 Objectives 
The objective is to test the hypothesis that the non-exposed ONJ cases are 
comparable to the exposed type in the current cohort, so as to substantiate 
the inclusion of the non-exposed type in GENVABO analysis. 
3.2 Methods 
This part of the study involves secondary analysis of GENVABO clinical 
phenotype data.  
3.2.1 Defining ONJ types 
The dimension of necrotic bone exposure, correct to the nearest millimetre, 
was recorded for each case in the CRF.  
The exposed type ONJ was defined as clinically evident necrotic jawbone, with 
a total dimension of bone exposure larger than 0.0 cm, which was visible 
through the oral mucosa or facial skin. For example, a case with 0.5 cm bone 
exposure was considered the exposed type. For individuals who were 
presented with more than one site of ONJ at the same time, the total dimension 
was calculated. For example, a case presenting with an ONJ site of 0.0 cm 
and another site of 3.0 cm would be categorised as the exposed type.  
The non-exposed type had no frank bone exposure, i.e. 0.0 cm in total, but 
was still presented with clinical features including jawbone pain, sinus tract, 
bone enlargement, gingival swelling or any other signs, that were not caused 
by common jawbone diseases such as odontogenic infections, or other bone 
disorders with similar manifestations (Fedele et al., 2010; Patel et al., 2012). 
61 
 
3.2.2 Outcomes 
3.2.2.1 Primary outcome 
The primary aim of the present analysis was to compare the two types using 
descriptive statistics. The primary objective was to detect if there were any 
major numerical differences in their phenotype data. 
3.2.2.2 Secondary outcome 
The secondary aim was to compare the two types using inferential statistics. 
The secondary objective was to detect if there were any phenotypically, 
statistically significant differences between the exposed and non-exposed 
types. 
3.2.3 Statistical analysis 
Related data were transferred into electronic spreadsheets. All analyses were 
performed in Stata version 12.1 (Stata Corp., College Station, TX, US) and all 
graphs were constructed in Microsoft Excel 2013.  
3.2.3.1 Primary outcome 
Phenotypic features were reported using descriptive statistics. Mean, median, 
standard deviation and range were calculated for numerical data, including 
age, BPs duration and ONJ onset time. Numbers and percentages were 
calculated for categorical data, including gender, underlying disease, BPs 
type, systemic factors and history of dentoalveolar surgery. The percentages 
calculated were also plotted in a bar chart. 
3.2.3.2 Secondary outcome 
Each phenotypic feature formed the outcome variable, and ONJ type as the 
explanatory variable, exposed type=1 and non-exposed type=0.  
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The association between the explanatory variable and each numerical 
outcome variable, including age, BPs duration and ONJ onset time, was 
investigated with random-effects univariable linear regression. For binary 
outcome variables, including gender, underlying diseases, BPs type, systemic 
factors, and dentoalveolar surgery history, random-effects univariable logistic 
regression was used. 
Multilevel random-effects were used to account for the clustering effect 
attributed to the participants being recruited in seven countries. The 
significance level for these analyses was 5%.  
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3.3 Results 
3.3.1 Exposed type versus non-exposed type ONJ; descriptive 
statistics  
344 participants (89.8%) had exposed ONJ, while 39 (10.2%) were of the non-
exposed type (Table 15).  
The two types had the same age median of 70 years. Both types had more 
female than male participants, although the non-exposed type had 
approximately 15% more females than the exposed type. They also shared 
the same top three underlying diseases: osteoporosis, multiple myeloma and 
metastatic breast cancer. Both had more participants on zoledronate than on 
alendronate, as well as similar BPs duration median of approximately three 
years, although the exposed type had nearly 15% more patients on 
zoledronate. They also shared very similar proportion of patients with history 
of smoking, and similar proportion of patients with history of dentoalveolar 
surgery, mainly tooth extraction and implant surgery. 
However, there were more patients with diabetes and on steroids amongst the 
exposed type than the non-exposed, whereas there were more patients on 
antiangiogenics amongst the non-exposed cases. Lastly, ONJ onset time was 
longer amongst the non-exposed cases than the exposed. 
The percentages calculated are plotted in a bar chart (Graph 1). The major 
differences were with use of steroids (20.1%), followed by gender (female) 
(15.4%), then with alendronate (15.1%), and zoledronate (14.3%). The rest 
differed by less than 10%. 
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3.3.2 Exposed type versus non-exposed type ONJ; inferential 
statistics 
In total, 16 comparisons between the two types were performed and only three 
were found statistically significant (p<0.05) (Table 16).  
With reference to the non-exposed cases, there was a statistically significantly 
larger proportion of exposed type cases who were managed with zoledronate 
(OR=2.10, 95% CI 1.05 to 4.19, p=0.036). In contrast, there was a statistically 
significantly smaller proportion of exposed type cases who were prescribed 
with alendronate (OR=0.44, 95% CI 0.22 to 0.89, p=0.023). On the other hand, 
the proportion of the exposed type cases who were on steroids was also 
statistically significantly larger than that of the non-exposed cases (OR=10.15, 
95% CI 1.36 to 75.60, p=0.024).  
Of note, the other 13 outcome variables, including age, gender, underlying 
diseases, BPs duration, three other systemic factors, history of dentoalveolar 
surgery, and ONJ onset time, were all found not statistically significant 
(p>0.05). Furthermore, the estimated coefficient for age was very close to 
zero, this implied that the two groups had very similar age (estimated 
coefficient 0.03 decades).   
65 
 
Table 15. Exposed type versus non-exposed type ONJ; descriptive 
statistics 
 
Exposed ONJ  
N = 344 
Non-exposed ONJ 
N = 39 
n % n % 
Age, decade Mean, median 
SD 
Range 
6.9, 7.0 
1.0 
3.7 to 8.9 
6.9, 7.0 
0.8 
4.9 to 8.8 
Gender Female 
Male 
238 
106 
69.2% 
30.8% 
33 
6 
84.6% 
15.4% 
Primary 
underlying 
disease 
Osteoporosis 
Multiple myeloma 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
117 
92 
75 
35 
25 
34.0% 
26.7% 
21.8% 
10.2% 
7.3% 
16 
8 
12 
2 
1 
41.0% 
20.5% 
30.8% 
5.1% 
2.6% 
BPs with longest 
duration 
Zoledronate 
Alendronate  
208 
89 
60.5% 
25.9% 
18 
16 
46.2% 
41.0% 
BPs duration, 
year 
Mean, median 
SD 
Range 
3.7, 2.8 
3.1 
0.1 to 19.9 
4.1, 3.1 
3.3 
0.2 to 11.0 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
34 
71 
78 
47 
9.9% 
20.6% 
22.7% 
13.7% 
1 
8 
1 
9 
2.6% 
20.5% 
2.6% 
23.1% 
History of dentoalveolar surgery 176 51.2% 17 43.6% 
ONJ onset time, 
year 
Mean, median 
SD 
Range 
4.0, 3.1 
3.2 
0.1 to 19.9 
4.5, 4.4 
3.3 
0.2 to 11.3 
 
 
Graph 1. Exposed type versus non-exposed type ONJ; differences in 
percentages 
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Table 16. Exposed type versus non-exposed type ONJ; random-effects 
univariable regression 
Numerical outcome variable 
N = 383;  
exposed ONJ=1, non-exposed ONJ=0 
Estimated 
coefficient 
95% CI p-value 
Demographics Age, decade 0.03 -0.28 to 0.34 0.868 
BPs duration, year -0.52 -1.56 to 0.51 0.319 
ONJ onset time, year -0.48 -1.55 to 0.58 0.373 
Binary outcome variable OR 95% CI p-value 
Demographics Gender (M=0, F=1) 0.41 0.17 to 1.00 0.051 
Primary underlying 
disease 
Osteoporosis 
Multiple myeloma 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
0.59 
1.56 
0.65 
2.10 
3.36 
0.29 
0.69 
0.31 
0.48 
0.44 
to 
to 
to 
to 
to 
1.20 
3.57 
1.35 
9.07 
25.74 
0.146 
0.287 
0.246 
0.322 
0.243 
BPs with longest 
duration 
Alendronate  
Zoledronate 
0.44 
2.10 
0.22 
1.05 
to 
to 
0.89 
4.19 
0.023* 
0.036* 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
3.89 
0.92 
10.15 
0.53 
0.51 
0.40 
1.36 
0.24 
to 
to 
to 
to 
29.49 
2.16 
75.60 
1.18 
0.189 
0.854 
0.024* 
0.120 
History of dentoalveolar surgery 1.42 0.72 to 2.81 0.310 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                LR chi2(1)         =      0.03 
Log likelihood  =  -519.6932                    Prob > chi2        =    0.8677 
 
------------------------------------------------------------------------------ 
   agedecade |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   .0264535   .1587981     0.17   0.868    -.2847851    .3376922 
       _cons |        6.9   .1504961    45.85   0.000     6.605033    7.194967 
-------------+---------------------------------------------------------------- 
    /sigma_u |   4.15e-23   .1392553                             0           . 
    /sigma_e |   .9398479   .0339581                      .8755933    1.008818 
         rho |   1.95e-45   1.31e-23                             0           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.00 Prob>=chibar2 = 1.000 
 
 
 
 
 
 
Random-effects ML regression                    Number of obs      =       364 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      52.0 
                                                               max =       241 
 
                                                LR chi2(1)         =      0.99 
Log likelihood  = -928.81894                    Prob > chi2        =    0.3193 
 
------------------------------------------------------------------------------------- 
durationyearplus1mo |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------------+---------------------------------------------------------------- 
               neve |  -.5245767   .5262421    -1.00   0.319    -1.555992    .5068389 
              _cons |   4.391983   .6190267     7.09   0.000     3.178713    5.605253 
--------------------+---------------------------------------------------------------- 
           /sigma_u |   .7374955   .5088548                      .1907436     2.85147 
           /sigma_e |   3.074501   .1161882                      2.855006    3.310872 
                rho |   .0544092   .0716544                      .0020085    .3706146 
------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.50 Prob>=chibar2 = 0.239 
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Random-effects ML regression                    Number of obs      =       351 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      50.1 
                                                               max =       240 
 
                                                LR chi2(1)         =      0.79 
Log likelihood  = -904.58442                    Prob > chi2        =    0.3731 
 
-------------------------------------------------------------------------------------- 
onsettimeyearplus1mo |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
---------------------+---------------------------------------------------------------- 
                neve |  -.4830353   .5419334    -0.89   0.373    -1.545205    .5791347 
               _cons |   4.604974    .577175     7.98   0.000     3.473732    5.736216 
---------------------+---------------------------------------------------------------- 
            /sigma_u |   .4790235          .                             .           . 
            /sigma_e |   3.166039   .1203842                      2.938668    3.411002 
                 rho |   .0223796          .                             .           . 
-------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.16 Prob>=chibar2 = 0.345 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      3.81 
Log likelihood  = -229.19938                    Prob > chi2        =    0.0509 
 
------------------------------------------------------------------------------ 
        m0f1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   .4081942    .187323    -1.95   0.051     .1660523    1.003434 
       _cons |   5.499634   2.440753     3.84   0.000     2.304455      13.125 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -14.20371   68.22386                       -147.92    119.5126 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0008236   .0280938                      7.58e-33    8.95e+25 
         rho |   2.06e-07   .0000141                      1.75e-65           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      2.11 
Log likelihood  = -230.66219                    Prob > chi2        =    0.1463 
 
------------------------------------------------------------------------------ 
          op |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   .5891809    .214569    -1.45   0.146     .2885736    1.202931 
       _cons |   1.968203   1.084531     1.23   0.219      .668399    5.795677 
-------------+---------------------------------------------------------------- 
    /lnsig2u |   -.009543   .7075365                     -1.396289    1.377203 
-------------+---------------------------------------------------------------- 
     sigma_u |   .9952399   .3520843                      .4975076    1.990929 
         rho |   .2314058   .1258404                      .0699709    .5464545 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    32.56 Prob >= chibar2 = 0.000 
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Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      1.13 
Log likelihood  = -217.56785                    Prob > chi2        =    0.2873 
 
------------------------------------------------------------------------------ 
          mm |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   1.564167   .6576059     1.06   0.287     .6861544    3.565699 
       _cons |    .124431   .0769226    -3.37   0.001     .0370442    .4179625 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -.6448878   1.169962                     -2.937971    1.648195 
-------------+---------------------------------------------------------------- 
     sigma_u |   .7243766   .4237465                      .2301589    2.279823 
         rho |   .1375565   .1387981                      .0158467    .6123848 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     3.96 Prob >= chibar2 = 0.023 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      1.35 
Log likelihood  = -204.36787                    Prob > chi2        =    0.2459 
 
------------------------------------------------------------------------------ 
      mbcny0 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   .6468609   .2428396    -1.16   0.246     .3099269     1.35009 
       _cons |   .3531666   .1812761    -2.03   0.043     .1291422    .9658082 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -2.372953   2.484644                     -7.242766    2.496861 
-------------+---------------------------------------------------------------- 
     sigma_u |   .3052952   .3792749                      .0267457    3.484869 
         rho |   .0275504   .0665671                      .0002174    .7868453 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.19 Prob >= chibar2 = 0.330 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      0.98 
Log likelihood  = -121.02974                    Prob > chi2        =    0.3224 
 
------------------------------------------------------------------------------ 
         mpc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   2.095471   1.566474     0.99   0.322     .4841322    9.069835 
       _cons |   .0540541   .0392414    -4.02   0.000     .0130282    .2242704 
-------------+---------------------------------------------------------------- 
    /lnsig2u |   -17.4872   1693.102                     -3335.907    3300.933 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0001595   .1350066                             0           . 
         rho |   7.73e-09   .0000131                             0           . 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
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Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      1.36 
Log likelihood  = -93.352532                    Prob > chi2        =    0.2434 
 
------------------------------------------------------------------------------ 
 othercancer |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   3.359484       3.49     1.17   0.243     .4385325    25.73614 
       _cons |    .015006   .0170489    -3.70   0.000     .0016187    .1391073 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -1.016579   1.462125                     -3.882292    1.849134 
-------------+---------------------------------------------------------------- 
     sigma_u |   .6015237   .4397515                      .1435394    2.520777 
         rho |   .0990856   .1305205                      .0062238    .6588754 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     1.82 Prob >= chibar2 = 0.089 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      5.16 
Log likelihood  = -218.23276                    Prob > chi2        =    0.0231 
 
------------------------------------------------------------------------------ 
         ale |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   .4395922   .1590043    -2.27   0.023     .2163531    .8931757 
       _cons |   1.231296   .5500004     0.47   0.641     .5130314    2.955158 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -1.042213    .848733                     -2.705699    .6212734 
-------------+---------------------------------------------------------------- 
     sigma_u |   .5938631   .2520156                      .2585026    1.364293 
         rho |   .0968207   .0742187                      .0199076    .3613351 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     9.68 Prob >= chibar2 = 0.001 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      4.41 
Log likelihood  = -247.69333                    Prob > chi2        =    0.0357 
 
------------------------------------------------------------------------------ 
         zol |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   2.098226     .74042     2.10   0.036     1.050706    4.190091 
       _cons |   .3744695    .186865    -1.97   0.049     .1408173    .9958106 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -.4144077   .7559657                     -1.896073    1.067258 
-------------+---------------------------------------------------------------- 
     sigma_u |   .8128539   .3072449                      .3875011    1.705109 
         rho |   .1672484   .1052882                        .04365    .4691419 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    20.15 Prob >= chibar2 = 0.000 
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Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      1.73 
Log likelihood  = -115.15112                    Prob > chi2        =    0.1887 
 
------------------------------------------------------------------------------ 
          dm |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   3.890536   4.020908     1.31   0.189      .513197    29.49408 
       _cons |   .0269028   .0284034    -3.42   0.001     .0033972    .2130478 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -1.502478    1.83603                     -5.101031    2.096074 
-------------+---------------------------------------------------------------- 
     sigma_u |   .4717815   .4331025                      .0780414    2.852048 
         rho |   .0633683   .1089735                      .0018479    .7120224 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.89 Prob >= chibar2 = 0.172 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       323 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      46.1 
                                                               max =       186 
 
                                                Wald chi2(1)       =      0.03 
Log likelihood  = -179.66959                    Prob > chi2        =    0.8544 
 
------------------------------------------------------------------------------ 
     smoking |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   .9236843   .3995445    -0.18   0.854     .3956688     2.15633 
       _cons |   .3477618   .1427491    -2.57   0.010     .1555539    .7774684 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -14.70182   69.34299                     -150.6116     121.208 
-------------+---------------------------------------------------------------- 
     sigma_u |    .000642   .0222594                      1.97e-33    2.09e+26 
         rho |   1.25e-07   8.69e-06                      1.18e-66           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      5.12 
Log likelihood  =  -187.7025                    Prob > chi2        =    0.0237 
 
------------------------------------------------------------------------------ 
     steroid |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   10.15164   10.39977     2.26   0.024     1.363102    75.60381 
       _cons |   .0338146    .035019    -3.27   0.001     .0044421    .2574088 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -2.191413   1.254914                     -4.650999    .2681736 
-------------+---------------------------------------------------------------- 
     sigma_u |   .3343034    .209761                      .0977346    1.143492 
         rho |   .0328545    .039875                      .0028951    .2844134 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     2.19 Prob >= chibar2 = 0.069 
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Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      2.42 
Log likelihood  = -158.25332                    Prob > chi2        =    0.1199 
 
------------------------------------------------------------------------------ 
     antiang |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        neve |   .5275138   .2169249    -1.56   0.120     .2356143    1.181044 
       _cons |   .2999513   .1140041    -3.17   0.002     .1424065    .6317883 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -14.34109   68.47682                     -148.5532     119.871 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0007689    .026326                      5.52e-33    1.07e+26 
         rho |   1.80e-07   .0000123                      9.27e-66           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       383 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      54.7 
                                                               max =       243 
 
                                                Wald chi2(1)       =      1.03 
Log likelihood  = -262.64982                    Prob > chi2        =    0.3102 
 
--------------------------------------------------------------------------------- 
alveolarsurgery |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
----------------+---------------------------------------------------------------- 
           neve |   1.421923   .4932651     1.01   0.310     .7204344    2.806454 
          _cons |   .5874569    .279619    -1.12   0.264     .2311103    1.493251 
----------------+---------------------------------------------------------------- 
       /lnsig2u |   -.604392   1.015532                     -2.594799    1.386015 
----------------+---------------------------------------------------------------- 
        sigma_u |   .7391932   .3753373                      .2732415     1.99972 
            rho |   .1424316    .124042                      .0221906    .5486375 
--------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     4.82 Prob >= chibar2 = 0.014 
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3.4 Discussion 
3.4.1 Main findings and comparison with previous studies 
Current results were mostly similar to previous studies, which further 
confirmed that non-exposed cases were largely comparable to the exposed 
type counterparts.  
For demographics, the two types shared nearly the same mean age and 
median. As for gender, both had more female than male participants and the 
difference in proportions was not statistically significant. These were all 
consistent with Schiodt et al., 2014 and Fedele et al., 2015. 
As for underlying diseases, similar to Schiodt et al., 2014, there was no 
statistically significant difference in the proportion of patients presented with 
various diseases between the two groups. As for alendronate and zoledronate 
therapy, same as Fedele et al., 2015, the proportion of patients on different 
BPs types was found statistically significantly different between exposed and 
non-exposed type ONJ. On the other hand, BPs duration was found similar.  
Results on diabetes and smoking history were also similar to Schiodt et al., 
2014, in which there were no major differences between the two groups. In the 
current cohort, there were significantly more exposed ONJ cases on steroids, 
but the proportion of patients on steroids was similar in the two groups in 
Fedele et al., 2015. The use of antiangiogenics has not been studied 
previously and was found similar between the two types in the current study.  
The current study and Fedele et al., 2015 found more exposed type cases 
reporting history of dentoalveolar surgery, whereas Schiodt et al., 2014 found 
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more non-exposed cases which were surgically-triggered. Of note, only 
Fedele et al., 2015 calculated a significant difference between the two ONJ 
types in the proportion of patients having tooth extractions before ONJ 
development. ONJ onset time has not been studied previously and the current 
study found that ONJ manifested about six months earlier in the exposed 
cases than in the non-exposed cases, but the difference was not statistically 
significant. 
Therefore, it can be summarised that the current analysis shared similar 
results with previous studies and that the non-exposed ONJ was found largely 
comparable to the exposed type. However, evidence supporting the two types 
as similar was based on results from three early studies only. Moreover, apart 
from the statistically significant differences between the two regarding use of 
alendronate, zoledronate, and steroids, there could still be notable differences 
although not statistically significant. For instance, there were 9.4% more non-
exposed cases who were managed with antiangiogenics, while p=0.120. 
Similar to patients diagnosed with metastatic breast cancer, the difference in 
proportion was 9.0%, while p=0.246. Also, there remained aspects that have 
not been tested but could be different between the two types. 
Nevertheless, all the available studies, i.e. Schiodt et al., 2014, Fedele et al., 
2015 and the current study demonstrated that exposed and non-exposed ONJ 
are largely similar, with regard to demographics, underlying diseases, medical 
history, as well as ONJ onset event and time. There was also evidence 
suggesting that the two types are radiologically similar (Mawardi et al., 2009; 
Hutchinson et al., 2010).  
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Further supported by the recent inclusion of the non-exposed type into the 
AAOMS definition (Ruggiero et al., 2014), therefore, for the first time, these 
cases would be included into an ONJ GWAS, i.e. GENVABO, and would be 
analysed together with the exposed counterparts.  
3.4.2 Study strengths 
3.4.2.1 Current study comparable to previous studies 
The study design of the current study was similar to Schiodt et al., 2014 and 
Fedele et al., 2015, in particular their statistical analyses, which enabled direct 
comparison of their results. 
Of note, there may be an overlap of cases of the current study with Fedele et 
al., 2015 as some of the clinical centres participated in both studies. Yet, the 
number and ratio of exposed and non-exposed cases were totally different. 
Therefore, the two studies remained different and should be considered as two 
independent studies.  
3.4.2.2 Clear definition of non-exposed type ONJ  
Another strength of the current analysis was the adoption of the definition of 
the non-exposed ONJ, described by Fedele et al., 2010 and Patel et al., 2012.  
The current study classified each case when the individual was enrolled for 
the GENVABO study. However, as this definition does not specify the time 
point at which non-exposed features are observed, it may have included 
healing ONJ, which may be of the exposed type at an earlier time. On the other 
hand, it may have missed an initially non-exposed ONJ, which may present 
with exposed jawbone later. Nonetheless, this is currently the best available 
gold standard, although further revision may be necessary. 
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3.4.2.3 Robust statistical analysis 
Detailed information was collected and thorough clinical phenotyping had 
been performed. New variables including the use of antiangiogenics and ONJ 
onset time were analysed for the first time. A bar chart was also plotted to 
illustrate the difference in percentages for each variable between the two 
types. In the univariable regressions, multilevel random-effects were used to 
account for the clustering effect attributed to the participants being recruited in 
seven countries. For the results, both descriptive statistics, i.e. mean, median, 
numbers and percentages, as well as inferential statistics, i.e. results from the 
univariable regressions, were carefully analysed. 
3.4.3 Study limitations 
Study limitations included missing data, relatively few non-exposed type cases 
and related issues. 
Data on ONJ dimension were missing in 10 cases (2.5%), making their ONJ 
type unavailable and their analysis impossible. 
In the current study, there were only 39 non-exposed cases versus 344 
exposed ONJ, giving a ratio of approximately 1:8.8. In contrast, Fedele et al., 
2015 recruited more non-exposed cases (N=192) and had a more favourable 
ratio of 1:3.2 versus the exposed. Schiodt et al., 2014 also had a more 
favourable ratio of the non-exposed versus the exposed (1:6.3). However, only 
14 non-exposed cases were recruited. 
As the overall cohort size of the non-exposed type was small, the numbers of 
non-exposed cases associated with different types of BPs were even smaller 
(zoledronate: N=18; alendronate: N=16). Therefore, due to statistical 
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consideration, cohort stratification according to BPs type as in Chapters 4, 5 
and 6 had not been performed. In fact, to date, cohort stratification has never 
been performed in any of the previous studies (Schiodt et al., 2014; Fedele et 
al., 2015). However, both the current analysis and Fedele et al., 2015 found 
that different BPs types were significantly associated with different ONJ types. 
Therefore, in future, if cohort size allows, stratification may be attempted.  
Similarly, there were even fewer non-exposed cases presented with certain 
medical history. Amongst the non-exposed cases, there was only one other 
cancer patient, one presented with diabetes and one managed with steroids. 
So, for these variables, they had a much wider 95% confidence interval for the 
OR, as well as a relatively larger standard error in the univariable regressions.  
Therefore, although it was found that steroid users had a higher odds of having 
the exposed type, i.e. a statistically significant difference between the two 
types with regard to steroids use, there was only one non-exposed case who 
was on steroids, compared to 78 out of 344 exposed cases. As a result, its 95% 
confidence interval was wide (1.36 to 75.60), accompanied by a large standard 
error (10.40). In contrast, Fedele et al., 2015 identified 49 out of 192 non-
exposed ONJ steroid users, and found no statistically significant difference 
between the two types. All in all, whether or not there was any difference 
between the two types with regard to the use of steroids remains controversial 
and inconclusive. Nonetheless, the non-exposed type is still considered 
comparable to the mainstream exposed ONJ.  
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3.5 Links to Chapters 5 and 6 
As the two types were found largely phenotypically similar to each other in the 
current cohort, the non-exposed type cases will be analysed together with the 
exposed counterparts in the GWAS in Chapter 6.  
To further show that they are similar, there will be additional risk factor analysis 
in Chapter 5. Results from cohorts with the exposed type cases only and with 
both exposed and non-exposed cases will be compared.  
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4 Control Cohort Validation 
  
 
 
CHAPTER 4 
Control Cohort Validation 
 
Follow-up time versus time to onset 
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4.1 Introduction 
4.1.1 Literature review 
One essential element of a case-control study, including a GWAS, is the 
selection of controls, which basically refers to the identification of individuals 
who do not have the condition under investigation (Wacholder and Rotunno, 
2009). 
ONJ is known as a type C chronic or continuous, dose and time related ADR 
(Edwards and Aronson, 2000). However, there were studies which matched 
cases and controls with regard to age, gender or underlying diseases only, 
while BPs dose and length had been completely neglected (Kyrgidis et al., 
2008; Wessel et al., 2008; Thumbigere-Math et al., 2013; Tsao et al., 2013). 
There were studies which considered BPs dose and duration in matching 
cases and controls. Some included controls based on a minimum requirement 
of receiving one dose (Thumbigere-Math et al., 2012), three months 
(Sedghizadeh et al., 2013) or five months of BPs (Vahtsevanos et al., 2009). 
In contrast, a median BPs duration of 21.5 months amongst the zoledronate 
patients, and 42.0 months for pamidronate, were reported in a recent study of 
963 ONJ patients (Gabbert et al., 2015).  
Therefore, with the absence of, or low requirement in, BPs dose or duration 
screening, the controls in these studies may still present with a risk of having 
ONJ after being recruited, i.e. risk of being “false-controls”. 
Another issue with controls selection through BPs duration screening is that 
there can be a time lag between end of BPs therapy and ONJ onset.  
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A recent study reported that ONJ can occur up to 10 years after BPs 
withdrawal (Parretta et al., 2014). Therefore, regardless of the length of BPs 
duration, if the controls had not be adequately reviewed, there may still be a 
risk of “false-control”.  
To date, controls selection through follow-up time screening remains 
uncommon and experimental.  
4.1.2 Objectives 
The objective is to test whether the controls in the current cohort had been 
adequately reviewed prior to recruitment to the GENVABO study, through 
comparing the controls’ follow-up time with cases’ time to onset. The other 
objective is to develop a new method in selecting super-controls, i.e. those 
who had been more adequately reviewed and thus carry a lower risk of being 
“false-controls”. 
4.2 Methods 
This part of the study involves secondary analysis of GENVABO clinical 
phenotype data. It consists of three sets of follow-up time and time to onset 
comparisons, in the overall, zoledronate and alendronate cohorts, followed by 
super-controls selection for further analyses.  
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4.2.1 Defining time to onset and follow-up time 
As described, a series of important time events were recorded in the CRF and 
used in calculating the following time periods. 
“Time to onset” applies to ONJ cases and is defined as the number of years 
elapsed between the initiation of BPs therapy and ONJ diagnosis, i.e. when 
ONJ was diagnosed according to the diagnostic criteria mentioned in 2.2.2, 
adjudicated by a local multidisciplinary team of clinical specialists.  
“Follow-up time” applies to BPs controls and is defined as time elapsed, in 
number of years, between initiation of BPs therapy and enrolment for the 
GENVABO study, i.e. the latest follow-up.  
Of note, for both cases and controls, the initiation of BPs therapy refers to the 
time when patients received the first dose of BPs. 
4.2.2 Time to onset versus follow-up time 
4.2.2.1 Outcomes 
4.2.2.1.1 Primary outcome 
The primary aim of the present analysis was to compare cases’ time to onset 
with controls’ follow-up time, using descriptive statistics. The primary objective 
was to detect if there were any major numerical differences between onset 
time and follow-up time. 
4.2.2.1.2 Secondary outcome 
The secondary aim was to compare cases’ time to onset with controls’ follow-
up time, using inferential statistics. The secondary objective was to detect if 
there were any statistically significant differences between onset time and 
follow-up time. 
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4.2.2.2 Statistical analysis 
All analyses were performed in Stata version 12.1 (Stata Corp., College 
Station, TX, US) and all graphs were constructed in Microsoft Excel 2013.  
4.2.2.2.1 Primary outcome 
Time to onset and follow-up time were reported using descriptive statistics. 
Mean, median, standard deviation and range were calculated. The number 
and cumulative percentage of (i) cases being diagnosed at different lengths of 
time, and (ii) controls being reviewed at different lengths of time, were also 
calculated and plotted in various line charts. 
4.2.2.2.2 Secondary outcome 
Onset time or follow-up time formed the outcome variable, and ONJ 
development was the explanatory variable, case=0 and control=1. 
The association between the explanatory variable and the outcome variable 
was investigated with random-effects univariable linear regressions. 
Multilevel random-effects were used to account for the clustering effect 
attributed to the participants being recruited in seven countries. The 
significance level for these analyses was 5%. 
4.2.3 Super-controls selection 
Findings from the onset time and follow-up time comparisons were carefully 
considered. Different selection outcomes include (i) rejecting the entire control 
cohort, (ii) accepting the entire control cohort, or (iii) accepting part of the 
cohort who were super-controls, i.e. those who had been more adequately 
reviewed. 
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4.3 Results 
Amongst the overall 393 cases, time events-related data were complete in 357 
cases, including 212 zoledronate patients and 94 alendronate patients. As for 
controls, 272 out of 276 had complete time events data, in which 203 were 
zoledronate patients, and only 30 were on alendronate. 
4.3.1 Time to onset versus follow-up time 
4.3.1.1 Overall cohort 
Considering all the cases and controls in the overall cohort, the controls’ 
follow-up time ranged from 0.1 to 20.4 years and its median was 2.2 years, 
which was about a year shorter than the cases’ time to onset (Table 17). The 
median onset time was 3.2 years and it ranged from 0.1 to 19.9 years. 
Graph 2 presents the number of (i) cases being diagnosed, and (ii) controls 
being reviewed at different lengths of time. For instance, in the first year, ONJ 
was diagnosed in 49 individuals. In other words, these 49 cases had an onset 
time of within a year. There were also 63 controls who had been reviewed for 
within a year at recruitment to the GENVABO study.  
In general, the numbers for both cases and controls were high in the first three 
years (N~50). For the cases, two peaks were observed in the second and in 
the fifth years. Only one peak was observed for the controls and it was also in 
the second year. In the first year, there were more controls recruited than 
cases being diagnosed. Whereas in the third, fifth to ninth, 11th, 12th and 15th 
years, the cases outnumbered the controls.  
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Graph 3 presents the cumulative percentage of (i) cases being diagnosed, and 
(ii) controls being reviewed at different lengths of time. For instance, ONJ was 
diagnosed in 49 individuals in the first year and in another 65 cases in the 
second year. Therefore, the cumulative percentage of cases being diagnosed 
in the second year was calculated as (49+65)/357=31.9%. Similarly, the 
cumulative percentage of controls being reviewed in the second year was 
calculated as (63+65)/272=47.1%.  
Both curves are of convex shapes. As there were more controls in the earlier 
years but more cases in later years, the control curve is on the left hand side 
of the case curve. From the first to the 11th year, the percentages amongst the 
controls were all higher than that of the cases. Afterwards, there was a smaller 
proportion of controls than cases.  
It took about six to seven years to capture the vast majority of cases (~80%). 
However, the vast majority of controls (80.5%) had only been reviewed for five 
years or less. Only about 10% of controls had been reviewed for eight or more 
years. 
Furthermore, it was found that the overall follow-up time was also statistically 
significantly shorter than the overall time to onset (estimated coefficient -0.82 
years, 95% CI -1.34 to -0.31 years, p=0.002) (Table 20). 
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4.3.1.2 Zoledronate cohort 
Similar to the overall cohort, the zoledronate controls’ follow-up time was also 
found shorter than the cases’ time to onset (Table 18). Their medians differed 
by 0.4 years (follow-up time: 1.7 years; onset time: 2.1 years).  
Graph 4 compares onset time with follow-up time in terms of number of 
individuals. The case (N=212) and the control cohorts (N=203) were of similar 
sizes. At most time points, the number of controls being reviewed were found 
comparable to the number of cases. Both peaked in the second year, which 
corresponded with the peaks observed in the overall cohort. However, in the 
first year, there were 17 more controls being recruited than the cases. 
Whereas in the fifth and sixth years, there were 19 more cases than controls.  
Graph 5. Zoledronate cohort onset time versus follow-up time; 
cumulative percentage over time 
 5 compares onset time with follow-up time with regard to cumulative 
percentage. The control curve is again on the left hand side of the case curve 
as there were more controls recruited in earlier years than in later years. From 
the first to the fourth years, there were more controls than cases, by 
approximately 10%. The difference in percentages then decreased and almost 
disappeared from the sixth year onwards.  
It took about four to five years to capture the vast majority of cases (~80%). 
However, 75.4% of controls had only been reviewed for three years or less. 
Only about 10% of controls had been reviewed for six or more years. 
Lastly, it was also found that the zoledronate controls’ follow-up time was 
statistically significantly shorter than the cases’ onset time (estimated 
coefficient -0.48 years, 95% CI -0.91 to -0.05 years, p=0.03) (Table 20). 
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4.3.1.3 Alendronate cohort 
The alendronate controls’ follow-up time was also found shorter than the 
cases’ time to onset (Table 19). Their medians differed by 1.8 years (follow-up 
time: 4.2 years; onset time: 6.0 years).  
Graph 6 compares the onset time with follow-up time amongst alendronate 
cases and controls in terms of number of individuals. In total, there were three 
times as many cases (N=94) as controls (N=30). In the first four years, the 
numbers were similar; in total, 16 cases and 14 controls were recruited 
respectively. The number of alendronate cases then peaked in the fifth year 
(N=18), which corresponded with the second peak observed amongst the 
overall cases in Graph 2. However, in the same year, only four controls were 
recruited and the numbers continued to decrease from the sixth year onwards.  
The control curve is also on the left hand side of the case curve and their 
differences in cumulative percentages were also large (Graph 7).  
It took about nine to 10 years to capture the vast majority of cases (~80%). 
However, 80.0% of controls had only been reviewed for eight years or less. 
Only about 10% of controls had been reviewed for 11 or more years.  
Although alendronate controls’ follow-up time was shorter than the cases’ time 
to onset, the difference was not found statistically significant (estimated 
coefficient -1.05 years, 95% CI -2.41 to 0.31 years, p=0.129) (Table 20). 
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4.3.1.4 Summary 
Controls’ follow-up time, in terms of mean and median, were found shorter 
than cases’ time to onset in all three cohorts: the overall, zoledronate and 
alendronate cohorts. Regression analyses also found that the follow-up time 
was statistically significantly shorter than the onset time in the overall and the 
zoledronate cohorts (p<0.05), but not in the alendronate cohort. 
Both time to onset and follow-up time, in terms of mean, median and peak time 
of ONJ diagnosis, were found earlier amongst the zoledronate patients than 
those managed with alendronate.  
There were similar number of cases and controls in the zoledronate cohort, 
and the overlap between the two curves is fairly good, except mainly in the 
first year when there were more controls than cases, right before the peak of 
ONJ diagnosis in the second year.  
In the alendronate cohort, there were two times more cases than controls and 
the overlap between the two curves at most time points is poor.  
All three cumulative percentage graphs show the control curve on the left hand 
side of the case curve as there were more controls recruited in earlier years 
than in later years. 
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4.3.2 Super-controls selection 
As the zoledronate and the alendronate cohorts showed different time to 
onset, follow-up time, and case to control ratio, separate, dedicated super-
control selections were performed.  
4.3.2.1 Zoledronate cohort 
In the zoledronate cohort, the controls’ follow-up time was found statistically 
significantly shorter than the cases’ time to onset. Therefore, the option of 
rejecting the entire zoledronate control cohort (N=203) was considered.  
However, when each time point was considered, follow-up time was found 
comparable to the onset time. First, both numbers of cases (N=56) and 
controls (N=58) peaked in the second year. Second, the number of controls 
being reviewed were found mostly similar to the number of cases at most time 
points (Graph 4), except in the first year when there were 17 more controls 
than cases.  
A follow-up time of within a year was not long enough to cover the peak of 
ONJ diagnosis in the second year. Therefore, these controls (N=57) may still 
present with the risk of having ONJ after recruitment into the study, i.e. risk of 
being “false-control”, and are not ideal for case-control risk factor analysis. 
Hence, having considered the peak time of diagnosis and the median onset 
time, both around the second year, the more precise and stringent median of 
2.1 years was chosen as the threshold in classifying the super-controls. Eighty 
eight controls had a follow-up time of 2.1 years or longer and were therefore 
selected as super-controls for additional analysis in the next Chapter. 
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4.3.2.2 Alendronate cohort 
Although the difference between the alendronate controls’ follow-up time and 
cases’ time to onset was not statistically significant, the decision of accepting 
the entire alendronate cohort (N=30) was considered inappropriate.  
Amongst the alendronate cases, peak time of ONJ diagnosis was in the fifth 
year while the median onset time was 6.0 years. However, 60.0% of the 
alendronate controls had a follow-up time of five years or less.   
If the same criteria for the zoledronate controls were adopted, i.e. the more 
stringent median to be chosen as the cut-off, only eight individuals had a 
follow-up time of 6.0 years or longer and qualified as super-controls in the 
alendronate cohort. Since this is too few for comparison with 94 cases, 
additional analysis will not follow due to statistical consideration. 
4.3.2.3 Summary 
Findings from the onset time and follow-up time comparisons had been 
carefully considered. In the zoledronate cohort, the median onset time, 2.1 
years, which was also around the peak time of diagnosis in the second year, 
was chosen as the cut-off in selecting super-controls. Eighty eight super-
controls had a follow-up time of 2.1 years or longer and will be subject to 
additional risk factor analysis in Chapter 5. When the same approach was 
applied to the alendronate cohort, i.e. using the median of 6.0 years as cut-off, 
which was also around the peak time of diagnosis in the fifth year, only eight 
super-controls would be selected. As the cohort size it too small, there will not 
be additional analysis in Chapter 5.  
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Table 17. Overall cohort onset time versus follow-up time 
 
Cases’ onset time 
N = 357 
Controls’ follow-up time 
N = 272 
Time, year 
Mean; median 
SD; range 
4.1; 3.2 
3.2; 0.1 to 19.9 
3.2; 2.2 
3.2; 0.1 to 20.4 
 
Graph 2. Overall cohort onset time versus follow-up time; number of 
individuals over time 
 
Year, nth 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
All case, n  49 65 57 28 44 30 24 19 10 8 8 8 2 1 2 1 
All control, n   63 65 45 31 15 10 11 6 6 6 3 4 2 2 1 1 
 
Graph 3. Overall cohort onset time versus follow-up time; cumulative 
percentage over time 
 
Year, nth 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
All case, % 13.7 31.9 47.9 55.7 68.1 76.5 83.2 88.5 91.3 93.6 95.8 98.0 98.6 98.9 99.4 99.7 
All control, % 23.2 47.1 63.6 75.0 80.5 84.2 88.2 90.4 92.6 94.9 96.0 97.4 98.2 98.9 99.3 99.6 
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Table 18. Zoledronate cohort onset time versus follow-up time 
 
Cases’ onset time 
N = 212 
Controls’ follow-up time 
N = 203 
Time, year 
Mean; median 
SD; range 
2.9; 2.1 
2.3; 0.1 to 12.1 
2.4; 1.7 
2.2; 0.1 to 12.5 
 
Graph 4. Zoledronate cohort onset time versus follow-up time; number 
of individuals over time 
 
Year, nth 1 2 3 4 5 6 7 8 9 10 11 12 13 
Zol case, n 40 56 44 20 17 13 8 7 3 1 1 0 2 
Zol control, n 57 58 38 21 8 3 5 3 5 3 0 1 1 
Zol = Zoledronate 
Graph 5. Zoledronate cohort onset time versus follow-up time; 
cumulative percentage over time 
 
Year, nth 1 2 3 4 5 6 7 8 9 10 11 12 13 
Zol case, % 18.9 45.3 66.0 75.5 83.5 89.6 93.4 96.7 98.1 98.6 99.1 99.1 100.0 
Zol control, % 28.1 56.7 75.4 85.7 89.7 91.1 93.6 95.1 97.5 99.0 99.0 99.5 100.0 
Zol = Zoledronate 
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Table 19. Alendronate cohort onset time versus follow-up time 
 
Cases’ onset time 
N = 94 
Controls’ follow-up time 
N = 30 
Time, year 
Mean; median 
SD; range 
6.5; 6.0 
3.1; 1.0 to 15.1 
5.4; 4.2 
4.1; 1.1 to 16.0 
 
Graph 6. Alendronate cohort onset time versus follow-up time; number 
of individuals over time 
 
Year, nth 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Ale case, n 1 3 7 5 18 13 13 8 5 6 6 6 0 0 2 1 
Ale control, n 0 6 2 6 4 4 1 1 0 1 2 0 0 0 2 1 
Ale = Alendronate 
Graph 7. Alendronate cohort onset time versus follow-up time; 
cumulative percentage over time  
 
Year, nth 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Ale case, % 1.1 4.3 11.7 17.0 36.2 50.0 63.8 72.3 77.7 84.0 90.4 96.8 96.8 96.8 98.9 100.0 
Ale control, % 0.0 20.0 26.7 46.7 60.0 73.3 76.7 80.0 80.0 83.3 90.0 90.0 90.0 90.0 96.7 100.0 
Ale = Alendronate 
0
2
4
6
8
10
12
14
16
18
20
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6
N
u
m
b
e
r 
o
f 
in
d
iv
id
u
a
l
Onset time v follow-up time, year
Ale case
Ale control
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6
C
u
m
u
la
ti
v
e
 %
Onset time v follow-up time, year
Ale case
Ale control
93 
 
Table 20. Onset time versus follow-up time; random-effects univariable 
linear regression 
case=0, control=1  N 
Estimated 
coefficient 
95% CI p-value 
All cases v All controls 629 -0.82 -1.34 to -0.31 0.002* 
Zol cases v Zol controls 415 -0.48 -0.91 to -0.05 0.030* 
Ale cases v Ale controls 124 -1.05 -2.41 to 0.31 0.129 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       629 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      89.9 
                                                               max =       498 
 
                                                LR chi2(1)         =      9.05 
Log likelihood  = -1620.2684                    Prob > chi2        =    0.0026 
 
------------------------------------------------------------------------------- 
         time |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
case0control1 |  -.8244194   .2621592    -3.14   0.002    -1.338242   -.3105968 
        _cons |    4.17588   .2393315    17.45   0.000     3.706799    4.644961 
--------------+---------------------------------------------------------------- 
     /sigma_u |   .2871645          .                             .           . 
     /sigma_e |    3.17442   .0897221                       3.00335    3.355234 
          rho |    .008117          .                             .           . 
------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.66 Prob>=chibar2 = 0.209 
 
 
 
 
 
Random-effects ML regression                    Number of obs      =       415 
Group variable: zolcountry                      Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         1 
                                                               avg =      59.3 
                                                               max =       357 
 
                                                LR chi2(1)         =      4.67 
Log likelihood  =  -923.9201                    Prob > chi2        =    0.0307 
 
---------------------------------------------------------------------------------- 
         zoltime |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-----------------+---------------------------------------------------------------- 
zolcase0control1 |  -.4769792   .2201609    -2.17   0.030    -.9084867   -.0454718 
           _cons |   2.850905     .15398    18.51   0.000     2.549109      3.1527 
-----------------+---------------------------------------------------------------- 
        /sigma_u |          0   .1183707                             .           . 
        /sigma_e |   2.242015   .0778186                      2.094565    2.399844 
             rho |          0  (omitted) 
---------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.00 Prob>=chibar2 = 1.000 
 
 
 
 
 
Random-effects ML regression                    Number of obs      =       124 
Group variable: alecountry                      Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         2 
                                                               avg =      17.7 
                                                               max =        77 
 
                                                LR chi2(1)         =      2.28 
Log likelihood  = -324.21379                    Prob > chi2        =    0.1307 
 
---------------------------------------------------------------------------------- 
         aletime |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-----------------+---------------------------------------------------------------- 
alecase0control1 |  -1.052529    .693214    -1.52   0.129    -2.411203    .3061455 
           _cons |   6.474264   .3409707    18.99   0.000     5.805974    7.142554 
-----------------+---------------------------------------------------------------- 
        /sigma_u |          0    .340432                             .           . 
        /sigma_e |   3.305834   .2099206                      2.918971     3.74397 
             rho |          0  (omitted) 
---------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.00 Prob>=chibar2 = 1.000 
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4.4 Discussion 
4.4.1 Main findings and comparison with previous studies 
4.4.1.1 Time to onset 
In the current cohort, the onset time amongst cases on zoledronate was 
shorter than those on alendronate. This has also been shown in a number of 
studies (Bamias et al., 2005; Mavrokokki et al., 2007; Pozzi et al., 2007; 
Boonyapakorn et al., 2008; Vahtsevanos et al., 2009; Thumbigere-Math et al., 
2012; Watters et al., 2012) and can be explained by the higher potency of 
zoledronate (Dunford et al., 2001). 
The median has been commonly calculated for time to onset. The median for 
the current zoledronate case cohort was 2.1 years. This is similar to the 
weighted average of 21.9 months (1.8 years) calculated in a previous review 
(Palaska et al., 2009), and a recent study of 109 ONJ cases associated with 
zoledronate and pamidronate, which reported a median onset time of 26.3 
months (2.2 years) (Watters et al., 2012). However, results from earlier, 
smaller studies were different. Mavrokokki et al., 2007, a study on a small 
group of zoledronate cases amongst a cohort of 59 patients, reported a 
median onset time of 12 months. While Pozzi et al., 2007 calculated a median 
of 36 months amongst 35 cases on zoledronate and pamidronate. 
As for cases on alendronate, their median time to onset was 6.0 years. This is 
longer than the weighted average of 4.6 years reported in Palaska et al., 2009, 
and nearly two times longer than findings from Mavrokokki et al., 2007, which 
studied a small group of alendronate cases amongst a cohort of 59 patients 
and reported a median of two years. 
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For the first time, the peak time of diagnosis and cumulative percentages of 
ONJ cases being diagnosed over time were analysed. For zoledronate cases, 
their peak time of diagnosis was in the second year. Whereas for the 
alendronate cohort, its peak time was in the fifth year. It took about four to five 
years for the vast majority, i.e. 80% cumulatively, of ONJ cases to be 
diagnosed amongst individuals prescribed with zoledronate. Again, it took 
about twice longer, i.e. nine to 10 years, to capture the majority of ONJ cases 
on alendronate. 
4.4.1.2 Follow-up time 
It is not possible to compare the follow-up time of the current control cohort 
with previous case-control studies as none reported the follow-up time of their 
controls recruited.   
Meanwhile, it would be inappropriate to compare follow-up time with BPs 
duration or study period as follow-up time is defined precisely as time elapsed 
between initiation of BPs therapy and the latest follow-up. 
4.4.1.3 Super-controls selection 
This was an original and novel approach. After careful consideration of the 
onset time median, peak time of diagnosis, and yearly cumulative percentages, 
the median was chosen as the cut-off for choosing super-controls. Using this 
criterion, 88 zoledronate super-controls were chosen for additional analysis. 
Using the same criterion in the alendronate cohort, eight super-controls were 
selected. Since the number is too small for comparison with 94 alendronate 
cases, additional analysis will not follow. 
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4.4.2 Study strengths  
4.4.2.1 Clear definition of time to onset and follow-up time 
An important strength of this part of the study is its clear definition of time to 
onset and follow-up time. Onset time has been precisely defined as the period 
from the initiation of BPs therapy to ONJ diagnosis. Clear diagnostic criteria 
for ONJ have also been adopted, so as to ensure consistency across clinicians 
and clinical centres in this multicentre study. In contrast, previous studies did 
not differentiate between ONJ diagnosis by clinicians from report of symptoms 
by patients, which is prone to inconsistency as well as errors associated with 
misreporting of ONJ manifestations by patients (Marx et al., 2005; 
Boonyapakorn et al., 2008; Lazarovici et al., 2009).  
The follow-up time has also been clearly defined. It refers to the period 
between the initiation of BPs therapy and patient recruitment, which 
differentiates follow-up time from cumulative duration of BPs therapy. In fact, 
unlike follow-up time, BPs duration is not comparable with cases’ time to onset 
since the end date of BPs therapy does not always coincide with ONJ 
diagnosis for cases, or the latest follow-up for controls. Therefore, it is not ideal 
to validate a control cohort through comparison between duration of BPs 
therapy and time to onset.  
4.4.2.2 Detailed analysis 
Both descriptive and inferential statistics have been carefully performed. Apart 
from testing if time to onset and follow-up time were statistically significantly 
different from each other, year by year comparison of the number of cases 
being diagnosed and controls having been reviewed was also performed. This 
has been an original and in-depth approach in providing more information in 
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addition to the regression analysis. As demonstrated in the zoledronate cohort, 
p<0.05 does not necessarily mean that there was a large difference between 
cases’ onset time and controls’ follow-up time. In fact, the medians only 
differed by 0.4 years and their distribution was found mostly similar to each 
other. The significant difference was due mainly to 57, out of a total of 203 
controls, who had only been reviewed for under a year.  
In contrast, as for the alendronate cohort, although the median follow-up time 
was by nearly two years shorter than that of the onset time, probably due to 
the small cohort size of the controls, their difference was not found statistically 
significant.  
4.4.2.3 Novel super-controls selection 
In the current study, different control cohort validation approaches have been 
considered. 
The first option was to compare the current cohort’s follow-up time with 
previous studies’ time to onset. However, there is no single up-to-date figure 
available as the most recent review study was published by Palaska et al., 
2009. Moreover, there is a wide range of time to onset figures reported. As in 
the case of zoledronate, it ranged widely from 0.5 to six years (Palaska et al., 
2009). Therefore, it was decided to compare the current cohort’s follow-up time 
with its own time to onset. This is considered more favourable as the 
participants were recruited by the same consortium under the same setting. In 
addition, the current time to onset figure was found comparable with a recent 
study of 109 ONJ cases (Watters et al., 2012).  
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An alternative approach also considered was to accept or reject the entire 
control cohort, on the basis of any statistically significant differences between 
time to onset and follow-up time. If this approach were chosen, the alendronate 
control cohort would have been considered “acceptable”, although the majority 
had a review period shorter than the median onset time and peak time of 
diagnosis. On the other hand, the entire zoledronate control cohort would have 
been rejected as its follow-up time was statistically significantly shorter than 
its time to onset. However, there were in fact 88 zoledronate super-controls.   
It is important to achieve the right balance in choosing the appropriate controls 
and is probably more sensible to select part of the cohort who were super-
controls, through careful comparison between follow-up time and time to 
onset, with reference to different evidences, including their medians and 
numbers of (i) cases being diagnosed, and (ii) controls being reviewed at 
different lengths of time, as performed in the current study.  
4.4.3 Study limitations 
Study limitations were mainly missing data, small cohort size amongst those 
on alendronate and other BPs, and their related issues. 
Time-related data were incomplete in 36 cases (9.2%) and four controls (1.4%), 
making the calculation of time amongst these individuals impossible. 
The alendronate cohort size was small and there were only 31 controls, versus 
109 cases, making the selection of super-controls and additional risk factor 
analysis impossible. However, a recent study only recruited 98 alendronate 
patients in total, which is by 42 patients less than the current alendronate 
cohort (Sedghizadeh et al., 2013).  
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In the GENVABO cohort, there were even fewer participants managed with 
other types of BPs. For instance, there were only 22 cases and 17 controls 
managed with pamidronate, followed by 15 cases and seven controls 
managed with ibandronate. Such cohort sizes are too small for stratification 
and further analysis. This is however understandable, as zoledronate is the 
most frequently prescribed intravenous BPs and alendronate for oral BPs 
(Filleul et al., 2010). 
Currently, the median was chosen as the threshold in selecting super-controls. 
If more controls were available, an even more stringent criterion, e.g. 80% 
cumulatively, could be used instead, which would further lower the risk of 
including “false-controls” for further analysis.   
4.5 Links to Chapter 5 
The time to onset median amongst zoledronate cases was 2.1 years and was 
chosen as the cut-off for selecting super-controls. Eighty eight zoledronate 
super-controls, having been reviewed for 2.1 years or longer, were selected 
and will be subject to additional risk factor analysis in Chapter 5. Meanwhile, 
there were only eight super-controls in the alendronate cohort. Since the 
number is too small for comparison with 94 alendronate cases, additional risk 
factor analysis will not follow. Of note, genotyping of these BPs-exposed 
controls is still in progress and they are currently not involved in the GWAS in 
Chapter 6.  
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5 Clinical Risk Factors 
 
 
 
CHAPTER 5 
Clinical Risk Factors 
 
ONJ cases versus BPs-exposed controls  
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5.1 Introduction 
5.1.1 Literature review  
ONJ is considered a multifactorial disease and a number of risk factors have 
been suggested (Landesberg et al., 2011). The investigation of these clinical 
factors in the current GENVABO GWAS is also important as there may be 
clinical-genetic interaction involved in the pathogenesis of ONJ (Izzotti et al., 
2013).  
To date, there have been several studies reporting risk factors for ONJ 
development. However, only eight investigated the combined effect of these 
factors through multivariable statistics (Table 21). Nonetheless, there 
remained a number of issues with respect to their design and methodology.  
Five studies considered BPs dosage or duration when recruiting controls 
(Kyrgidis et al., 2008; Vahtsevanos et al., 2009; Thumbigere-Math et al., 2012, 
2013; Sedghizadeh et al., 2013). However, their requirements were not ideal. 
For instance, the minimum BPs dosage requirement in Thumbigere-Math et 
al., 2012 was one dose only, while the minimum BPs therapy duration 
requirement in Sedghizadeh et al., 2013 was only three months. In fact, none 
screened specifically the follow-up time of the controls. Therefore, as 
explained in the previous Chapter, they may carry a risk of recruiting “false-
controls”. 
Another issue was with the size of their cohorts. Out of all eight studies, four 
recruited less than 100 participants (Kyrgidis et al., 2008; Katz et al., 2011; 
Thumbigere-Math et al., 2013; Tsao et al., 2013). On the other hand, for those 
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with a larger cohort, their case cohorts remained small. For instance, 
Thumbigere-Math et al., 2012 recruited only 18 cases for comparison with 558 
controls. In fact, none of the eight studies had a case cohort larger than 100. 
This indicates that these studies can provide only a narrow representation of 
ONJ phenotype.  
Furthermore, there was no cohort stratification according to BPs type in any of 
the studies. For instance, zoledronate and alendronate have very different 
potency, indication, ONJ incidence and time to ONJ onset. However, in two 
studies, individuals on zoledronate and alendronate were analysed together 
(Wessel et al., 2008; Sedghizadeh et al., 2013). As for zoledronate and 
pamidronate, although both are usually prescribed intravenously, their ONJ 
incidences were reported as 0-20% and 0-4% respectively (Kühl et al., 2012), 
and their difference in time to onset was almost a year (Palaska et al., 2009). 
However, most studies did not differentiate zoledronate patients from those on 
pamidronate, and some included ibandronate patients as well (Kyrgidis et al., 
2008; Vahtsevanos et al., 2009; Katz et al., 2011; Thumbigere-Math et al., 
2012, 2013). Although this boosted the overall cohort sizes, it may risk 
inappropriate and irrelevant comparison of cases and controls on different 
types of BPs. In other words, it is not desirable to compare, for example, a 
case on alendronate with a control on zoledronate, as they would also be very 
different with regard to underlying diseases, BPs dosage and concomitant 
medications.  
Possibly due to these limitations, current evidences on ONJ clinical risk factors 
remained controversial and were largely unhelpful in understanding the 
pathophysiology of ONJ (Campisi et al., 2014). 
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Table 21. Previous studies on factors for ONJ development using multivariable technique 
Study 
Case,  
n 
Case  
inclusion 
Control,  
n 
Control inclusion Underlying disease BPs type Risk factors Protective factors 
Sedghizadeh 
et al. 2013* 
69 
AAOMS 
Stage 0 to 3 
84 
Minimum BPs 
duration: 3 months 
Cancer, 
Osteoporosis 
Alendronate (Ale), 
Ibandronate (Iba), 
Pamidronate (Pam), 
Risedronate (Ris), 
Zoledronate (Zol) 
- Longer duration BPs 
therapy 
- Older age 
- Asian race 
/ 
Thumbigere-
Math et al. 
2013* 
25 AAOMS definition 48 
Minimum i.v. BPs 
dose: 10 
Breast cancer, 
Lung cancer,  
Multiple myeloma, 
Prostate cancer, 
Renal cell carcinoma 
Zol, Pam 
- Periodontal disease / 
Tsao et al. 
2013* 
22 ASBMR definition 41 
Matched age and 
gender 
Breast cancer,  
Multiple myeloma 
i.v. BPs 
- Periodontal disease / 
Thumbigere-
Math et al., 
2012* 
18 AAOMS definition 558 
Minimum i.v. BPs 
dose: 1 
Breast cancer, 
Lung cancer,  
Multiple myeloma, 
Prostate cancer, 
Renal cell carcinoma 
Zol, Pam 
- Diabetes, 
- Smoking, 
- Steroids,  
- Hypothyroidism, 
- Pam infusion, 
- Zol infusion 
/ 
Katz et al. 
2011* 
12 AAOMS definition 66 / Multiple myeloma Zol, Pam 
- Smoking / 
Vahtsevanos 
et al. 2009* 
80 AAOMS definition 1541 
Minimum BPs 
duration: 5 months 
Breast cancer,  
Multiple myeloma, 
Prostate cancer 
Zol, Pam, Iba 
- Each dose of Zol, Pam 
administered, 
- Ever received Zol, Pam, 
- Denture, 
- Extraction 
- Each dose of all 
BPs administered, 
- Ever received Iba  
 
Wessel et al. 
2008* 
30 
International 
classification 
of disease (ICD-9) 
diagnostic code 
150 
Matched age, 
gender, 
cancer type and 
year of cancer 
diagnosis 
Breast cancer, 
Kidney cancer, 
Lung cancer,  
Multiple myeloma, 
Prostate cancer 
Zol, Pam, Oral BPs 
- Smoking, 
- Obesity, 
- Zol  
/ 
Kyrgidis et 
al., 2008* 
20 Developed ONJ 40 
1 less to 3 more 
doses of BPs than 
cases; matched age 
Breast cancer Zol, Pam, Iba 
- Extraction 
- Denture 
/ 
* No cohort stratification according to BPs type. 
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5.1.2 Objectives 
The objective is to investigate ONJ clinical risk factors, in a large, multicentre 
cohort, coupled with cohort stratification according to BPs type and ONJ type, 
as well as with super-controls, all analysed using multivariable statistics. 
5.2 Methods 
This part of the study consists of a pre-analysis, the main risk factor analysis, 
followed by a post-hoc analysis. Information related to clinical risk factors was 
recorded in the CRF, then transferred into electronic spreadsheets. All 
statistical analyses were performed in Stata version 12.1 (Stata Corp., College 
Station, TX, US). 
5.2.1 Analysis cohorts 
In addition to the overall cohort which included all cases and controls, analyses 
were carried out in five more stratified cohorts (Table 22). Stratified cohorts 
were limited to zoledronate and alendronate only because others were much 
smaller, for example, the pamidronate cohort had 39 individuals only.  
There were cohorts with the exposed type ONJ cases, managed with 
zoledronate and alendronate respectively. As discussed in Chapter 4, there 
was also the zoledronate super-controls cohort. However, the number of the 
non-exposed cases (zoledronate: N=18; alendronate: N=16), as well as the 
alendronate super-controls (N=18), were too small, hence, there would not be 
analyses for these small groups.  
Risk factor analyses were carried out for each respective cohort and their 
results were summarised and compared with each other.    
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Table 22. Analysis cohorts 
Cohorts 
Overall 
cohort 
Zoledronate 
all cases 
and all 
controls 
Zoledronate 
exposed 
type cases 
and all 
controls 
Zoledronate 
all cases 
and super-
controls 
Alendronate 
all cases 
and all 
controls 
Alendronate 
exposed 
type cases 
and all 
controls 
Cases, n 393 230 208 230 109 89 
Controls, n 276 204 204 88 31 31 
Total 669 434 412 318 140 120 
 
5.2.2 Pre-risk factor analysis 
Prior to risk factor analysis, there was pre-analysis to study the differences 
across different cohorts. Phenotypic features of (i) the zoledronate users 
against the alendronate users, and (ii) the zoledronate super-controls against 
controls reviewed for less than 2.1 years were compared. Of note, ONJ types 
had already been compared in Chapter 3 and were found largely 
phenotypically similar.  
This pre-analysis served to explain the final ONJ risk factor results.  
5.2.2.1 Outcomes 
5.2.2.1.1 Primary outcome 
The primary aim was to make comparisons across different cohorts using 
descriptive statistics. The primary objective was to detect if there were any 
major differences with respect to their phenotype data. 
5.2.2.1.2 Secondary outcome 
The secondary aim was to make comparisons across the cohorts using 
inferential statistics. The objective was to detect if there were any 
phenotypically, statistically significant differences between different cohorts. 
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5.2.2.2 Statistical analysis 
5.2.2.2.1 Primary outcome 
In both comparisons, mean, median, standard deviation and range were 
calculated for numerical phenotypic data, while numbers and percentages 
were calculated for categorical data. The percentages were also plotted in a 
bar chart, constructed in Microsoft Excel 2013. 
5.2.2.2.2 Secondary outcome 
When comparing the two BPs types, the explanatory variable was zoledronate 
user=1, while alendronate user=0. As for control status, its explanatory 
variable was super-control=1 and control reviewed <2.1 years=0. Each 
phenotypic feature formed the outcome variable.  
For numerical outcome variables, random-effects linear regression was 
performed, and random-effects logistic regression for binary phenotypic data. 
The significance level for these analyses was 5%.  
Multilevel random-effects were used to account for the clustering effect 
attributed to the participants being recruited in seven countries. 
5.2.3 Risk factor analysis 
5.2.3.1 Outcomes 
5.2.3.1.1 Primary outcome 
The primary aim was to investigate the association between ONJ development 
and its previously reported potential risk factors, as discussed in Chapter 1, 
using descriptive statistics. The primary objective was to report the prevalence 
of these factors amongst the ONJ cases and BPs-exposed controls. 
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5.2.3.1.2 Secondary outcome 
The secondary aim was to investigate the association between ONJ 
development and potential risk factors, using inferential statistics. The 
objective was to detect if there were any statistically significant factors. 
5.2.3.2 Statistical analysis 
5.2.3.2.1 Primary outcome 
The prevalence of each potential risk factor amongst the cases and the 
controls was studied. Their numbers and percentages were calculated; the 
percentages were also presented in a bar chart. For numerical data including 
age and BPs duration, their mean, median, standard deviation and range were 
calculated. 
5.2.3.2.2 Secondary outcome 
The association between ONJ development and each potential risk factor was 
first investigated using random-effects univariable logistic regression. ONJ 
development, i.e. case=1 and control=0, was the outcome variable, while each 
factor formed the explanatory variable. In total, 12 factors related to 
demographics, BPs history and medical history were analysed.  
Factors that were significant at the 10% level in the univariable analysis were 
then entered together into a random-effects multivariable logistic regression, 
using a 5% significance level. Multilevel random-effects were used in both the 
univariable and multivariable analyses to account for the clustering effect 
attributed to the participants being recruited in seven countries. 
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5.2.4 Post-hoc analysis 
5.2.4.1 Outcomes 
5.2.4.1.1 Primary outcome 
The primary aim was to study the interrelationship amongst the significant 
factors identified in the current risk factor analysis, using descriptive statistics. 
The primary objective was to detect if there was any strong interrelationship 
between the factors. 
5.2.4.1.2 Secondary outcome 
The secondary aim was to study the interrelationship amongst the significant 
factors using inferential statistics. The secondary objective was to detect if 
there was any statistically significant association between any of these factors. 
5.2.4.2 Statistical analysis 
5.2.4.2.1 Primary outcome 
Two factors were studied at a time. For numerical factors data, their mean, 
median, standard deviation and range were calculated, while numbers and 
percentages were calculated for categorical data.  
5.2.4.2.2 Secondary outcome 
Similarly, two factors were studied at a time. For numerical variables, 
univariable linear regression was applied, and univariable logistic regression 
for binary variables. Multilevel random-effects were also used to account for 
the clustering effect attributed to the participants being recruited in seven 
countries. The significance level for these analyses was also 5%.    
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5.3 Results 
5.3.1 Pre-risk factor analysis  
5.3.1.1 Zoledronate users versus alendronate users 
There were 434 zoledronate users, including both cases and controls, as well 
as 140 alendronate users (Table 23).  
On average, those who had zoledronate were by approximately four years 
younger than the alendronate users. As for BPs duration, zoledronate therapy 
was by about four years shorter than that of alendronate. For the categorical 
phenotypic data, the percentages calculated were also shown in a bar chart 
(Graph 8). The major differences were with underlying diseases, ranging from 
9.0 to 92.2%, followed by gender proportion (female) (32.9%), then with use 
of antiangiogenics (24.7%). 
It was also confirmed that the zoledronate users were statistically significantly 
younger than the alendronate users (estimated coefficient -0.49 decades, 95% 
CI -0.68 to -0.29 decades, p<0.001) (Table 24). Zoledronate therapy was also 
statistically significantly shorter than that of alendronate (estimated coefficient 
-3.62 years, 95% CI -4.10 to -3.15 years, p<0.001). 
As for underlying diseases, the zoledronate group had a larger proportion of 
multiple myeloma and metastatic breast cancer patients than the alendronate 
group, both statistically significant (multiple myeloma: OR=48.44, 95% CI 
11.84 to 198.21, p<0.001; metastatic breast cancer: OR=9.87, 95% CI 4.25 to 
22.93, p<0.001). The zoledronate group also had more antiangiogenics users, 
also statistically significant (OR=9.87, 95% CI 4.25 to 22.93, p<0.001).  
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In contrast, the proportion of osteoporosis patients amongst the zoledronate 
users was statistically significantly smaller than in the alendronate group 
(OR=0.001, 95% CI 0.000 to 0.003, p<0.001). 
As for diabetes, smoking history and use of steroids, these were not found 
statistically significantly different between the two groups (p>0.05). 
Of note, as none of the alendronate users were presented with metastatic 
prostate cancer or other cancers, these two variables could not be analysed 
with logistic regressions. 
5.3.1.2 Zoledronate super-controls versus controls reviewed for less 
than 2.1 years 
There were 88 super-controls while 115 zoledronate controls were reviewed 
for less than 2.1 years (Table 25).  
The two groups shared similar age, gender proportion, and the presence of 
systemic factors. On average, the super-controls were by approximately one 
to two years younger than the other controls. Their difference in the proportion 
of female patients was of 5.8% only. For the systemic factors, difference in 
proportion ranged from 0.4 to 11.8% (Graph 9). 
However, there were 15.4% more multiple myeloma patients, but 11.0% less 
metastatic prostate cancer patients amongst the super-controls than in the 
other controls. Also, on average, the length of zoledronate therapy was by 2.13 
years longer amongst the super-controls than in controls reviewed for less 
than 2.1 years.  
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With the regression analysis, the two groups’ difference was not statistically 
significant with regard to age, gender, metastatic cancers, as well as diabetes, 
smoking, use of steroids and antiangiogenics (p>0.05) (Table 26). In particular, 
for age, the estimated coefficient was nearly zero, indicating that the super-
controls and the rest of the controls shared very similar age.  
However, there was a higher proportion of multiple myeloma patients amongst 
the super-controls (OR=1.87, 95% CI 1.06 to 3.28, p=0.030). Compared to the 
other controls, BPs duration of super-controls was by approximately two years 
longer (estimated coefficient 2.13 years, 95% CI 1.74 to 2.52 years, p<0.001).  
5.3.1.3 Summary 
It was found that the zoledronate and alendronate users were different in many 
aspects, including age, gender, underlying diseases and BPs duration. 
Chapter 3 also reported that the zoledronate and alendronate cases had 
different proportion of individuals presented with different ONJ types. In 
addition, Chapter 4 found that the two groups had different ONJ time to onset 
and follow-up time amongst the cases and controls respectively. Therefore, in 
the subsequent ONJ risk factor analysis, it is necessary to perform cohort 
stratification according to BPs type.  
As for the zoledronate super-controls and controls reviewed for less than 2.1 
years, they were found largely phenotypically similar, except mainly that the 
super-controls had longer BPs duration. With a dedicated super-control cohort 
and an all controls cohort, the contribution of super-control selection towards 
ONJ risk factor analysis could then be investigated, through follow-up time 
screening and BPs duration adjustment.  
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Table 23. Zoledronate users versus alendronate users; descriptive 
statistics 
 
Zoledronate users 
N = 434 
Alendronate users 
N = 140 
n % n % 
Age, decade Mean, median 
SD 
Range 
6.7, 6.8  
1.1 
 3.5 to 8.8  
7.1, 7.2 
1.0 
3.7 to 8.9 
Gender Female 
Male 
251 
180 
57.8% 
41.5% 
127 
13 
90.7% 
9.3% 
Primary 
underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
179 
9 
133 
74 
39 
41.2% 
2.1% 
30.6% 
17.1% 
9.0% 
2 
132 
6 
0 
0 
1.4% 
94.3% 
4.3% 
0.0% 
0.0% 
BPs duration, 
year 
Mean, median 
SD 
Range 
2.2, 1.6  
2.0 
 0.1 to 12.1  
5.9, 5.3 
3.3 
0.1 to 16.0 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
36 
90 
76 
126 
8.3% 
20.7% 
17.5% 
29.0% 
14 
29 
32 
6 
10.0% 
20.7% 
22.9% 
4.3% 
 
 
Graph 8. Zoledronate users versus alendronate users; differences in 
percentages 
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Table 24. Zoledronate users versus alendronate users; random-effects 
univariable regression 
 
N = 574; zol user=1, ale user=0 
Estimated 
coefficient 
95% CI p-value 
Demographics Age, decade -0.49 -0.68 to -0.29 <0.001* 
BPs duration, year -3.62 -4.10 to -3.15 <0.001* 
 OR 95% CI p-value 
Demographics Gender (M=0, F=1) 0.14 0.08 to 0.26 <0.001* 
Primary underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
48.44 
0.001 
9.87 
11.84 
0.000 
4.25 
to 
to 
to 
198.21 
0.003 
22.93 
<0.001* 
<0.001* 
<0.001* 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
0.85 
0.92 
0.87 
8.23 
0.43 
0.57 
0.52 
3.49 
to 
to 
to 
to 
1.65 
1.50 
1.45 
19.39 
0.623 
0.743 
0.600 
<0.001* 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       573 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      81.9 
                                                               max =       439 
 
                                                LR chi2(1)         =     23.20 
Log likelihood  = -828.93201                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------ 
   agedecade |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |  -.4854701   .0999552    -4.86   0.000    -.6813788   -.2895615 
       _cons |   7.131429   .0868905    82.07   0.000     6.961126    7.301731 
-------------+---------------------------------------------------------------- 
    /sigma_u |   1.38e-23   .0551672                             0           . 
    /sigma_e |   1.028102   .0303699                      .9702682    1.089383 
         rho |   1.80e-46   1.44e-24                             0           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.00 Prob>=chibar2 = 1.000 
 
 
 
 
 
 
Random-effects ML regression                    Number of obs      =       553 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      79.0 
                                                               max =       436 
 
                                                LR chi2(1)         =    187.61 
Log likelihood  = -1252.9492                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------------- 
durationyearplus1mo |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------------+---------------------------------------------------------------- 
            ale1zol |  -3.623507   .2414999   -15.00   0.000    -4.096838   -3.150176 
              _cons |   5.908647   .2627249    22.49   0.000     5.393716    6.423579 
--------------------+---------------------------------------------------------------- 
           /sigma_u |   .3369396    .318299                      .0528983    2.146161 
           /sigma_e |    2.32325   .0705365                      2.189034    2.465695 
                rho |   .0206002   .0382695                      .0001909    .2978102 
------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.65 Prob>=chibar2 = 0.209 
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Random-effects logistic regression              Number of obs      =       571 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      81.6 
                                                               max =       437 
 
                                                Wald chi2(1)       =     40.18 
Log likelihood  = -336.14551                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------ 
        m0f1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |   .1427345   .0438386    -6.34   0.000     .0781801    .2605922 
       _cons |   9.768454   2.844477     7.83   0.000     5.520322    17.28571 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -15.49344   69.48694                     -151.6853    120.6985 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0004322   .0150147                      1.15e-33    1.62e+26 
         rho |   5.68e-08   3.94e-06                      4.04e-67           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       574 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      82.0 
                                                               max =       439 
 
                                                Wald chi2(1)       =     29.13 
Log likelihood  = -304.61971                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------ 
          mm |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |   48.43764    34.8224     5.40   0.000     11.83707    198.2083 
       _cons |   .0144904    .010321    -5.94   0.000     .0035875    .0585281 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -14.86351   67.59564                     -147.3485    117.6215 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0005921   .0200133                      1.01e-32    3.48e+25 
         rho |   1.07e-07   7.20e-06                      3.09e-65           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       574 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      82.0 
                                                               max =       439 
 
                                                Wald chi2(1)       =    160.31 
Log likelihood  = -72.873583                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------ 
          op |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |   .0012229   .0006478   -12.66   0.000      .000433    .0034536 
       _cons |   38.16264   26.43574     5.26   0.000     9.817491    148.3462 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -.1630237   1.044889                     -2.210969    1.884921 
-------------+---------------------------------------------------------------- 
     sigma_u |   .9217218   .4815485                      .3310505    2.566288 
         rho |   .2052382   .1704376                      .0322388    .6668725 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     3.16 Prob >= chibar2 = 0.038 
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Random-effects logistic regression              Number of obs      =       574 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      82.0 
                                                               max =       439 
 
                                                Wald chi2(1)       =     28.33 
Log likelihood  = -292.21356                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------ 
         mbc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |   9.868222   4.244143     5.32   0.000     4.247687    22.92584 
       _cons |   .0447761   .0186846    -7.44   0.000     .0197629    .1014479 
-------------+---------------------------------------------------------------- 
    /lnsig2u |   -14.9814   78.29119                     -168.4293    138.4665 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0005583   .0218531                      2.67e-37    1.17e+30 
         rho |   9.47e-08   7.42e-06                      2.16e-74           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       574 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      82.0 
                                                               max =       439 
 
                                                Wald chi2(1)       =      0.24 
Log likelihood  = -169.44684                    Prob > chi2        =    0.6226 
 
------------------------------------------------------------------------------ 
          dm |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |   .8457715   .2878785    -0.49   0.623     .4340366    1.648086 
       _cons |   .1144833   .0372176    -6.67   0.000     .0605374    .2165015 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -2.309598   2.270671                     -6.760031    2.140835 
-------------+---------------------------------------------------------------- 
     sigma_u |   .3151209   .3577679                      .0340469    2.916597 
         rho |   .0292996   .0645804                      .0003522    .7211126 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.30 Prob >= chibar2 = 0.291 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       490 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      70.0 
                                                               max =       358 
 
                                                Wald chi2(1)       =      0.11 
Log likelihood  = -271.57868                    Prob > chi2        =    0.7432 
 
------------------------------------------------------------------------------ 
     smoking |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |    .922354   .2275339    -0.33   0.743     .5687431    1.495819 
       _cons |   .3411765   .0733709    -5.00   0.000     .2238341    .5200345 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -15.00241   78.63884                     -169.1317    139.1269 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0005524   .0217208                      1.88e-37    1.63e+30 
         rho |   9.28e-08   7.29e-06                      1.07e-74           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
 
 
 
116 
 
Random-effects logistic regression              Number of obs      =       574 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      82.0 
                                                               max =       439 
 
                                                Wald chi2(1)       =      0.27 
Log likelihood  = -274.77976                    Prob > chi2        =    0.6004 
 
------------------------------------------------------------------------------ 
     steroid |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |   .8721095   .2278207    -0.52   0.600     .5226514    1.455224 
       _cons |   .3629296   .1069439    -3.44   0.001     .2037043    .6466133 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -1.440503   1.130699                     -3.656631    .7756259 
-------------+---------------------------------------------------------------- 
     sigma_u |   .4866299   .2751159                       .160684    1.473754 
         rho |   .0671478   .0708258                       .007787    .3976608 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     3.62 Prob >= chibar2 = 0.029 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       574 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      82.0 
                                                               max =       439 
 
                                                Wald chi2(1)       =     23.22 
Log likelihood  =  -285.3335                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------ 
     antiang |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     ale1zol |   8.226492   3.597859     4.82   0.000     3.490932    19.38599 
       _cons |    .035678   .0172043    -6.91   0.000     .0138657    .0918035 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -2.038965   1.404621                     -4.791972    .7140426 
-------------+---------------------------------------------------------------- 
     sigma_u |   .3607817   .2533808                      .0910828    1.429066 
         rho |   .0380591   .0514241                      .0025154    .3830069 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     1.79 Prob >= chibar2 = 0.091 
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Table 25. Zoledronate super-controls versus controls reviewed for less 
than 2.1 years; descriptive statistics 
 
Zol super-controls 
N = 88 
Zol other controls 
N = 115 
n % n % 
Age, decade Mean, median 
SD 
Range 
6.4, 6.3 
1.1 
3.5 to 8.4 
6.5, 6.5 
1.2 
3.6 to 8.8 
Gender Female 
Male 
51 
37 
58.0% 
42.0% 
60 
53 
52.2% 
46.1% 
Primary 
underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
48 
1 
24 
11 
4 
54.5% 
1.1% 
27.3% 
12.5% 
4.5% 
45 
2 
31 
27 
10 
39.1% 
1.7% 
27.0% 
23.5% 
8.7% 
BPs duration, 
year 
Mean, median 
SD 
Range 
3.1, 2.4 
2.1 
0.2 to 11.4 
0.9, 0.9 
0.5 
0.1 to 2.0 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
6 
18 
17 
41 
6.8% 
20.5% 
19.3% 
46.6% 
1 
24 
18 
40 
0.9% 
20.9% 
15.7% 
34.8% 
 
 
Graph 9. Zoledronate super-controls versus controls reviewed for less 
than 2.1 years; differences in percentages 
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Table 26. Zoledronate super-controls versus controls reviewed for less 
than 2.1 years; random-effects univariable regression 
 
N = 203; super-control=1, control=0 
Estimated 
coefficient 
95% CI p-value 
Demographics Age, decade -0.05 -0.37 to 0.27 0.775 
BPs duration, year 2.13 1.74 to 2.52 <0.001* 
 OR 95% CI p-value 
Demographics Gender (M=0, F=1) 1.25 0.71 to 2.20 0.436 
Primary underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
1.87 
0.65 
0.91 
0.47 
0.50 
1.06 
0.06 
0.47 
0.22 
0.15 
to 
to 
to 
to 
to 
3.28 
7.28 
1.73 
1.00 
1.65 
0.030* 
0.726 
0.764 
0.050 
0.255 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
0.86 
0.89 
1.29 
1.64 
0.29 
0.44 
0.62 
0.93 
to 
to 
to 
to 
2.52 
1.78 
2.68 
2.89 
0.786 
0.739 
0.494 
0.090 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                LR chi2(1)         =      0.08 
Log likelihood  = -317.44673                    Prob > chi2        =    0.7749 
 
------------------------------------------------------------------------------- 
    agedecade |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |  -.0467799   .1635825    -0.29   0.775    -.3673956    .2738358 
        _cons |   5.926057   .5501489    10.77   0.000     4.847784    7.004329 
--------------+---------------------------------------------------------------- 
     /sigma_u |   .6677328   .4280959                       .190056    2.345977 
     /sigma_e |   1.140739   .0569315                      1.034439    1.257962 
          rho |   .2551964   .2449862                      .0156613    .7985627 
------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    2.64 Prob>=chibar2 = 0.052 
 
 
 
 
 
 
Random-effects ML regression                    Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                LR chi2(1)         =     91.85 
Log likelihood  = -355.69217                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------------- 
durationyearplus1mo |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------------+---------------------------------------------------------------- 
      supercontrol1 |   2.130059    .197631    10.78   0.000      1.74271    2.517409 
              _cons |   .9313044   .1301213     7.16   0.000     .6762714    1.186337 
--------------------+---------------------------------------------------------------- 
           /sigma_u |          0    .101241                             .           . 
           /sigma_e |   1.395482   .0692459                      1.266153     1.53802 
                rho |          0  (omitted) 
------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.00 Prob>=chibar2 = 1.000 
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Random-effects logistic regression              Number of obs      =       200 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         5 
                                                               avg =     100.0 
                                                               max =       195 
 
                                                Wald chi2(1)       =      0.61 
Log likelihood  =  -137.1129                    Prob > chi2        =    0.4363 
 
------------------------------------------------------------------------------- 
         m0f1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |   1.251269    .360316     0.78   0.436     .7116035    2.200204 
        _cons |   1.132278   .2134434     0.66   0.510     .7825189    1.638367 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -15.22063   125.9873                     -262.1512    231.7099 
--------------+---------------------------------------------------------------- 
      sigma_u |   .0004953   .0312017                      1.19e-57    2.07e+50 
          rho |   7.46e-08   9.40e-06                      4.3e-115           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      4.73 
Log likelihood  = -137.60553                    Prob > chi2        =    0.0296 
 
------------------------------------------------------------------------------- 
           mm |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |   1.866884   .5357084     2.18   0.030     1.063806    3.276215 
        _cons |   .6427944   .1228204    -2.31   0.021     .4420087    .9347884 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -17.84907   131.3971                     -275.3827    239.6845 
--------------+---------------------------------------------------------------- 
      sigma_u |   .0001331   .0087434                      1.59e-60    1.11e+52 
          rho |   5.38e-09   7.07e-07                      7.7e-121           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      0.12 
Log likelihood  = -15.557712                    Prob > chi2        =    0.7263 
 
------------------------------------------------------------------------------- 
           op |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |   .6494178   .8007071    -0.35   0.726     .0579463    7.278182 
        _cons |    .017701   .0126261    -5.66   0.000     .0043736    .0716409 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -13.88066   130.7024                     -270.0527    242.2914 
--------------+---------------------------------------------------------------- 
      sigma_u |    .000968   .0632568                      2.28e-59    4.10e+52 
          rho |   2.85e-07   .0000372                      1.6e-118           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =  3.0e-06 Prob >= chibar2 = 0.499 
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Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      0.09 
Log likelihood  = -117.66111                    Prob > chi2        =    0.7636 
 
------------------------------------------------------------------------------- 
          mbc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |   .9053199   .2993924    -0.30   0.764     .4734856    1.731001 
        _cons |   1.023834   1.064039     0.02   0.982     .1335371    7.849769 
--------------+---------------------------------------------------------------- 
     /lnsig2u |    .324526   1.475223                     -2.566858     3.21591 
--------------+---------------------------------------------------------------- 
      sigma_u |    1.17617   .8675561                      .2770856     4.99259 
          rho |   .2960203   .3074251                       .022805    .8834035 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     1.86 Prob >= chibar2 = 0.087 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      3.84 
Log likelihood  = -95.829741                    Prob > chi2        =    0.0501 
 
------------------------------------------------------------------------------- 
          mpc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |   .4655924   .1817129    -1.96   0.050     .2166687    1.000497 
        _cons |   .3067543   .0674904    -5.37   0.000     .1993031    .4721363 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -14.72752   125.3469                      -260.403     230.948 
--------------+---------------------------------------------------------------- 
      sigma_u |   .0006338   .0397232                      2.85e-57    1.41e+50 
          rho |   1.22e-07   .0000153                      2.5e-114           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      1.29 
Log likelihood  =  -50.24736                    Prob > chi2        =    0.2554 
 
------------------------------------------------------------------------------- 
           oc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |         .5   .3047247    -1.14   0.255     .1514278    1.650951 
        _cons |   .0952381   .0315185    -7.11   0.000     .0497864    .1821843 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -15.06212   149.4056                     -307.8917    277.7674 
--------------+---------------------------------------------------------------- 
      sigma_u |   .0005362   .0400533                      1.39e-67    2.07e+60 
          rho |   8.74e-08   .0000131                      5.9e-135           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
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Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      0.07 
Log likelihood  = -53.471739                    Prob > chi2        =    0.7858 
 
------------------------------------------------------------------------------- 
           dm |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |   .8617989   .4716094    -0.27   0.786     .2948464     2.51893 
        _cons |   .0848842   .0294747    -7.10   0.000     .0429794    .1676458 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -14.26258   126.9207                     -263.0225    234.4973 
--------------+---------------------------------------------------------------- 
      sigma_u |   .0007997   .0507485                      7.68e-58    8.33e+50 
          rho |   1.94e-07   .0000247                      1.8e-115           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       184 
Group variable: country                         Number of groups   =         1 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =       6.0 
                                                               max =         6 
 
                                                Wald chi2(1)       =      0.11 
Log likelihood  =  -126.6014                    Prob > chi2        =    0.7386 
 
------------------------------------------------------------------------------- 
supercontrol1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
      smoking |   .8884613   .3148638    -0.33   0.739     .4435875    1.779499 
        _cons |    .844157   .1421902    -1.01   0.315     .6068011    1.174357 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -14.35137   44.35143                     -101.2786    72.57583 
--------------+---------------------------------------------------------------- 
      sigma_u |    .000765   .0169635                      1.02e-22    5.75e+15 
          rho |   1.78e-07   7.89e-06                      3.15e-45           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      0.47 
Log likelihood  = -93.084287                    Prob > chi2        =    0.4939 
 
------------------------------------------------------------------------------- 
      steroid |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |    1.29028   .4807017     0.68   0.494      .621675    2.677961 
        _cons |    .185516   .0476158    -6.56   0.000     .1121777    .3068008 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -14.52757   124.3208                     -258.1918    229.1367 
--------------+---------------------------------------------------------------- 
      sigma_u |   .0007005   .0435404                      8.60e-57    5.71e+49 
          rho |   1.49e-07   .0000185                      2.2e-113           1 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
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Random-effects logistic regression              Number of obs      =       203 
Group variable: country                         Number of groups   =         2 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =     101.5 
                                                               max =       197 
 
                                                Wald chi2(1)       =      2.88 
Log likelihood  = -135.09266                    Prob > chi2        =    0.0896 
 
------------------------------------------------------------------------------- 
      antiang |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
supercontrol1 |   1.635638   .4740535     1.70   0.090     .9267986    2.886617 
        _cons |   .5333334   .1044209    -3.21   0.001     .3633647    .7828072 
--------------+---------------------------------------------------------------- 
     /lnsig2u |  -16.82379   1097.172                     -2167.242    2133.594 
--------------+---------------------------------------------------------------- 
      sigma_u |   .0002222   .1219007                             0           . 
          rho |   1.50e-08   .0000165                             0           . 
------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
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5.3.2 Risk factor analysis 
5.3.2.1 Overall cohort 
This cohort consisted of all 669 individuals, including 393 cases and 276 
controls (Table 27). On average, the cases were by three to four years older 
than the controls, and their BPs duration was by about a year longer than the 
controls. The prevalence of other ONJ risk factors was also calculated (Table 
27, Graph 10). The prevalence of use of antiangiogenics amongst the cases 
and the controls were 14.5% and 34.1% respectively, resulting in a difference 
of 19.6%. Other major differences were with underlying diseases, up to 17.1%, 
and about 15.4-16.5% for BPs type. The rest differed by less than 10%. 
In the univariable random-effects logistic regression, the following explanatory 
variables were significant at the 10% level: age, multiple myeloma, 
zoledronate, BPs duration and use of antiangiogenics (Table 28). These 
factors were then entered together into a multivariable random-effects logistic 
regression. After adjusting for other covariates, three factors remained 
statistically significant at the 5% level (Table 29). First, an increase in age by 
10 years was associated with an increase in the odds of ONJ development by 
56% (95% CI 1.27 to 1.91, p<0.001). Second, an increase in BPs duration by 
a year was associated with an increase in the odds of having ONJ by 13% 
(95% CI 1.03 to 1.24, p=0.009). However, risk of ONJ was by 56% lower 
amongst those managed with antiangiogenics, than those who were not (95% 
CI 0.27 to 0.74, p=0.002).  
Of note, gender, multiple myeloma and metastatic cancers, zoledronate, as 
well as potential systemic risk factors including diabetes, smoking history and 
use of steroids were all not statistically significant (p>0.05). 
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5.3.2.2 Zoledronate all cases and all controls 
About 65% of the participants were managed with zoledronate and there were 
230 cases and 204 controls in this cohort (Table 30).  
Similar to the overall cohort, the zoledronate cases were also by approximately 
three to four years older than the controls. Cases’ duration on zoledronate was 
by approximately 0.5 years longer than the controls. Between the two groups, 
the major difference in the prevalence of ONJ risk factors was with use of 
antiangiogenics (cases: 19.1%; controls: 40.2%) (Graph 11). The rest differed 
by less than 10%. 
In the univariable random-effects logistic regression, explanatory variables 
that were significant at the 10% level are: age, other cancers, BPs duration 
and use of antiangiogenics (Table 31). 
Similar to the previous model, age, BPs duration and use of antiangiogenics 
remained statistically significant in the multivariable logistic regression 
(p<0.05) (Table 32). Individuals who were older, or managed with a longer 
length of BPs had higher odds of having ONJ (age: adjusted OR=1.64, 95% 
CI 1.31 to 2.07, p<0.001; BPs duration: adjusted OR=1.14, 95% CI 1.01 to 
1.28, p=0.029). Whereas antiangiogenics was again a protective factor 
(adjusted OR=0.37, 95% CI 0.21 to 0.63, p<0.001). After adjusting for other 
covariates, underlying diseases became statistically not significant (p>0.05). 
5.3.2.3 Zoledronate exposed type cases and all controls  
208 exposed type ONJ cases were compared with 204 controls who were also 
managed with zoledronate.  
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In the univariable regression, same variables which were significant at the 10% 
level in the previous zoledronate model were also significant in the current 
cohort (Table 33). They were age, other cancers, BPs duration and use of 
antiangiogenics. These variables were then entered together into a 
multivariable regression.  
Age, BPs duration and use of antiangiogenics remained statistically significant 
(p<0.05) (Table 34). First, an increase in age by 10 years was associated with 
an increase in the odds of ONJ development by 63% (95% CI 1.29 to 2.07, 
p<0.001). Second, an increase in BPs duration by a year was associated with 
an increase in the odds of having ONJ by 16% (95% CI 1.03 to 1.30, p=0.017). 
Finally, antiangiogenics was again a protective factor (adjusted OR=0.38, 95% 
CI 0.22 to 0.67, p=0.001). 
On the other hand, other potential risk factors including gender, underlying 
diseases, diabetes, smoking history and use of steroids were all not 
statistically significant (p>0.05). 
5.3.2.4 Zoledronate all cases and super-controls 
There were 230 cases and 88 super-controls in the current cohort (Table 35). 
Super-controls carry a lower risk of ONJ development, i.e. a lower risk of being 
“false-controls”, and their details and selection criteria can be found in the 
previous chapter. 
As reported in 5.3.1.2, the super-controls were found largely phenotypically 
similar to those who were reviewed for less than 2.1 years, except the super-
controls were presented with a larger proportion of multiple myeloma patients, 
and were also on a significantly longer length of zoledronate therapy.  
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Therefore, BPs duration of the controls was adjusted through super-controls 
selection. In the final case-control multivariable random-effects logistic 
regression, the statistically significant factors identified were: age, other 
cancers and antiangiogenics (p<0.05) (Table 36).  
Similar to the two previous zoledronate models, an increase in age by 10 years 
was associated with an increase in the odds of ONJ development by 72%  
(95% CI 1.26 to 2.34, p=0.001). Individuals who were on BPs for other cancers 
had 3.87 the odds of ONJ, compared to the multiple myeloma patients (95% 
CI 1.16 to 12.84, p=0.027). Lastly, once again, antiangiogenics was a 
protective factor (adjusted OR=0.27, 95% CI 0.14 to 0.53, p<0.001). 
5.3.2.5 Alendronate all cases and all controls 
The alendronate cohort had 109 cases versus 31 controls (Table 37). On 
average, the cases were by two to four years older than the controls, and their 
BPs duration was by about one to two years longer than the controls. The 
major differences in the prevalence of ONJ risk factors between the two groups 
were use of steroids and smoking (Graph 12). The prevalence of use of 
steroids amongst the cases and the controls were 28.4% and 3.2% 
respectively, resulting in a difference of 25.2%. As for history of smoking, 
23.9% of cases and 9.7% of controls were current or previous smokers, 
resulting in a difference of 14.2%. The rest differed by less than 10%. 
Of note, none of the alendronate patients were presented with metastatic 
prostate cancers and there were no alendronate controls presented with 
multiple myeloma. Therefore, statistically, it would not be possible to analyse 
underlying diseases as a risk factor in the following alendronate cohorts. 
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Similarly, as none of the alendronate controls were managed with concomitant 
antiangiogenics, due to statistical consideration, this variable would also be 
excluded. So, six factors including age, gender, alendronate duration, 
diabetes, smoking and use of steroids were analysed in the two alendronate 
cohorts.  
In the univariable regressions, age, BPs duration and use of steroids were 
significant at the 10% level (Table 38). When entered together into the final 
multivariable random-effects logistic regression, only use of steroids remained 
statistically significant (p<0.05) (Table 39). Individuals who were on steroids 
had 9.61 the odds of ONJ development, compared to those who were not on 
the medication (95% CI 1.19 to 77.49, p=0.034).  
Of note, age, gender, BPs duration, as well as potential systemic risk factors 
including diabetes and smoking history were all not statistically significant 
(p>0.05). 
5.3.2.6 Alendronate exposed type cases and all controls  
89 exposed type ONJ cases and 31 controls who were also managed with 
alendronate were analysed.  
Very similar to the previous model in 5.3.2.5, age, BPs duration and the use 
of steroids were again significant at the 10% level in the univariable 
regressions (Table 40). In the final multivariable random-effects logistic 
regression, again, only use of steroids remained statistically significant 
(p<0.05) (Table 41). The odds of ONJ development amongst the steroids 
patients, versus those who were not, was 12.07 (95% CI 1.45 to 100.22, 
p=0.021).  
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Similarly, variables including age, gender, BPs duration, diabetes and smoking 
were all not statistically significant (p>0.05).  
5.3.2.7 Summary 
In general, the overall and the zoledronate cohorts shared similar results. The 
four overall and zoledronate cohorts all found age as a statistically significant 
risk factor and antiangiogenics a significant protective factor for ONJ (Table 
42). BPs duration was also found a significant risk factor in the overall cohort, 
the zoledronate all cases and controls cohort and the zoledronate exposed 
type cases cohort, except in the zoledronate super-control cohort. However, 
other cancers was found a significant risk factor in the zoledronate super-
control cohort. 
The two alendronate cohorts had different results from the overall and the 
zoledronate cohorts. Only one risk factor, use of steroids, was identified.  
Other potential risk factors, including gender, underlying diseases except other 
cancers, diabetes and smoking were not found statistically significant in the 
overall and all stratified cohorts.  
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Table 27. Overall cohort; descriptive statistics 
 
Cases  
N = 393 
Controls 
N = 276 
n % n % 
Age, decade Mean, median 
SD 
Range 
6.9, 7.0  
0.9 
3.7 to 8.9   
6.6, 6.6 
1.1 
3.5 to 8.8   
Gender Female 
Male 
278 
115 
70.7% 
29.3% 
168 
101 
60.9% 
36.6% 
Primary 
underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
103 
137 
89 
37 
27 
26.2% 
34.9% 
22.6% 
9.4% 
6.9% 
107 
49 
63 
38 
14 
38.8% 
17.8% 
22.8% 
13.8% 
5.1% 
BPs with longest 
duration 
Zoledronate 
Alendronate 
230 
109 
58.5% 
27.7% 
204 
31 
73.9% 
11.2% 
BPs duration, 
year 
Mean, median 
SD 
Range 
3.7, 2.8 
3.1 
0.1 to 19.9 
2.6, 1.7 
2.8 
0.1 to 20.4 
Systemic factor Diabetes 
Smoking 
Steroids 
Antiangiogenics 
36 
81 
82 
57 
9.2% 
20.6% 
20.9% 
14.5% 
19 
47 
42 
94 
6.9% 
17.0% 
15.2% 
34.1% 
 
 
Graph 10. Overall cohort; differences in percentages 
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Table 28. Overall cohort risk factor analysis; random-effects univariable 
logistic regression 
Variable 
N = 669; case=1, control=0 
OR 95% CI p-value 
Demographics Age, decade 
Gender (M=0, F=1) 
1.48 
1.31 
1.25 
0.92 
to 
to 
1.76 
1.85 
<0.001 
0.136 
Primary underlying 
disease 
 Osteoporosis (reference) 
Multiple myeloma 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
0.59 
0.85 
0.61 
1.37 
0.38 
0.52 
0.34 
0.65 
to 
to 
to 
to 
0.94 
1.39 
1.11 
2.89 
0.025 
0.524 
0.106 
0.411 
BPs with longest 
duration 
 Alendronate (reference) 
Zoledronate 0.47 0.29 to 0.75 0.002 
BPs duration, year 1.12 1.05 to 1.19 <0.001 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
1.22 
1.32 
1.20 
0.39 
0.66 
0.85 
0.77 
0.26 
to 
to 
to 
to 
2.27 
2.05 
1.87 
0.58 
0.530 
0.216 
0.421 
<0.001 
* Significant results, p<0.1 
Table 29. Overall cohort risk factor analysis; random-effects 
multivariable logistic regression 
Variable 
N = 669; case=1, control=0 
Adjusted 
OR 
95% CI p-value 
Demographics Age, decade 1.56 1.27 to 1.91 <0.001* 
Primary underlying 
disease 
 Osteoporosis (reference) 
Multiple myeloma 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
1.10 
1.19 
0.68 
2.44 
0.32 
0.37 
0.19 
0.62 
to 
to 
to 
to 
3.72 
3.83 
2.42 
9.52 
0.881 
0.767 
0.555 
0.199 
BPs with longest 
duration 
 Alendronate (reference) 
Zoledronate 0.83 0.26 to 2.67 0.759 
BPs duration, year 1.13 1.03 to 1.24 0.009* 
Systemic factor Antiangiogenics 0.44 0.27 to 0.74 0.002* 
* Significant results, p<0.05  
Random-effects logistic regression              Number of obs      =       553 
Group variable: Country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         6 
                                                               avg =      79.0 
                                                               max =       436 
 
                                                Wald chi2(8)       =     48.32 
Log likelihood  =  -313.7397                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------------------ 
           control0case1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------------+---------------------------------------------------------------- 
               agedecade |   1.555517   .1631779     4.21   0.000     1.266431    1.910593 
                         | 
disease1op2mm3mbc4mpc5oc | 
                      2  |   1.097612   .6832128     0.15   0.881     .3240525     3.71777 
                      3  |   1.193194   .7104921     0.30   0.767     .3714154    3.833208 
                      4  |   .6836885    .440533    -0.59   0.555     .1933698    2.417285 
                      5  |   2.438939   1.694729     1.28   0.199     .6247873    9.520716 
                         | 
                 ale1zol |   .8334261   .4950679    -0.31   0.759     .2601599    2.669893 
     durationyearplus1mo |   1.130775    .053236     2.61   0.009     1.031104    1.240082 
                 antiang |   .4446622   .1146006    -3.14   0.002     .2683207     .736896 
                   _cons |   .6257754   .7890183    -0.37   0.710      .052865    7.407451 
-------------------------+---------------------------------------------------------------- 
                /lnsig2u |   .9894949   1.057461                     -1.083091    3.062081 
-------------------------+---------------------------------------------------------------- 
                 sigma_u |   1.640084   .8671625                      .5818483    4.622984 
                     rho |   .4498312   .2617038                      .0933045    .8666009 
------------------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    44.82 Prob >= chibar2 = 0.000 
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Table 30. Zoledronate cohort; descriptive statistics 
 
Cases  
N = 230 
Controls 
N = 204 
n % n % 
Age, decade Mean, median 
SD 
Range 
6.8, 6.9  
0.9 
3.7 to 8.8  
6.5, 6.5 
1.2 
3.5 to 8.8   
Gender Female 
Male 
139 
91 
60.4% 
39.6% 
112 
89 
54.9% 
43.6% 
Primary 
underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
85 
6 
78 
36 
25 
37.0% 
2.6% 
33.9% 
15.7% 
10.9% 
94 
3 
55 
38 
14 
46.1% 
1.5% 
27.0% 
18.6% 
6.9% 
BPs duration, 
year 
Mean, median 
SD 
Range 
2.4, 1.8 
2.1 
0.1 to 12.1 
1.9, 1.3 
1.8 
0.1 to 11.4 
Systemic factor Diabetes 
Smoking 
Steroids 
Antiangiogenics 
21 
48 
41 
44 
9.1% 
20.9% 
17.8% 
19.1% 
15 
42 
35 
82 
7.4% 
20.6% 
17.2% 
40.2% 
 
 
Graph 11. Zoledronate cohort; differences in percentages 
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Table 31. Zoledronate all cases and all controls risk factor analysis; 
random-effects univariable logistic regression 
Variable 
N = 434; case=1, control=0 
OR 95% CI p-value 
Demographics Age, decade 
Gender (M=0, F=1) 
1.46 
1.16 
1.19 
0.77 
to 
to 
1.80 
1.74 
<0.001 
0.489 
Primary underlying 
disease 
 Multiple myeloma (reference) 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
Osteoporosis 
1.42 
0.98 
2.22 
1.55 
0.87 
0.54 
1.05 
0.31 
to 
to 
to 
to 
2.30 
1.75 
4.66 
7.63 
0.158 
0.937 
0.036 
0.592 
BPs duration, year 1.15 1.04 to 1.28 0.010 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
1.25 
1.05 
0.85 
0.37 
0.60 
0.62 
0.49 
0.23 
to 
to 
to 
to 
2.61 
1.77 
1.47 
0.59 
0.544 
0.851 
0.560 
<0.001 
* Significant results, p<0.1 
Table 32. Zoledronate all cases and all controls risk factor analysis; 
random-effects multivariable logistic regression 
Variable 
N = 434; case=1, control=0 
Adjusted 
OR 
95% CI p-value 
Demographics Age, decade 1.64 1.31 to 2.07 <0.001* 
Primary underlying 
disease 
 Multiple myeloma (reference) 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
Osteoporosis 
1.05 
0.55 
2.24 
1.20 
0.60 
0.29 
0.98 
0.21 
to 
to 
to 
to 
1.86 
1.06 
5.08 
6.78 
0.864 
0.074 
0.055 
0.835 
BPs duration, year 1.14 1.01 to 1.28 0.029* 
Systemic factor Antiangiogenics 0.37 0.21 to 0.63 <0.001* 
* Significant results, p<0.05 
Random-effects logistic regression              Number of obs      =       423 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         1 
                                                               avg =      60.4 
                                                               max =       359 
 
                                                Wald chi2(7)       =     39.94 
Log likelihood  = -247.80784                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------------------ 
           control0case1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------------+---------------------------------------------------------------- 
               agedecade |   1.643162   .1929767     4.23   0.000     1.305309    2.068462 
                         | 
disease1op2mm3mbc4mpc5oc | 
                      1  |   1.201488   1.061016     0.21   0.835     .2128313    6.782705 
                      3  |   1.051046   .3049317     0.17   0.864     .5952092    1.855984 
                      4  |   .5498149   .1840336    -1.79   0.074     .2853009    1.059571 
                      5  |   2.235851   .9361492     1.92   0.055     .9841138    5.079727 
                         | 
     durationyearplus1mo |   1.137335   .0672319     2.18   0.029      1.01291    1.277044 
                 antiang |   .3668259   .1005691    -3.66   0.000     .2143355    .6278064 
                   _cons |   .8935603   1.630464    -0.06   0.951     .0250006    31.93717 
-------------------------+---------------------------------------------------------------- 
                /lnsig2u |   1.560471   1.234561                     -.8592232    3.980165 
-------------------------+---------------------------------------------------------------- 
                 sigma_u |   2.181986   1.346897                      .6507618    7.316139 
                     rho |    .591368   .2983339                      .1140452    .9420958 
------------------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    40.80 Prob >= chibar2 = 0.000 
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Table 33. Zoledronate exposed type cases and all controls risk factor 
analysis; random-effects univariable logistic regression 
Variable 
N = 412; case=1, control=0 
OR 95% CI p-value 
Demographics Age, decade 
Gender (M=0, F=1) 
1.47 
1.05 
1.19 
0.69 
to 
to 
1.81 
1.61 
<0.001 
0.807 
Primary underlying 
disease 
 Multiple myeloma (reference) 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
Osteoporosis 
1.25 
0.97 
2.17 
1.68 
0.75 
0.53 
1.01 
0.34 
to 
to 
to 
to 
2.06 
1.76 
4.62 
8.28 
0.391 
0.919 
0.046 
0.526 
BPs duration, year 1.17 1.04 to 1.30 0.007 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
1.32 
1.05 
0.97 
0.39 
0.63 
0.61 
0.56 
0.24 
to 
to 
to 
to 
2.78 
1.80 
1.68 
0.63 
0.464 
0.857 
0.916 
<0.001 
* Significant results, p<0.1 
Table 34. Zoledronate exposed type cases and all controls risk factor 
analysis; random-effects multivariable logistic regression 
Variable 
N = 412; case=1, control=0 
Adjusted 
OR 
95% CI p-value 
Demographics Age, decade 1.63 1.29 to 2.07 <0.001* 
Primary underlying 
disease 
 Multiple myeloma (reference) 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
Osteoporosis 
0.93 
0.57 
2.15 
1.33 
0.52 
0.29 
0.93 
0.24 
to 
to 
to 
to 
1.68 
1.11 
4.95 
7.55 
0.820 
0.097 
0.073 
0.746 
BPs duration, year 1.16 1.03 to 1.30 0.017* 
Systemic factor Antiangiogenics 0.38 0.22 to 0.67 0.001* 
* Significant results, p<0.05 
Random-effects logistic regression              Number of obs      =       402 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         1 
                                                               avg =      57.4 
                                                               max =       341 
 
                                                Wald chi2(7)       =     36.76 
Log likelihood  = -234.60338                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------------------ 
           control0case1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------------+---------------------------------------------------------------- 
               agedecade |   1.632859   .1975877     4.05   0.000     1.288093    2.069904 
                         | 
disease1op2mm3mbc4mpc5oc | 
                      1  |   1.332352    1.17886     0.32   0.746     .2352225    7.546733 
                      3  |   .9337199    .281048    -0.23   0.820     .5176146    1.684328 
                      4  |   .5668481    .193916    -1.66   0.097     .2899177    1.108303 
                      5  |   2.147587   .9156893     1.79   0.073     .9311403    4.953208 
                         | 
     durationyearplus1mo |   1.155636   .0699389     2.39   0.017     1.026376    1.301175 
                 antiang |   .3829983   .1078409    -3.41   0.001     .2205585    .6650738 
                   _cons |   .8207362   1.489371    -0.11   0.913     .0234179    28.76468 
-------------------------+---------------------------------------------------------------- 
                /lnsig2u |   1.555411   1.221825                     -.8393212    3.950143 
-------------------------+---------------------------------------------------------------- 
                 sigma_u |   2.176472   1.329634                      .6572698    7.207135 
                     rho |   .5901446   .2955275                      .1160716    .9404362 
------------------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    42.47 Prob >= chibar2 = 0.000 
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Table 35. Zoledronate all cases and super-controls risk factor analysis; 
random-effects univariable logistic regression 
Variable 
N = 318; case=1, control=0 
OR 95% CI p-value 
Demographics Age, decade 
Gender (M=0, F=1) 
1.61 
1.04 
1.22 
0.62 
to 
to 
2.11 
1.75 
0.001 
0.879 
Primary underlying 
disease 
 Multiple myeloma (reference) 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
Osteoporosis 
1.70 
1.73 
3.91 
2.50 
0.93 
0.78 
1.26 
0.26 
to 
to 
to 
to 
3.09 
3.81 
12.09 
23.70 
0.082 
0.176 
0.018 
0.424 
BPs duration, year 0.88 0.78 to 0.98 0.026 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
Antiangiogenics 
1.36 
1.15 
0.75 
0.28 
0.52 
0.60 
0.39 
0.16 
to 
to 
to 
to 
3.58 
2.19 
1.46 
0.49 
0.534 
0.672 
0.405 
<0.001 
* Significant results, p<0.1 
Table 36. Zoledronate all cases and super-controls risk factor analysis; 
random-effects multivariable logistic regression 
Variable 
N = 318; case=1, control=0 
Adjusted 
OR 
95% CI p-value 
Demographics Age, decade 1.72 1.26 to 2.34 0.001* 
Primary underlying 
disease 
 Multiple myeloma (reference) 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
Osteoporosis 
1.46 
0.76 
3.87 
1.22 
0.71 
0.31 
1.16 
0.12 
to 
to 
to 
to 
3.02 
1.83 
12.84 
12.76 
0.305 
0.539 
0.027* 
0.871 
BPs duration, year 0.85 0.75 to 0.96 0.012* 
Systemic factor Antiangiogenics 0.27 0.14 to 0.53 <0.001* 
* Significant results, p<0.05 
Random-effects logistic regression              Number of obs      =       308 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         1 
                                                               avg =      44.0 
                                                               max =       245 
 
                                                Wald chi2(7)       =     36.41 
Log likelihood  = -155.75418                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------------------ 
           control0case1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------------+---------------------------------------------------------------- 
               agedecade |   1.720325   .2717417     3.43   0.001     1.262278    2.344584 
                         | 
disease1op2mm3mbc4mpc5oc | 
                      1  |   1.215054    1.45772     0.16   0.871     .1157163     12.7584 
                      3  |   1.461376   .5402008     1.03   0.305     .7081309    3.015855 
                      4  |    .757711   .3418003    -0.62   0.539     .3129898    1.834328 
                      5  |   3.867291   2.368035     2.21   0.027     1.164651    12.84156 
                         | 
     durationyearplus1mo |   .8476574   .0556472    -2.52   0.012     .7453161    .9640515 
                 antiang |   .2730945   .0912799    -3.88   0.000      .141842    .5258006 
                   _cons |   .7630063   1.194809    -0.17   0.863     .0354497    16.42267 
-------------------------+---------------------------------------------------------------- 
                /lnsig2u |   .5753094   1.385041                     -2.139322     3.28994 
-------------------------+---------------------------------------------------------------- 
                 sigma_u |   1.333297   .9233355                      .3431249    5.180855 
                     rho |   .3507969   .3154271                      .0345506     .890815 
------------------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    10.95 Prob >= chibar2 = 0.000 
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Table 37. Alendronate cohort; descriptive statistics 
 
Cases  
N = 109 
Controls 
N = 31 
n % n % 
Age, decade Mean, median 
SD 
Range 
7.2, 7.2  
1.0 
3.7 to 8.9   
6.8, 7.0 
0.9 
4.7 to 8.3   
Gender Female 
Male 
98 
11 
89.9% 
10.1% 
29 
2 
93.5% 
6.5% 
Primary 
underlying 
disease 
Multiple myeloma 
Osteoporosis 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
2 
104 
3 
0 
0 
1.8% 
95.4% 
2.8% 
0.0% 
0.0% 
0 
28 
3 
0 
0 
0.0% 
90.3% 
9.7% 
0.0% 
0.0% 
BPs duration, 
year 
Mean, median 
SD 
Range 
6.1, 5.8 
3.0 
1.0 to 15.1 
4.9, 3.7 
3.8 
1.1 to 16.0 
Systemic factor Diabetes 
Smoking 
Steroids 
Antiangiogenics 
12 
26 
31 
6 
11.0% 
23.9% 
28.4% 
5.5% 
2 
3 
1 
0 
6.5% 
9.7% 
3.2% 
0.0% 
 
 
Graph 12. Alendronate cohort; differences in percentages 
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Table 38. Alendronate all cases and all controls risk factor analysis; 
random-effects univariable logistic regression 
Variable 
N = 140; case=1, control=0 
OR 95% CI p-value 
Demographics Age, decade 
Gender (M=0, F=1) 
1.52 
0.98 
0.95 
0.18 
to 
to 
2.44 
5.42 
0.078 
0.982 
BPs duration, year 1.14 0.98 to 1.32 0.087 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
1.64 
2.38 
10.59 
0.32 
0.62 
1.35 
to 
to 
to 
8.27 
9.06 
83.15 
0.552 
0.204 
0.025 
* Significant results, p<0.1 
Table 39. Alendronate all cases and all controls risk factor analysis; 
random-effects multivariable logistic regression 
Variable 
N = 140; case=1, control=0 
Adjusted 
OR 
95% CI p-value 
Demographics Age, decade 1.44 0.82 to 2.52 0.201 
BPs duration, year 1.12 0.96 to 1.31 0.137 
Systemic factor Steroids 9.61 1.19 to 77.49 0.034* 
* Significant results, p<0.05 
Random-effects logistic regression              Number of obs      =       130 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         5 
                                                               avg =      18.6 
                                                               max =        77 
 
                                                Wald chi2(3)       =      8.74 
Log likelihood  = -60.294216                    Prob > chi2        =    0.0330 
 
------------------------------------------------------------------------------------- 
      control0case1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------------+---------------------------------------------------------------- 
          agedecade |    1.44071   .4114249     1.28   0.201      .823186    2.521477 
durationyearplus1mo |   1.122129   .0870279     1.49   0.137     .9638886    1.306347 
            steroid |   9.608944   10.23406     2.12   0.034     1.191512    77.49127 
              _cons |   .1700376   .3780319    -0.80   0.425     .0021784    13.27266 
--------------------+---------------------------------------------------------------- 
           /lnsig2u |  -.9931067   1.992145                     -4.897639    2.911425 
--------------------+---------------------------------------------------------------- 
            sigma_u |   .6086248   .6062343                      .0863955    4.287538 
                rho |   .1012007   .1812037                      .0022637    .8482032 
------------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.78 Prob >= chibar2 = 0.188 
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Table 40. Alendronate exposed type cases and all controls risk factor 
analysis; random-effects univariable logistic regression 
Variable 
N = 120; case=1, control=0 
OR 95% CI p-value 
Demographics Age, decade 
Gender (M=0, F=1) 
1.59 
1.09 
0.97 
0.18 
to 
to 
2.59 
6.63 
0.064 
0.926 
BPs duration, year 1.14 0.98 to 1.33 0.086 
Systemic factor Diabetes 
Smoking (no=0, yes/ex=1) 
Steroids 
1.97 
2.17 
11.94 
0.38 
0.55 
1.51 
to 
to 
to 
10.14 
8.54 
94.45 
0.419 
0.266 
0.019 
* Significant results, p<0.1 
Table 41. Alendronate exposed type cases and all controls risk factor 
analysis; random-effects multivariable logistic regression 
Variable 
N = 120; case=1, control=0 
Adjusted 
OR 
95% CI p-value 
Demographics Age, decade 1.65 0.91 to 3.00 0.099 
BPs duration, year 1.12 0.96 to 1.31 0.151 
Systemic factor Steroids 12.07 1.45 to 100.22 0.021* 
* Significant results, p<0.05 
Random-effects logistic regression              Number of obs      =       111 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         4 
                                                               avg =      15.9 
                                                               max =        65 
 
                                                Wald chi2(3)       =      9.93 
Log likelihood  = -53.626716                    Prob > chi2        =    0.0191 
 
------------------------------------------------------------------------------------- 
      control0case1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------------+---------------------------------------------------------------- 
          agedecade |   1.652229   .5028146     1.65   0.099     .9099729    2.999937 
durationyearplus1mo |   1.119731   .0881522     1.44   0.151     .9596259    1.306549 
            steroid |   12.07205   13.03632     2.31   0.021     1.454082    100.2244 
              _cons |   .0522791   .1235148    -1.25   0.212     .0005097    5.362669 
--------------------+---------------------------------------------------------------- 
           /lnsig2u |   -.871987   1.781273                     -4.363217    2.619243 
--------------------+---------------------------------------------------------------- 
            sigma_u |   .6466219    .575905                      .1128598    3.704771 
                rho |   .1127619   .1782104                      .0038568    .8066512 
------------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     1.08 Prob >= chibar2 = 0.150 
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Table 42. Summary of risk factor analysis 
 
Overall cohort 
N = 669 
Zoledronate all 
cases and all 
controls 
N = 434 
Zoledronate 
exposed type 
cases and all 
controls 
N = 412 
Zoledronate all 
cases and 
super-controls 
N = 318 
Significant risk 
factors 
- Age 
- BPs duration 
- Age 
- BPs duration 
- Age 
- BPs duration 
- Age 
- Other cancers 
Significant 
protective 
factors 
- Antiangiogenics - Antiangiogenics - Antiangiogenics 
- Antiangiogenics 
(with BPs 
duration adjusted) 
 
 
Alendronate all 
cases and all 
controls 
N = 140 
Alendronate 
exposed type 
cases and all 
controls 
N = 120 
Significant risk 
factors 
- Steroids - Steroids 
Significant 
protective 
factors 
/ / 
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5.3.3 Post-hoc analysis 
In the overall and zoledronate cohorts, age, BPs duration, other cancers and 
antiangiogenics were found statistically significant. It would be useful to study 
the relationship between these four factors, two factors at a time, and their 
results can be found below.  
Meanwhile, as there was only one significant factor identified in the 
alendronate cohorts, i.e. use of steroids, post-hoc analysis to study the 
interrelationship between factors was not indicated.  
5.3.3.1 Relationships between age and BPs duration, other cancers, 
and antiangiogenics   
The relationship between age and BPs duration is first presented in Graph 13. 
The vertical axis represents BPs duration, in number of years, while the 
horizontal axis was age in decade. Each dot represents an individual, including 
both cases and controls. The trend line illustrates that when age increases, 
BPs duration is also found to increase.  
It was also found that age was statistically significantly associated with BPs 
duration (p=0.003) (Table 43). An increase in age by 10 years was associated 
with an increase in BPs duration by 0.34 years (95% CI 0.11 to 0.57 years). 
Concerning the relationship between age and underlying diseases, descriptive 
statistics reported that other cancers patients, mainly kidney or lung cancers, 
were the youngest (median: 65 years old), followed by metastatic breast 
cancer patients, with a median age of 66 years old. Multiple myeloma patients 
had a median age of 69 years old, while metastatic prostate cancer patients 
were the oldest (median: 73 years old) (Table 44). 
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There was also a statistically significant association between age and other 
cancers (Table 44). Patients diagnosed with other cancers, were found 
statistically significantly younger than those with multiple myeloma (p=0.004) 
and metastatic prostate cancer (p<0.001). On average, other cancers patients 
were by nearly five years younger than the multiple myeloma patients 
(estimated coefficient 0.49 decades, 95% CI 0.16 to 0.82 decades), and by 
nearly 10 years younger than the metastatic prostate cancer patients 
(estimated coefficient 0.96 decades, 95% CI 0.58 to 1.33 decades). Although 
not statistically significant, other cancers patients were also found slightly 
younger than the metastatic breast cancer patients (estimated coefficient 0.17 
decades, 95% CI -0.17 to 0.51 decades, p=0.326).  
Lastly, those who were on antiangiogenics were found younger than the non-
users, by approximately two years on average (Table 45). However, this was 
not found statistically significant (estimated coefficient -0.17 decades, 95% CI 
-0.36 to 0.02 decades, p=0.076). 
5.3.3.2 Relationships between BPs duration and other cancers, and 
antiangiogenics 
As reported above, BPs duration was longer amongst older patients. However, 
it was found shorter amongst individuals with other cancers.  
Descriptive statistics showed that metastatic prostate cancer patients had the 
shortest BPs duration (median: 1.3 years). This was followed by patients with 
other metastatic cancers, whose BPs duration median was 1.4 years. Multiple 
myeloma patients had a median of 1.8 years, while metastatic breast cancer 
patients were on the longest length of BPs (median: 2.1 years) (Table 46). 
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Inferential statistics also calculated that, on average, BPs duration amongst 
the other cancers patients was by 0.97 years shorter than in the metastatic 
breast cancer patients (95% CI 0.21 to 1.72 years, p=0.012), and by 0.60 years 
shorter than in the multiple myeloma patients, although not statistically 
significant (95% CI -0.13 to 1.33 years, p=0.107) (Table 46). However, 
metastatic prostate cancer patients had an even shorter BPs duration than 
other cancers patients, although it was also not statistically significant 
(estimated coefficient -0.33 years, 95% CI -1.16 to 0.50 years, p=0.439). 
The relationship between BPs duration and antiangiogenics, the only 
protective factor identified, was also investigated. Those prescribed with 
antiangiogenics (median: 1.8 years) had a shorter BPs duration than the non-
users (median: 2.4 years). The difference was also found statistically 
significant (estimated coefficient -1.04 years, 95% CI -1.59 to -0.48 years, 
p<0.001) (Table 47). 
5.3.3.3 Relationship between other cancers and antiangiogenics  
To recapitulate, for other cancers patients, they were found statistically 
significantly younger than the multiple myeloma and metastatic prostate 
cancer patients. They were also on significantly shorter BPs than the 
metastatic breast cancer patients.  
As for patients managed with antiangiogenics, compared with the non-users, 
their BPs duration was statistically significantly shorter. However, there was 
no significant difference in age between the two groups. 
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Lastly, it was found that metastatic breast cancer patients had the smallest 
proportion of individuals prescribed with concomitant antiangiogenics (10.8%) 
(Table 48).  This was followed by metastatic prostate cancer patients (14.7%) 
and other cancers patients (22.0%). Lastly, multiple myeloma patients had the 
largest proportion of individuals prescribed with antiangiogenics (55.2%). 
It was also found that the proportion of patients prescribed with 
antiangiogenics was statistically significantly higher amongst the multiple 
myeloma patients than in the other cancers patients (OR=4.11, 95% CI 1.86 
to 9.11, p<0.001). But the differences were not found statistically significant 
when other cancers patients were compared with metastatic breast cancer or 
prostate cancer patients (metastatic breast cancer: OR=0.43, 95% CI 0.17 to 
1.07, p=0.070; metastatic prostate cancer: OR=0.62, 95% CI 0.23 to 1.65, 
p=0.338). 
5.3.3.4 Summary 
In summary, older age, a risk factor, was associated with longer BPs duration, 
another risk factor (Table 49). However, patients with other cancers, also a 
risk factor, were found younger and were on shorter BPs therapy. On the other 
hand, patients on antiangiogenics, the only protective factor, were also on 
shorter BPs and had less individuals diagnosed with other cancers. Lastly, age 
and use of antiangiogenics were not found to be related to each other.   
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Graph 13. Relationship between age and BPs duration; descriptive 
statistics 
 
Table 43. Relationship between age and BPs duration; random-effects 
univariable linear regression 
 
Estimated 
coefficient 
95% CI p-value 
Age, decade 0.34 0.11 to 0.57 0.003* 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       643 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         8 
                                                               avg =      91.9 
                                                               max =       500 
 
                                                LR chi2(1)         =      8.59 
Log likelihood  =  -1617.063                    Prob > chi2        =    0.0034 
 
------------------------------------------------------------------------------------- 
durationyearplus1mo |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------------+---------------------------------------------------------------- 
          agedecade |   .3408038   .1159028     2.94   0.003     .1136384    .5679691 
              _cons |   1.370327    .878688     1.56   0.119    -.3518697    3.092524 
--------------------+---------------------------------------------------------------- 
           /sigma_u |   .6037081   .3382039                      .2013606    1.810004 
           /sigma_e |   2.976109    .083522                       2.81683    3.144395 
                rho |   .0395224   .0427189                      .0030963    .2191381 
------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    4.25 Prob>=chibar2 = 0.020 
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Table 44. Relationship between age and other cancers 
 Age, decade 
Estimated 
coefficient 
95% CI p-value 
Other cancers 
N = 41 
Mean; median 6.3; 6.5 
SD; range 1.1; 3.5 to 8.5 
(reference) 
Multiple myeloma 
N = 209 
Mean; median 6.8; 6.9 
SD; range 1.0; 3.7 to 8.8 
0.49 0.16 to 0.82 0.004* 
MBC  
N = 152 
Mean; median 6.4; 6.6 
SD; range 1.1; 3.5 to 8.7 
0.17 -0.17 to 0.51 0.326 
MPC  
N = 75 
Mean; median 7.2; 7.3 
SD; range 0.7; 4.7 to 8.6 
0.96 0.58 to 1.33 <0.001* 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       477 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         1 
                                                               avg =      68.1 
                                                               max =       400 
 
                                                LR chi2(3)         =     38.68 
Log likelihood  = -672.86581                    Prob > chi2        =    0.0000 
 
--------------------------------------------------------------------------------------- 
            agedecade |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
----------------------+---------------------------------------------------------------- 
disease1oc2mm3mbc4mpc | 
                   2  |   .4928414      .1692     2.91   0.004     .1612156    .8244672 
                   3  |   .1718212   .1750012     0.98   0.326    -.1711749    .5148173 
                   4  |   .9581562   .1921602     4.99   0.000     .5815291    1.334783 
                      | 
                _cons |   6.196751    .183421    33.78   0.000     5.837252    6.556249 
----------------------+---------------------------------------------------------------- 
             /sigma_u |   .1483004   .1216415                      .0297136    .7401662 
             /sigma_e |   .9879315   .0321644                      .9268597    1.053027 
                  rho |   .0220371   .0354748                      .0004246    .2449305 
--------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    1.07 Prob>=chibar2 = 0.150 
 
 
Table 45. Relationship between age and antiangiogenics 
 Age, decade 
Estimated 
coefficient 
95% CI p-value 
Non-
antiangiogenics 
users N = 518 
Mean; median 6.8; 6.9 
SD; range 1.0; 3.5 to 8.9  
(reference) 
Antiangiogenics 
users N = 150 
Mean; median 6.6; 6.7 
SD; range 1.1; 3.5 to 8.7 
-0.17 -0.36 to 0.02 0.076 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       668 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         8 
                                                               avg =      95.4 
                                                               max =       505 
 
                                                LR chi2(1)         =      3.14 
Log likelihood  =  -968.9758                    Prob > chi2        =    0.0765 
 
------------------------------------------------------------------------------ 
   agedecade |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     antiang |  -.1709936    .096428    -1.77   0.076    -.3599891    .0180019 
       _cons |   6.922934   .1185134    58.41   0.000     6.690652    7.155216 
-------------+---------------------------------------------------------------- 
    /sigma_u |   .2069043   .1169383                      .0683419    .6264006 
    /sigma_e |   1.026627   .0282773                       .972674    1.083573 
         rho |   .0390321   .0425878                      .0029784    .2194926 
------------------------------------------------------------------------------ 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    1.25 Prob>=chibar2 = 0.132 
145 
 
Table 46. Relationship between BPs duration and other cancers 
 BPs duration, year 
Estimated 
coefficient 
95% CI p-value 
Other cancers 
N = 41 
Mean; median 1.9; 1.4 
SD; range 1.5; 0.2 to 6.6 
(reference) 
Multiple myeloma 
N = 201 
Mean; median 2.5; 1.8 
SD; range 2.3; 0.1 to 13.0 
0.60 -0.13 to 1.33 0.107 
MBC  
N = 148 
Mean; median 2.9; 2.1 
SD; range 2.5; 0.1 to 12.1 
0.97 0.21 to 1.72 0.012* 
MPC  
N = 75 
Mean; median 1.6; 1.3 
SD; range 1.3; 0.1 to 6.4 
-0.33 -1.16 to 0.50 0.439 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       465 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         1 
                                                               avg =      66.4 
                                                               max =       397 
 
                                                LR chi2(3)         =     19.71 
Log likelihood  = -1022.2313                    Prob > chi2        =    0.0002 
 
--------------------------------------------------------------------------------------- 
  durationyearplus1mo |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
----------------------+---------------------------------------------------------------- 
disease1oc2mm3mbc4mpc | 
                   2  |   .6021902   .3735855     1.61   0.107    -.1300239    1.334404 
                   3  |   .9659151   .3847516     2.51   0.012     .2118159    1.720014 
                   4  |  -.3273354   .4234272    -0.77   0.439    -1.157237    .5025666 
                      | 
                _cons |   1.893618   .3404712     5.56   0.000     1.226307     2.56093 
----------------------+---------------------------------------------------------------- 
             /sigma_u |          0   .1058981                             .           . 
             /sigma_e |   2.180182   .0714826                      2.044485    2.324885 
                  rho |          0  (omitted) 
--------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.00 Prob>=chibar2 = 1.000 
 
 
Table 47. Relationship between BPs duration and antiangiogenics 
 BPs duration, year 
Estimated 
coefficient 
95% CI p-value 
Non-
antiangiogenics 
users N = 497 
Mean; median 3.5; 2.4 
SD; range 3.2; 0.1 to 20.4 
(reference) 
Antiangiogenics 
users N = 146 
Mean; median 2.3; 1.8 
SD; range 2.2; 0.2 to 13.0 
-1.04 -1.59 to -0.48 <0.001* 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       643 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         8 
                                                               avg =      91.9 
                                                               max =       500 
 
                                                LR chi2(1)         =     13.21 
Log likelihood  = -1614.7574                    Prob > chi2        =    0.0003 
 
------------------------------------------------------------------------------------- 
durationyearplus1mo |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------------+---------------------------------------------------------------- 
            antiang |  -1.035916   .2839912    -3.65   0.000    -1.592529   -.4793037 
              _cons |   3.874373    .336901    11.50   0.000     3.214059    4.534687 
--------------------+---------------------------------------------------------------- 
           /sigma_u |   .5901826   .3642284                      .1760643    1.978342 
           /sigma_e |   2.965774    .083326                      2.806874    3.133671 
                rho |   .0380917   .0454305                      .0021962     .242578 
------------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    2.50 Prob>=chibar2 = 0.057 
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Table 48. Relationship between other cancers and antiangiogenics 
 Use of antiangiogenics OR 95% CI p-value 
Other cancers 
N = 41 
N = 9; 22.0% (reference) 
Multiple myeloma 
N = 201 
N = 111; 55.2% 4.11 1.86 to 9.11 <0.001* 
MBC  
N = 148 
N = 16; 10.8% 0.43 0.17 to 1.07 0.070 
MPC  
N = 75 
N = 11; 14.7% 0.62 0.23 to 1.65 0.338 
* Significant results, p<0.05 
Random-effects logistic regression              Number of obs      =       478 
Group variable: country                         Number of groups   =         7 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         1 
                                                               avg =      68.3 
                                                               max =       400 
 
                                                Wald chi2(3)       =     76.12 
Log likelihood  =  -249.1721                    Prob > chi2        =    0.0000 
 
--------------------------------------------------------------------------------------- 
              antiang |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
----------------------+---------------------------------------------------------------- 
disease1oc2mm3mbc4mpc | 
                   2  |   4.111549   1.669348     3.48   0.000     1.855262    9.111829 
                   3  |   .4319143   .2003892    -1.81   0.070     .1739712    1.072303 
                   4  |   .6190657   .3095763    -0.96   0.338     .2323145     1.64967 
                      | 
                _cons |   .2442107   .1114292    -3.09   0.002     .0998564    .5972462 
----------------------+---------------------------------------------------------------- 
             /lnsig2u |  -2.913035   2.691662                     -8.188595    2.362525 
----------------------+---------------------------------------------------------------- 
              sigma_u |   .2330465   .3136411                      .0166675    3.258486 
                  rho |   .0162404   .0430036                      .0000844    .7634481 
--------------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =     0.07 Prob >= chibar2 = 0.392 
 
 
Table 49. Summary of post-hoc analysis 
  Significant risk factor 
Significant 
protective 
factor 
  Age BPs duration Other cancers 
Anti-
angiogenics 
Significant 
risk factor 
Age / 
Significant; 
↑ BPs duration 
~ 
 age 
Significant; 
other cancers 
~ 
 age 
Not significant 
BPs 
duration 
Significant; 
↑ age 
~ 
 BPs duration 
/ 
Significant; 
other cancers 
~ 
 BPs duration 
Significant; 
anti-
angiogenics 
~ 
 BPs duration 
Other 
cancers 
Significant; 
↑ age 
~ 
 other 
cancers 
Significant; 
↑ BPs duration 
~ 
 other 
cancers 
/ 
Significant; 
anti-
angiogenics 
~ 
 other 
cancers 
Significant 
protective 
factor 
Anti-
angiogenics 
Not significant 
Significant; 
↑ BPs duration 
~ 
 anti-
angiogenics 
Significant; 
other cancer 
~ 
 anti-
angiogenics 
/ 
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5.4 Discussion 
5.4.1 Main findings and comparison with previous studies 
5.4.1.1 Cohort stratification 
5.4.1.1.1 Overall, zoledronate and alendronate cohorts 
Results from the overall cohort were found similar to the three zoledronate 
cohorts. This may be explained by the fact that over 60% of the entire cohort 
was managed with zoledronate, hence similar significant factors were found.  
Amongst the three zoledronate cohorts, their results were similar. All three 
identified age and antiangiogenics as significant factors. BPs duration was 
also found a significant risk factor for ONJ development in two of the cohorts, 
except in the one with super-controls when BPs duration was adjusted.  
Results from the two alendronate cohorts had also been consistent, as both 
identified the use of steroids as the only significant risk factor.  
So, the significant factors identified in the zoledronate and the alendronate 
cohorts were found different. This may be explained by findings from earlier 
parts of the current study. In 5.3.1.1, it was found that the zoledronate and 
alendronate users, including both cases and controls, were largely 
phenotypically different, with respect to age, gender, underlying diseases and 
BPs duration. In Chapter 4, it was reported that both time to onset and follow-
up time were shorter amongst those on zoledronate than the alendronate 
patients. Chapter 3 also reported that their cases had different proportion of 
individuals presented with different ONJ types. Therefore, it is possible that 
ONJ related to different types of BPs may have different pathophysiology 
mechanisms.  
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This also helps prove the importance of cohort stratification. If, similar to most 
previous studies, there was only one analysis for all participants on different 
types of BPs, steroids as a risk factor amongst the alendronate patients could 
never be identified. Also, its results would be biased and can represent its 
largest group only, such as the zoledronate patients in the case of GENVABO.  
Nevertheless, cohort stratification in ONJ risk factor analysis remains new; the 
alendronate cohort was also small, in particular the alendronate-exposed 
controls. Therefore, the current findings remain preliminary. 
5.4.1.1.2 Exposed type case cohorts 
Concerning the exposed type cases cohorts, both the zoledronate and 
alendronate cohorts shared the same results with their respective all cases 
cohorts. For zoledronate, both had age and BPs duration as risk factors and 
antiangiogenics as protective factor, while the use of steroids was identified as 
a risk factor for both the alendronate all case and exposed type cases cohorts.  
This further supported findings from Chapter 3 that the exposed and non-
exposed types were similar. In other words, the inclusion of the non-exposed 
cases into the all cases cohorts did not change the statistical results. However, 
this may be explained by the fact that the majority of the cases were of the 
exposed type and the removal of approximately 20 non-exposed cases from 
each cohort, i.e. 5.1% and 14.3% respectively for the zoledronate and 
alendronate case cohorts, was not significant enough to change the final 
results. Nonetheless, this was a first attempt using an alternative approach to 
investigate whether or not the two ONJ types are similar.  
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5.4.1.1.3 Super-controls cohort 
As reported in 5.3.1.2, zoledronate super-controls, i.e. controls who had been 
reviewed for 2.1 years or longer, and controls reviewed for less than 2.1 years 
were found largely phenotypically similar. This explained the largely similar 
results shared by the zoledronate super-controls cohort and the other two 
zoledronate cohorts, i.e. age as a significant risk factor and antiangiogenics as 
a significant protective factor were reported in all three cohorts.  
However, the main difference was with BPs duration. BPs duration of super-
controls was by approximately two years longer than the other controls. 
Therefore, in the all controls cohorts, i.e. all controls managed with zoledronate 
with different follow-up time, BPs duration was found a significant risk factor 
for ONJ. When there were only super-controls, BPs duration was adjusted, or, 
it became a significant protective factor. An increase in BPs duration by a year 
was associated with a decrease in the odds of having ONJ by about 15% (95% 
CI 0.75 to 0.96, p=0.012). 
In fact, the all controls cohorts in the current study represented most previous 
ONJ risk factor studies, while the super-controls cohort illustrated the 
importance of control validation.  
As explained in Chapter 4, the criteria in control screening had been 
inconsistent in most previous studies. Also, none performed screening using 
the actual follow-up time. Therefore, these controls may have been “under-
reviewed”, i.e. the opposite of super-controls, and have a high risk of being a 
“false-control”. These controls are also more likely to have a shorter BPs 
duration (Palaska et al., 2009). As a result, BPs duration was often found 
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longer amongst the ONJ cases and was also more likely to be reported a risk 
factor, which was also the case in the two zoledronate all control cohorts in the 
current study as predicted (Thumbigere-Math et al., 2012; Sedghizadeh et al., 
2013; Tsao et al., 2013).  
Meanwhile, once with control validation, BPs duration was no longer a 
significant risk factor. This suggested that BPs duration, a traditional risk factor 
for ONJ, may not be as strong as researchers think; and it may have been 
resulted from sampling bias in most previous studies. Further discussion on 
BPs duration will continue in 5.4.1.2.1. 
Another risk factor, other cancers, not found significant in the other two 
zoledronate cohorts, became a significant risk factor in the super-controls 
cohort. This may be because, as reported in 5.3.1.2, there were fewer other 
cancers patients amongst the super-controls than the controls reviewed for 
less than 2.1 years, although the difference was not statistically significant. 
Although other cancers was significant as a risk factor (p=0.027), it had a 
relatively large standard error (2.37), and its 95% CI was also wide (1.16 to 
12.84). Therefore, this finding remains preliminary.   
In conclusion, analysing with super-controls should help minimise the risk of 
potential “false-controls” and thus yielding more robust risk factor results. 
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5.4.1.2 Significant risk factors 
5.4.1.2.1 BPs duration 
BPs duration, a traditional risk factor for ONJ, was also found a significant risk 
factor in three out of six cohorts in the current study. An increase in a year of 
BPs duration was associated with a 13 to 16% increase in the odds of having 
ONJ. This applied to the overall cohort, the zoledronate all cases and all 
controls cohort, and the zoledronate exposed type cases and all controls 
cohort.  
This had also been supported by three previous multivariable studies, 
including a large study reporting a 2.5-year difference in BPs duration between 
18 cases and 558 controls (Thumbigere-Math et al., 2012). A more recent 
study also reported a difference of 2.6 years in BPs duration between 69 cases 
and 84 controls (Sedghizadeh et al., 2013). This smaller study, with 22 cases 
and 41 controls, also found BPs duration by 1.2 years longer amongst the 
cases, which was closer to the results of the current study in which a  
difference of 1.1 years was reported in the overall cohort (Tsao et al., 2013). 
Of note, the differences in BPs duration were all statistically significant in these 
three studies. 
Although BPs duration was also found longer amongst the alendronate cases 
than the controls, unlike in the overall and the zoledronate cohorts, it was not 
found statistically significant at the multivariable level in the two alendronate 
cohorts in the current study. This may be because the length of BPs therapy 
was found statistically significantly different between the zoledronate and the 
alendronate users, as reported in the pre-risk factor analysis in 5.3.1.1, as well 
as different case-control ratio in the alendronate and the zoledronate cohorts. 
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There were also two previous multivariable studies reporting no statistically 
significant difference in BPs duration between ONJ cases and controls. They 
were Thumbigere-Math et al., 2013 and Katz et al., 2011, which studied 25 
cases and 48 controls, and 12 cases and 66 controls respectively. 
On the other hand, with regard to the post-hoc analysis in the current study, 
BPs duration was found to correlate with age, another risk factor. This applied 
to the overall cohort, the zoledronate all cases and all controls cohort, and the 
zoledronate exposed type cases and all controls cohort. However, 
interestingly, in the super-controls cohort, regardless of duration of BPs 
therapy being significantly shorter amongst the cases than the controls, the 
case patients remained significantly older.  
In summary, it remains unclear whether BPs duration is a true ONJ risk factor, 
or a confounding factor, or, as discussed in 5.4.1.1.3, it may have been 
overestimated in some cohorts and in some previous studies due to sampling 
bias involving the recruitment of the inadequately reviewed “false-controls”.      
5.4.1.2.2 Age 
Age, another risk factor identified in the current study, was significant in the 
overall and all three zoledronate cohorts. On average, the cases were by 
approximately three years older than the controls, and an increase in age by 
10 years was associated with a 56 to 72% increase in the odds of having ONJ.  
Probably because there was a significant difference in age between the 
zoledronate and the alendronate users, as reported in the pre-risk factor 
analysis, it was not found a significant risk factor in the two alendronate cohorts, 
although the alendronate cases were also found older than the controls. 
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Age as an ONJ risk factor has also been supported by two previous 
multivariable studies. Sedghizadeh et al., 2013 reported that their 69 cases 
were by six years older than the 84 controls, while a larger study, Vahtsevanos 
et al., 2009, observed a 3.6 years age difference between the 80 cases and 
1,541 controls, which was close to the results of the current study. Of note, 
both differences were statistically significant.  
However, the mechanism of how age relates to ONJ development remains 
largely unknown as this has never been formally studied. Traditionally, age 
was not perceived as an ONJ risk factor. Therefore, it was often adjusted in 
the final multivariable model with its statistical results unreported (Thumbigere-
Math et al., 2013; Tsao et al., 2013), or, matched between the cases and 
controls in some other studies (Kyrgidis et al., 2008; Wessel et al., 2008; Tsao 
et al., 2013). 
In the post-hoc analysis in the current study, it was found that age correlated 
with BPs duration, which may explain, probably due to its relationship with BPs, 
age became a significant risk factor. However, in the zoledronate super-
controls cohort, when BPs duration was no longer a risk factor, interestingly, 
the results for age remained the same. This important finding suggested that, 
age was unlikely to be a confounder and may have direct association with ONJ. 
There were also previous studies reporting that cases were younger than the 
controls, but the difference was not statistically significant (Kyrgidis et al., 2008; 
Katz et al., 2011; Thumbigere-Math et al., 2012).     
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5.4.1.2.3 Steroids 
In the two alendronate cohorts, use of steroids, an immunosuppressant, was 
found a significant risk factor. This was also supported by Thumbigere-Math 
et al., 2012, a study of 18 cases and 558 controls who were on zoledronate 
and/or pamidronate.  
However, the same did not apply to the zoledronate cohorts or the overall 
cohort in the current study. Also, even in the two alendronate cohorts, this 
finding needs to be interpreted with caution. Amongst the 109 alendronate 
cases, there were 31 patients on steroids. In contrast, there was only one 
steroid user amongst the 31 alendronate-exposed controls recruited. As a 
result, steroids, though statistically significant, showed a wide 95% CI for the 
OR (1.19 to 77.49), as well as a large standard error (10.23).  
Therefore, as summarised in a recent review, data for steroids have been 
considered occasionally positive but remained not well-proven (Campisi et al., 
2014).  
5.4.1.2.4 Other cancers 
Other cancers, mainly kidney or lung cancers, was also found a significant risk 
factor in the zoledronate super-controls cohort only in the current study. There 
were a small number of individuals presented with other cancers, i.e. 27 out of 
393 cases versus 14 out of 276 controls. As a result, its OR also showed a 
wide 95% CI (1.16 to 12.84) and a large standard error (2.37).  
In the literature, other cancers had never been reported a risk factor for ONJ 
(Wessel et al., 2008; Thumbigere-Math et al., 2012, 2013). Hence the reason 
why these patients are presented with a higher risk of ONJ remains unknown.  
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In the current post-hoc analysis, other cancers did not appear to associate 
positively with any other risk factors. First, instead of being older, these 
patients were found younger, and were also on shorter BPs, than the multiple 
myeloma, metastatic prostate, and metastatic breast cancer patients. This 
suggested that other cancers per se may have an effect towards ONJ, but its 
role as a potential risk factor remains largely preliminary. 
5.4.1.3 Significant protective factor 
5.4.1.3.1 Antiangiogenics 
From the mainstream understanding of ONJ development, antiangiogenics 
has long been considered a robust risk factor (Campisi et al., 2014). However, 
there were also studies observing no differences in the proportion of 
antiangiogenics users between the cases and controls (Thumbigere-Math et 
al., 2012; Tsao et al., 2013). Surprisingly, in the current study, the use of 
antiangiogenics was found a protective factor in the overall and the three 
zoledronate cohorts. Of note, due to statistical consideration, antiangiogenics 
was excluded from analysis in the alendronate cohorts as none of their 
controls were managed with concomitant antiangiogenics. 
Interestingly, the current post-hoc analysis found that those on 
antiangiogenics had a much shorter BPs duration than the non-users. There 
was also a smaller proportion of other cancers patients prescribed with 
antiangiogenics. As both BPs duration and other cancers were found to be risk 
factors for ONJ, this may explain why antiangiogenics appeared as a 
protective factor.  
In summary, based on these conflicting results, the role of antiangiogenics in 
ONJ development remains controversial.  
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5.4.2 Study strengths  
5.4.2.1 Well-executed cohort stratification 
Instead of different cohorts from independent studies, the present stratification 
had been done within a cohort of individuals recruited under the same criteria. 
This homogeneous setting allowed direct and fair comparison across the 
stratified cohorts.  
Each set of the stratification had been inspired by findings from previous 
Chapters. The two exposed case zoledronate and alendronate cohorts were 
created to crosscheck the outcome in Chapter 3, which further proved that the 
exposed and the non-exposed types were similar. Risk factor analysis with 
zoledronate super-controls, their selection method outlined in Chapter 4, also 
yielded interesting results and demonstrated the importance of follow-up time 
screening in controls recruitment.   
Cohort stratification has also been well supported by detailed pre-analysis, 
which studied the differences across stratified cohorts. It helped explain why 
the alendronate and zoledronate cohorts had different risk factor results as the 
alendronate and zoledronate users were found largely phenotypically different. 
Pre-analysis also helped explain why BPs duration was not found a significant 
risk factor in the zoledronate super-controls cohort, unlike other zoledronate 
cohorts, as the length of BPs therapy was found significantly longer amongst 
the super-controls than controls reviewed for less than 2.1 years. 
There was also much consideration on the cohort sizes of the stratified 
cohorts. With the clinical team’s effort in participant recruitment, GENVABO 
had a large overall cohort. It also had the largest case cohort amongst all 
157 
 
multivariable studies, which enabled different combinations of stratification. 
For the zoledronate cohorts, they all had a size larger than 300, while both 
alendronate cohorts were larger than 100. However, due to the small number 
of non-exposed cases, alendronate super-controls, as well as individuals on 
BPs other than alendronate and zoledronate, these cohorts were not 
analysed. 
In addition to the five stratified cohorts, the overall non-stratified cohort was 
still analysed, mainly for comparison with previous studies as cohort 
stratification had never been performed.  
In summary, cohort stratification has been well-executed in the current 
GENVABO study. It was also proved important in analysing ONJ risk factors, 
as discussed in 5.4.1.1. 
5.4.2.2 Robust risk factor analysis 
For all univariable, multivariable regression models, multilevel random-effects 
were used to account for the clustering effect attributed to the participants 
being recruited in seven countries. Statistical results including the ORs, 
estimated coefficients, their 95% CI and standard error, had all been 
thoroughly scrutinised and discussed. 
As ONJ is a multifactorial condition, it seemed sensible to perform 
multivariable analyses. Therefore, similar to previous large-scale ONJ risk 
factor studies, multivariable technique was also performed in the current 
analysis, which allowed the factors to be considered together in one single 
model (Vahtsevanos et al., 2009; Thumbigere-Math et al., 2012).  
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The 12 variables analysed in GENVABO covered most of the significant risk 
factors identified in the eight previous multivariable studies. Factors such as 
obesity and denture were not included, mainly because their results remain 
controversial in the literature (Campisi et al., 2014). With regard to periodontal 
disease, a significant risk factor reported in two multivariable studies with 
approximately 60 to 70 participants; it was manageable to record periodontal 
health in such small cohorts (Thumbigere-Math et al., 2013; Tsao et al., 2013). 
However, in GENVABO, it would not be feasible to accurately phenotype 
periodontal status, a chronic condition, for all 669 participants. Nonetheless, 
most sound and consistent factors were analysed in the current study. 
5.4.2.3 Novel pre-risk factor and post-hoc analyses 
Pre-risk factor and post-hoc analyses had never been performed in any of the 
multivariable studies and GENVABO was the first in designing such analyses 
to complement ONJ risk factor studies. 
Pre-risk factor analysis in the current chapter compared (i) the zoledronate 
users against the alendronate users, and (ii) the zoledronate super-controls 
against controls reviewed for less than 2.1 years. Together with the 
comparison between the exposed and the non-exposed type ONJ in Chapter 
3, these pre-analyses served to explain the risk factor results in the overall and 
all five stratified cohorts. Similar to Chapter 3, the current pre-risk factor 
analysis made thorough comparisons with regard to over 10 phenotypic 
features. There were both descriptive and inferential statistics. A bar chart was 
plotted to illustrate the difference in percentages for the variables. Multilevel 
random-effects were also used in all univariable regressions to account for the 
clustering effect. 
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As for post-hoc analysis, association between all significant risk and potential 
factors were checked and a total of six multilevel random-effects univariable 
regression tests were performed. There were also both descriptive and 
inferential statistics. A graph was plotted to visualise the positive and 
significant association between age and BPs duration. Table 49 was also 
constructed to summarise the interrelationship of all significant factors. 
Multilevel random-effects were also used in all univariable regressions to 
account for the clustering effect. 
The key strength of post-hoc analysis has been generating additional 
information. For instance, both GENVABO and Sedghizadeh et al., 2013 
identified age and BPs duration as risk factors. However, only GENVABO 
could prove that the two factors were related positively and significantly with 
each other. Furthermore, for factors of similar nature, it would be interesting to 
see if there were any interaction between each other using post-hoc analysis. 
The current study investigated thoroughly the relationships between other 
cancers, BPs duration and concomitant antiangiogenics, which were all 
related to underlying diseases and BPs therapy. Unfortunately, there were no 
such analyses in Wessel et al., 2008 and Thumbigere-Math et al., 2012; and 
the interrelationship between ONJ, smoking, diabetes and obesity, which were 
all life-style related factors, remained unknown. 
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5.4.3 Study limitations 
5.4.3.1 Osteoporosis and alendronate patients 
There were 88 less osteoporotic controls than cases. There were also 78 fewer 
alendronate controls than cases; and even fewer alendronate super-controls, 
making additional risk factor analysis with these super-controls impractical. 
This may be explained by the low incidence of ONJ amongst osteoporotic and 
alendronate patients (Kühl et al., 2012), which may cause a low follow-up rate 
for ONJ screening, leading to the small number of controls available for 
recruitment into the GENVABO study. However, the current participants had 
already been recruited under a multicentre setting, which has been most 
effective in recruiting large number of patients.  
In May 2013, a proposal was drafted and submitted to the Department of Twin 
Research at King’s College London. It was for permission to access its 
database of a large registry with osteoporotic patients (Moayyeri et al., 2013). 
Unfortunately, Twin Research replied that they had no dental records for these 
patients and the proposal was rejected. Otherwise, it would have been ideal 
to also include these patients into the GENVABO study. 
5.4.3.2 BPs duration 
BPs duration was recorded and analysed as a surrogate variable for 
cumulative BPs dose in the current study. As there were patients prescribed 
with different types of BPs, this may present a problem when all participants 
were analysed together in the overall cohort, e.g. the same duration of 
zoledronate and alendronate does not imply the same cumulative BPs dose. 
However, it is completely different in the stratified cohorts. When the 
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participants were grouped according to their BPs type, their BPs duration 
should then be roughly proportional to their cumulative BPs dose. It was 
because the dose of the same BPs type is usually similar (Ruggiero et al., 
2014). For instance, alendronate is usually prescribed as 10mg a day, or 70mg 
per week. Zoledronate is usually prescribed as 4mg per three weeks, except 
for few osteoporotic patients who were prescribed with 5mg per year. 
With regard to phenotyping of BPs dose, it requires detailed medical records 
and its calculation may not be familiar to many dental clinicians. In contrast, 
BPs duration requires a start and an end date only, which is much more 
convenient and accurate in phenotyping. Moreover, the literature found that 
BPs duration was as strong an ONJ risk factor as BPs dose (Campisi et al., 
2014). Therefore, it is considered appropriate to analyse BPs duration in 
replacement of cumulative BPs dose, provided that cohort stratification 
according to BPs type has been performed. 
5.4.3.3 Systemic factors and other potential factors 
Four systemic factors were studied: they were diabetes, smoking, use of 
steroids and antiangiogenics. Details such as the severity and control of 
diabetes, blood glucose level, and dosage of concomitant medications were 
not recorded, mainly because data collection of such information may 
complicate clinical phenotyping and discourage participation from clinical 
centres. Nevertheless, the presence or absence of diabetes history, current or 
previous smoking history, presence or absence of concomitant medication use 
had all been thoroughly phenotyped and analysed in GENVABO, which was 
comparable to previous ONJ risk factor studies (Wessel et al., 2008; Katz et 
al., 2011; Thumbigere-Math et al., 2012). 
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Regardless of such convenient clinical phenotyping, data for smoking were 
missing in 97 individuals. Fortunately, the p-value for smoking was greater 
than 0.1 at the univariable level in all six cohorts and was excluded from the 
final multivariable model. Therefore, the final results of these cohorts had not 
been affected by the missing data. On the other hand, data for diabetes, 
steroids and antiangiogenics were all complete.  
One major limitation has been the missing data on dentoalveolar surgery 
history amongst the controls due to an issue with the CRF design. However, 
unlike smoking, dental extraction is considered a strong risk factor and is going 
to be present in the final multivariable model and influence the final results 
(Campisi et al., 2014). In response, the clinical team leaders were contacted 
and retrieval of such information is still in progress. Regrettably, it is impossible 
to include this dental factor at the time of writing. However, its analysis in 
GENVABO may still be possible in the near future. 
As discussed in 5.4.2.2, some factors were not analysed in the current study. 
However, it is not possible to include every single potential factor and some 
weak factors may even affect the accuracy of the results. All in all, GENVABO 
analysed the majority of the important factors and the outcome was generally 
reliable and helpful in understanding the development of ONJ.    
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5.5 Links to other Chapters 
This Chapter further supports findings from Chapter 3 that the exposed and 
non-exposed types are similar, i.e. the inclusion of the non-exposed cases into 
the all cases cohorts did not change its risk factor analysis results. 
BPs duration was not found a significant risk factor in the super-control cohort, 
i.e. controls who had been reviewed for 2.1 years or longer, investigated in 
Chapter 4. This suggested that BPs duration may have been overestimated in 
some previous studies, possibly due to the recruitment of the inadequately 
reviewed controls, who were also more likely to have a shorter BPs duration. 
Age, BPs duration, the use of steroids and other cancers were identified as 
significant risk factors in this Chapter, while the use of antiangiogenics was the 
only significant protective factor. Further search for genetic risk factor 
continues in Chapter 6.  
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6 Genetic Risk Factors 
 
 
 
CHAPTER 6 
Genetic Risk Factors 
 
ONJ cases versus population controls; 
Replication cases versus discovery cases 
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6.1 Introduction 
6.1.1 Literature review 
6.1.1.1 ADR pharmacogenetics 
Inter-individual genetic variants are known to determine potential disparate 
responses to medications, including toxicity. It was estimated in a systematic 
review that genetic variability could contribute to ADR development in more 
than half of the medications examined (Phillips et al., 2001). Examples of 
genetic factors contributing to individuals’ susceptibility to ADR include HLA-
B*15:02 for carbamazepine-induced Stevens-Johnson syndrome (SJS) 
(Chung et al., 2004), SLCO1B1 for statin-induced myopathy (Link et al., 2008), 
and HLA-B*57:01 for abacavir-induced hypersensitivity reactions 
(Hetherington et al., 2002; Mallal et al., 2002). 
Therefore, in addition to clinical risk factors, genetic variants may also 
contribute to ONJ development. In the past few years, there have been a 
number of pharmacogenetic studies on ONJ (Sarasquete et al., 2008; English 
et al., 2010; Katz et al., 2011; Arduino et al., 2011; Di Martino et al., 2011; 
Marini et al., 2011; Such et al., 2011; Nicoletti et al., 2012; La Ferla et al., 2012; 
Balla et al., 2012; Stockmann et al., 2013). 
Due to wider genome coverage and the advantage of being hypothesis-free, 
GWAS are considered more powerful than candidate gene studies (Tabor et 
al., 2002; Kraft et al., 2009). However, in ONJ, there are currently only two 
GWAS (Sarasquete et al., 2008; Nicoletti et al., 2012). Possibly due to their 
relatively small cohort sizes, no genome-wide significant variants were 
identified. 
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6.1.1.2 Extreme phenotyping 
Having small cohorts also made extreme phenotyping impossible. It refers to 
focusing on individuals with extreme phenotype, i.e. more extreme disease 
behaviour, so as to enhance the efficiency in identifying genetic variants (Li et 
al., 2011).   
Extreme phenotyping has been commonly practised in ADR GWAS. In the 
case of statin-induced myopathy, there were separate analyses according to 
myopathy type (Link et al., 2008). The OR of SLCO1B1 rs4149056 amongst 
patients with incipient myopathy, who may or may not have muscle symptoms, 
was 9.6. Whereas in definite myopathy, all are presented with muscle 
symptoms and the OR became much higher (OR=27.2). In another GWAS on 
phenytoin-related severe cutaneous adverse reactions, the OR of CYP2C9*3 
was 11.96 amongst the SJS and toxic epidermal necrolysis patients (Chung 
et al., 2014). This was slightly higher than the OR amongst the less extreme 
DRESS patients, i.e. drug reactions with eosinophilia and systemic symptoms 
(OR=9.22).  
In a study on carbamazepine-induced skin reactions, extreme phenotyping 
was also performed and only SJS patients were analysed (Chung et al., 2004). 
It yielded a very strong marker, HLA-B*15:02 (OR=895). As a result, its 
screening prior to carbamazepine therapy is now recommended by the FDA 
(Leckband et al., 2013).  
Prior to GENVABO, extreme phenotyping had never been attempted in GWAS 
on ONJ, which may further explain why no genome-wide significant variants 
were identified (Sarasquete et al., 2008; Nicoletti et al., 2012).      
167 
 
6.1.1.3 Replication study 
Another important aspect of GWAS is the need to replicate results in an 
independent population with similar phenotype. This is considered the gold 
standard in minimising potential technical or methodological bias, leading to 
any spurious association signal in the discovery GWAS (McCarthy et al., 2008; 
Bush and Moore, 2012). 
In the literature, it was found that replication studies had also been routinely 
performed in ADR GWAS. For instance, Link et al., confirmed the association 
of SLCO1B1 with statin-induced myopathy in its candidate gene replication 
study. There was also replication to support its discovery GWAS results in 
phenytoin-related severe cutaneous adverse reactions (Chung et al., 2014). 
In ONJ, four candidate gene studies attempted to replicate association with 
rs1934951 in gene CYP2C8 suggested by Sarasquete et al., 2008 (English et 
al., 2010; Katz et al., 2011; Such et al., 2011; Balla et al., 2012). However, 
participants in these studies had different phenotype from the discovery 
GWAS, regarding ethnicity, underlying disease and BPs history. Therefore, 
none found CYP2C8 a significant genetic risk factor. On the other hand, there 
remains no attempted replication for gene RBMS3 suggested by Nicoletti et 
al., 2012. 
6.1.2 Objectives 
The objective is to investigate ONJ genetic risk factors, in a large, multicentre, 
well-phenotyped cohort, coupled with extreme phenotyping. The other 
objective is to test whether the replication cohort cases are phenotypically 
similar to the discovery cohort cases. 
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6.2 Methods 
This part of the study involves GWAS discovery analysis, designed and 
performed by the GENVABO genetic team. Later, the replication case cohort 
was compared with the discovery case cohort, designed and performed by the 
author from the clinical team.  
6.2.1 GWAS discovery analysis 
6.2.1.1 Outcome 
The aim of the GWAS was to investigate the association between ONJ 
development and genetic factors. The objective was to detect if there were any 
genome-wide significant genetic factors. 
6.2.1.2 Statistical analysis 
358 Caucasian cases were matched with 2,554 Caucasian population 
controls. Genotyping of SNPs and CNVs using 1,072,820 probes was 
performed. Associations between genetic variants and ONJ were tested using 
logistic regression and Fisher’s Exact test through PLINK, a statistical software 
for GWAS. The genome-wide significance threshold was 5E-8. GWAS result 
provided by the genetic team as of 9 October 2014 is presented below in 6.3.1. 
6.2.2 Replication cohort analysis 
6.2.2.1 Outcomes 
6.2.2.1.1 Primary outcome 
The primary aim was to compare the discovery and replication case cohorts 
using descriptive statistics. The primary objective was to detect if there were 
any major numerical differences in their phenotype data. 
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6.2.2.1.2 Secondary outcome 
The secondary aim was to compare the two cohorts using inferential statistics. 
The objective was to detect if there were any phenotypically, statistically 
significant differences between the discovery and the replication cohorts. 
6.2.2.2 Statistical analysis 
All analyses were performed in Stata version 12.1 (Stata Corp., College 
Station, TX, US). 
6.2.2.2.1 Primary outcome 
For numerical data, including age, BPs duration and ONJ onset time, their 
mean, median, standard deviation and range were calculated. For categorical 
data, including gender, underlying disease, BPs type and ONJ features, 
numbers and percentages were calculated. The percentages calculated were 
also plotted in a bar chart, constructed in Microsoft Excel 2013. 
6.2.2.2.2 Secondary outcome 
The explanatory variable was discovery case=0 and replication case=1, and 
each phenotypic feature formed the outcome variable.  
The association between the explanatory variable and each numerical 
outcome variable, including age, BPs duration and onset time, was 
investigated with random-effects univariable linear regression. Random-
effects univariable logistic regression was used for binary outcome variables, 
including gender, underlying disease, BPs type, dentoalveolar surgery history 
and ONJ type. 
Multilevel random-effects were used to account for the clustering effect 
attributed to the participants being recruited in eight countries. The 
significance level for these analyses was 5%.  
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6.3 Results 
6.3.1 GWAS results 
6.3.1.1 Discovery cohort 
With all 358 Caucasian cases compared with 2,554 Caucasian population 
controls, i.e. individuals not exposed to BPs whose anonymous genotype data 
had been collected in previous studies and their database was made available 
for research purpose, although two top SNPs were found, both were not 
genome-wide significant (p>5E-8).    
Table 50 summarises the two top SNPs found and the Manhattan plot 
illustrates the results of the GWAS (Figure 5). The y-axis stands for the –log10 
of the p-value and the horizontal dotted line indicates the genome-wide 
significance threshold, 5E-8. The x-axis records the chromosome position of 
the SNPs, while each dot in the plot represents a SNP. The two top SNPs at 
chromosomes 14 and 15, just below the horizontal dotted line, are highlighted 
in bright green. 
Of note, there were also additional GWAS analyses with the exposed ONJ 
cases, non-exposed ONJ cases, zoledronate-associated and alendronate-
associated ONJ cases. None of these four cohorts yielded positive results and 
no genome-wide significant SNP was found (p>5E-8). 
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6.3.1.2 Cohorts with extreme phenotyping 
ONJ onset time and event were chosen for extreme phenotyping. Other 
features such as ONJ site and type were not suitable, as they do not have 
strong indication of disease severity. As for jawbone exposure dimension and 
pain intensity, these are cross-sectional data and are supposed to change over 
time. Therefore, early onset ONJ and non-surgery triggered ONJ, also known 
as spontaneous cases, were targeted.  
Amongst all the cases, their ONJ onset time was sorted and the first quartile 
was selected (N=85). These early onset cases were then compared with 2,554 
Caucasian population controls. A SNP, rs10277926, with high OR but 
borderline genome-wide significance, was identified (OR=6.28, p=1.69E-07) 
(Table 51 and Figure 6). This SNP is located at gene BBS9 in chromosome 7. 
Also relating to ONJ onset, whether or not a case had been triggered by 
dentoalveolar surgery prior to ONJ development was investigated. A hundred 
and seventy seven non-surgery triggered cases were again compared with 
2,554 Caucasian population controls. For the first time, a genome-wide 
significant genetic risk factor was found, rs12440268, as indicated by the red 
dot above the dotted line in the Manhattan plot (OR=2.66, p=1.21E-08) (Table 
52 and Figure 7). This SNP is located at gene TJP1 in chromosome 15. 
Of note, the same SNP rs12440268 was not significant in the discovery cohort 
GWAS when there was no extreme phenotyping.  
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Table 50. Discovery cohort GWAS result 
SNP Gene Chromosome OR p-value 
Frequency  
case 
Frequency 
control 
rs10484024 FOXN3 14 0.65 3.15E-07 0.3701 0.4679 
rs12440268 TJP1 15 2.05 5.52E-07 0.1047 0.0585 
 
Figure 5. Discovery cohort GWAS result 
 
Table 51. GWAS result with ONJ onset time as extreme phenotype 
SNP Gene Chromosome OR p-value 
Frequency  
case 
Frequency 
control 
rs10277926 BBS9 7 6.28 1.69E-07 0.1111 0.0262 
 
Figure 6. GWAS result with ONJ onset time as extreme phenotype 
 
Table 52. GWAS result with ONJ onset event as extreme phenotype 
SNP Gene Chromosome OR p-value 
Frequency  
case 
Frequency 
control 
rs12440268 TJP1 15 2.66 1.21E-8 0.1356 0.0585 
rs4340077 SHANK2 11 2.12 5.59E-8 0.2288 0.1337 
 
Figure 7. GWAS result with ONJ onset event as extreme phenotype 
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6.3.2 Replication cases versus discovery cases  
The replication cohort consisted of 130 new ONJ cases who had been 
recruited at seven centres in Hungary, Italy and the UK since October 2013. 
The replication cases were mostly Caucasians (N=127, 97.7%) and they 
shared similar age, gender ratio and BPs history with the 393 discovery cases 
(Table 53). However, their top three underlying diseases were different. There 
were a smaller proportion of multiple myeloma patients but a larger proportion 
of metastatic cancer patients in the replication cohort. With regard to ONJ 
onset, the two groups shared very similar onset time, but there were nearly 
20% more non-surgery-triggered ONJ in the replication cohort. The proportion 
of non-exposed type ONJ was also higher by approximately 10% in the 
replication cohort than in the discovery cohort. 
The percentages calculated were also plotted in Graph 14. The major 
differences were with dentoalveolar surgery history (17.6%), followed by 
multiple myeloma (14.7%), then with the non-exposed type of ONJ (11.6%), 
and metastatic breast cancer (10.5%). The rest differed by less than 10%. 
As for the results using univariable regressions, 13 comparisons were made 
and only two were found statistically significant (p<0.05) (Table 54). There was 
a statistically significantly smaller proportion of multiple myeloma patients in 
the replication cohort than in the discovery cohort (OR=0.38, 95% CI 0.20 to 
0.71, p=0.002). There was also a significantly smaller proportion of exposed 
type ONJ amongst the replication cases (OR=0.27, 95% CI 0.15 to 0.49, 
p<0.001). In contrast, the two groups had very similar age and BPs duration 
as their estimated coefficients were both nearly zero.   
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Table 53. Replication cases versus discovery cases; descriptive 
statistics 
 
Replication cases 
N = 130 
Discovery cases 
N = 393 
n % n % 
Age, decade Mean, median 
SD 
Range 
6.9, 7.0 
1.0 
4.3 to 8.8 
6.9, 7.0  
0.9 
3.7 to 8.9 
Gender Female 
Male 
99 
31 
76.2% 
23.8% 
278 
115 
70.7% 
29.3% 
Primary 
underlying 
disease 
Osteoporosis 
Multiple myeloma 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
42 
15 
43 
18 
12 
32.3% 
11.5% 
33.1% 
13.8% 
9.2% 
137 
103 
89 
37 
27 
34.9% 
26.2% 
22.6% 
9.4% 
6.9% 
BPs with longest 
duration 
Zoledronate 
Alendronate  
66 
27 
50.8% 
20.8% 
230 
109 
58.5% 
27.7% 
BPs duration, 
year 
Mean, median 
SD 
Range 
3.6, 2.8 
3.0 
0.2 to 15.1 
3.7, 2.8 
3.1 
0.1 to 19.9 
History of dentoalveolar surgery 42 32.3% 196 49.9% 
ONJ onset time, 
year 
Mean, median 
SD 
Range 
4.2, 3.2 
3.4 
0.2 to 15.9 
4.0, 3.1 
3.2 
0.1 to 19.9 
ONJ type Exposed 
Non-exposed 
101 
28 
77.7% 
21.5% 
344 
39 
87.5% 
9.9% 
 
 
Graph 14. Replication cases versus discovery cases; differences in 
percentages 
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Table 54. Replication cases versus discovery cases; random-effects 
univariable regression 
Numerical outcome variable 
N = 523;  
replication case=1, discovery case=0 
Estimated 
coefficient 
95% CI p-value 
Demographics Age, decade 0.06 -0.17 to 0.30 0.593 
BPs duration, year -0.01 -0.66 to 0.63 0.971 
ONJ onset time, year 0.21 -0.48 to 0.89 0.554 
Binary outcome variable OR 95% CI p-value 
Demographics Gender (M=0, F=1) 1.32 0.84 to 2.09 0.234 
Primary underlying 
disease 
Osteoporosis 
Multiple myeloma 
Metastatic breast cancer 
Metastatic prostate cancer 
Other cancers 
1.28 
0.38 
1.23 
1.55 
1.38 
0.75 
0.20 
0.70 
0.85 
0.67 
to 
to 
to 
to 
to 
2.18 
0.71 
2.18 
2.82 
2.86 
0.361 
0.002* 
0.475 
0.156 
0.383 
BPs with longest 
duration 
Alendronate  
Zoledronate 
0.88 
0.78 
0.49 
0.48 
to 
to 
1.57 
1.27 
0.662 
0.320 
History of dentoalveolar surgery  0.96 0.58 to 1.58 0.870 
ONJ type (non-exposed=0, exposed=1) 0.27 0.15 to 0.49 <0.001* 
* Significant results, p<0.05 
Random-effects ML regression                    Number of obs      =       520 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.0 
                                                               max =       315 
 
                                                LR chi2(1)         =      0.29 
Log likelihood  = -709.79303                    Prob > chi2        =    0.5915 
 
------------------------------------------------------------------------------ 
   agedecade |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   .0635444    .118905     0.53   0.593    -.1695052     .296594 
       _cons |   6.918775   .1038517    66.62   0.000     6.715229    7.122321 
-------------+---------------------------------------------------------------- 
    /sigma_u |   .2151734   .1121535                      .0774679    .5976611 
    /sigma_e |     .93945   .0294764                      .8834178    .9990361 
         rho |   .0498453   .0497372                      .0047449    .2423313 
------------------------------------------------------------------------------ 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    3.68 Prob>=chibar2 = 0.028 
 
 
 
 
 
 
Random-effects ML regression                    Number of obs      =       500 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      62.5 
                                                               max =       315 
 
                                                LR chi2(1)         =      0.00 
Log likelihood  = -1270.7593                    Prob > chi2        =    0.9709 
 
------------------------------------------------------------------------------ 
 bpsduration |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |  -.0120185   .3290896    -0.04   0.971    -.6570223    .6329853 
       _cons |   3.700783   .2145834    17.25   0.000     3.280207    4.121359 
-------------+---------------------------------------------------------------- 
    /sigma_u |   .2578408          .                             .           . 
    /sigma_e |   3.067509   .0972623                      2.882681    3.264188 
         rho |   .0070157          .                             .           . 
------------------------------------------------------------------------------ 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    1.08 Prob>=chibar2 = 0.149 
 
 
 
 
 
176 
 
Random-effects ML regression                    Number of obs      =       486 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      60.8 
                                                               max =       313 
 
                                                LR chi2(1)         =      0.35 
Log likelihood  = -1258.7426                    Prob > chi2        =    0.5545 
 
------------------------------------------------------------------------------- 
onsettimeyear |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
    disc0rep1 |   .2071783   .3503873     0.59   0.554    -.4795681    .8939247 
        _cons |   4.045819   .2408647    16.80   0.000     3.573733    4.517905 
--------------+---------------------------------------------------------------- 
     /sigma_u |   .3032485          .                             .           . 
     /sigma_e |   3.217667   .1035807                      3.020925    3.427223 
          rho |   .0088039          .                             .           . 
------------------------------------------------------------------------------- 
Likelihood-ratio test of sigma_u=0: chibar2(01)=    0.78 Prob>=chibar2 = 0.188 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      1.42 
Log likelihood  = -308.97034                    Prob > chi2        =    0.2336 
 
------------------------------------------------------------------------------ 
  genderm0f1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |    1.32108    .308857     1.19   0.234     .8354596    2.088972 
       _cons |   2.417955   .2681004     7.96   0.000     1.945664     3.00489 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -14.64457    63.1747                     -138.4647    109.1756 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0006607   .0208682                      8.57e-31    5.10e+23 
         rho |   1.33e-07   8.38e-06                      2.23e-61           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      0.83 
Log likelihood  = -322.71431                    Prob > chi2        =    0.3614 
 
------------------------------------------------------------------------------ 
          op |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   1.280831   .3473685     0.91   0.361     .7527331    2.179427 
       _cons |   .8920066   .3370086    -0.30   0.762      .425379     1.87051 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -.1213772    .676062                     -1.446434     1.20368 
-------------+---------------------------------------------------------------- 
     sigma_u |   .9411163   .3181265                      .4851888    1.825475 
         rho |   .2121148   .1129849                      .0667772    .5032081 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    26.36 Prob >= chibar2 = 0.000 
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Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      9.14 
Log likelihood  = -272.52902                    Prob > chi2        =    0.0025 
 
------------------------------------------------------------------------------ 
          mm |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   .3819533   .1215663    -3.02   0.002     .2046887    .7127325 
       _cons |   .2931688   .1063026    -3.38   0.001     .1440367    .5967086 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -2.434049   2.691291                     -7.708882    2.840784 
-------------+---------------------------------------------------------------- 
     sigma_u |   .2961099    .398459                      .0211854    4.138743 
         rho |     .02596   .0680521                      .0001364    .8388825 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.05 Prob >= chibar2 = 0.408 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      0.51 
Log likelihood  = -290.40188                    Prob > chi2        =    0.4752 
 
------------------------------------------------------------------------------ 
         mbc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |    1.23112   .3584796     0.71   0.475     .6957385    2.178485 
       _cons |   .2112751   .0743994    -4.41   0.000     .1059503     .421303 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -.6950247   .9463805                     -2.549896    1.159847 
-------------+---------------------------------------------------------------- 
     sigma_u |   .7064433   .3342821                      .2794454    1.785902 
         rho |   .1317158   .1082345                      .0231861    .4922505 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     4.71 Prob >= chibar2 = 0.015 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      2.01 
Log likelihood  = -174.90879                    Prob > chi2        =    0.1559 
 
------------------------------------------------------------------------------ 
         mpc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   1.546246   .4748876     1.42   0.156      .846945    2.822943 
       _cons |   .1039301   .0179521   -13.11   0.000     .0740816    .1458048 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -15.59693   65.59378                     -144.1584    112.9645 
-------------+---------------------------------------------------------------- 
     sigma_u |   .0004104   .0134587                      4.97e-32    3.39e+24 
         rho |   5.12e-08   3.36e-06                      7.51e-64           1 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.00 Prob >= chibar2 = 1.000 
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Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      0.76 
Log likelihood  = -138.30473                    Prob > chi2        =    0.3835 
 
------------------------------------------------------------------------------ 
          oc |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   1.382564   .5138943     0.87   0.383      .667262    2.864665 
       _cons |   .0664944   .0228191    -7.90   0.000     .0339372     .130285 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -3.118112   3.288697                      -9.56384    3.327616 
-------------+---------------------------------------------------------------- 
     sigma_u |   .2103345   .3458633                      .0083799    5.279377 
         rho |   .0132691    .043059                      .0000213    .8944259 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =     0.14 Prob >= chibar2 = 0.353 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      0.19 
Log likelihood  = -293.31582                    Prob > chi2        =    0.6620 
 
------------------------------------------------------------------------------ 
         ale |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   .8784757   .2603917    -0.44   0.662     .4913856    1.570497 
       _cons |   .4951851   .1428485    -2.44   0.015     .2813308    .8716014 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -.8184197   .7972496                        -2.381    .7441608 
-------------+---------------------------------------------------------------- 
     sigma_u |   .6641748   .2647566                      .3040692     1.45075 
         rho |   .1182334   .0831166                      .0273356    .3901488 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    10.28 Prob >= chibar2 = 0.001 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       523 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      65.4 
                                                               max =       317 
 
                                                Wald chi2(1)       =      0.99 
Log likelihood  = -346.56035                    Prob > chi2        =    0.3198 
 
------------------------------------------------------------------------------ 
         zol |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   .7796776   .1950586    -0.99   0.320     .4774882    1.273114 
       _cons |   .8177601    .243927    -0.67   0.500     .4557469    1.467331 
-------------+---------------------------------------------------------------- 
    /lnsig2u |  -.7700118   .7404435                     -2.221254    .6812307 
-------------+---------------------------------------------------------------- 
     sigma_u |   .6804466   .2519161                      .3293523    1.405812 
         rho |   .1233741   .0800811                      .0319194    .3752834 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    20.40 Prob >= chibar2 = 0.000 
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Random-effects logistic regression              Number of obs      =       513 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      64.1 
                                                               max =       313 
 
                                                Wald chi2(1)       =      0.03 
Log likelihood  = -327.00548                    Prob > chi2        =    0.8695 
 
-------------------------------------------------------------------------------------- 
dentoalveolarsurgery |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
---------------------+---------------------------------------------------------------- 
           disc0rep1 |   .9588694   .2452068    -0.16   0.870     .5808795    1.582825 
               _cons |   .4789111    .279119    -1.26   0.207      .152812    1.500902 
---------------------+---------------------------------------------------------------- 
            /lnsig2u |   .8027772   .7004123                     -.5700058     2.17556 
---------------------+---------------------------------------------------------------- 
             sigma_u |   1.493898   .5231722                      .7520121    2.967679 
                 rho |   .4041819   .1686725                      .1466835    .7280423 
-------------------------------------------------------------------------------------- 
Likelihood-ratio test of rho=0: chibar2(01) =    40.50 Prob >= chibar2 = 0.000 
 
 
 
 
 
 
Random-effects logistic regression              Number of obs      =       512 
Group variable: country                         Number of groups   =         8 
 
Random effects u_i ~ Gaussian                   Obs per group: min =         7 
                                                               avg =      64.0 
                                                               max =       312 
 
                                                Wald chi2(1)       =     18.80 
Log likelihood  = -179.77165                    Prob > chi2        =    0.0000 
 
------------------------------------------------------------------------------ 
    typen0e1 |         OR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   disc0rep1 |   .2733811     .08178    -4.34   0.000      .152103    .4913593 
       _cons |   38.07222   30.32796     4.57   0.000     7.990047    181.4124 
-------------+---------------------------------------------------------------- 
    /lnsig2u |   .7917122   .9892541                      -1.14719    2.730614 
-------------+---------------------------------------------------------------- 
     sigma_u |   1.485655   .7348454                       .563496    3.916926 
         rho |   .4015201   .2377194                      .0880213    .8234309 
------------------------------------------------------------------------------ 
Likelihood-ratio test of rho=0: chibar2(01) =    27.51 Prob >= chibar2 = 0.000 
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6.4 Discussion 
6.4.1 Main findings 
6.4.1.1 TJP1 gene 
SNP rs12440268 was found to be genome-wide significant (p<5E-8). This 
SNP is related to gene TJP1, which encodes protein at the tight junctions. 
Tight junctions are intercellular junctions in simple epithelia and endothelia, as 
well as stratified squamous epithelia including the gingivae, lingual and other 
types of oral mucosa (Franke and Pape, 2012). Their main purpose is to 
maintain epithelial stratification and integrity, which defends the body against 
any pathogens, toxins and allergens (Brandner et al., 2003).  
To date, there are no previous studies investigating the status of tight junctions 
amongst those diagnosed with ONJ. A recent study, which investigated the 
effect of alendronate on human oral mucosa, reported that epithelial integrity 
was unaffected amongst ONJ-free individuals who were managed with 
alendronate (Donetti et al., 2014). This only suggests that BPs per se may 
have no effect on tight junctions.  
However, it may be different under the influence of genetic variants, such as 
rs12440268. In fact, the association of ONJ with TJP1 further supported the 
pathogenesis hypothesis of impaired wound healing. In other words, 
individuals with this polymorphism may have “less protective” oral mucosa and 
hence poorer healing ability than those not presented with the polymorphism. 
Nonetheless, this marker had a relatively small OR (OR=2.66), and it was 
significant amongst the 177 non-surgery triggered cases only, but not the 
entire cohort of 358 cases.  
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6.4.1.2 BBS9 gene 
rs10277926, though not genome-wide significant, had the largest OR amongst 
all identified top SNPs (OR=6.28, p=1.69E-07). This SNP is related to gene 
BBS9, also known as PTHB1, which stands for parathyroid hormone 
responsive-B1 (Nishimura et al., 2005). It is reported that this gene is down-
regulated by parathyroid hormone in osteoblasts (Kang et al., 2011a). 
BBS refers to Bardet-Biedl syndrome, a genetic disorder caused by BBS gene 
mutation. The syndrome does have a link with the jawbone; features including 
jawbone atresia, high arched palate and malocclusion have been reported 
(Majumdar et al., 2012; Ferreira do Amaral et al., 2014). Moreover, association 
of BBS9 gene with nonsyndromic sagittal craniosynostosis, a congenital 
anomaly with skull development, has also been reported in a previous GWAS 
(Justice et al., 2012). 
In other words, individuals with this polymorphism may have different bone 
remodelling activity, and even different jawbone phenotype, from those not 
presented with the polymorphism. Nonetheless, at this stage, this marker is 
not found statistically significant and further confirmation is required. 
6.4.1.3 Replication cohort 
Power calculation by the genetic team suggested 200 cases to be recruited 
for replication. Currently, 65% of the target has been met. The discovery and 
replication case cohorts are supposed to be phenotypically similar. At present, 
the two groups share very similar ethnicity, age and BPs duration, and similar 
gender proportion, BPs type, ONJ onset time and event. The major differences 
are with underlying disease and ONJ type, i.e. the replication cohort has a 
smaller proportion of multiple myeloma cases as well as exposed type ONJ. 
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6.4.2 Study strengths 
6.4.2.1 Collaborative teamwork 
There was a dedicated clinical team, consisting of specialists in Oral Medicine, 
Oral and Maxillofacial Surgery, Oncology, Haematology, Rheumatology and 
Radiology, who played a key role in recruiting and adjudicating GENVABO 
participants. The team also included the non-exposed cases and proved that 
they were comparable to the exposed ones. In addition to recruiting a large 
cohort of ONJ patients, another contribution was the detailed analysis of 
clinical phenotype. There were also robust analyses of the clinical risk factors 
to complement the genetic risk factor results.  
The genetic team has great experience in pharmacogenetics and has 
previously successfully identified genetic variants associated with drug-related 
liver toxicity (DILI) and serious skin rashes (SSR) (Holden et al., 2014). Their 
main contributions were genotyping, matching the ONJ cases with population 
controls, and very importantly, designing and performing robust GWAS 
analyses.  
The two teams worked closely together and had regular communications 
including emails, teleconferences and visits to each other’s office. This 
facilitated the planning of the first extreme phenotyping in ONJ GWAS, 
resulting in the very first genome-wide significant SNP for ONJ development.       
6.4.2.2 Large and well-phenotyped discovery cohort 
Compared with previous GWAS on ONJ (Sarasquete et al., 2008; Nicoletti et 
al., 2012), GENVABO is the largest. There were 23 centres from eight 
countries, and 393 ONJ cases were recruited, including non-exposed ONJ. 
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Three hundred and fifty eight Caucasian cases were analysed, which was 
nearly 12 times more than in previous studies and thus providing more 
adequate power (Jorgensen and Williamson, 2008). 
Clinical phenotyping was also more thorough than the other two ONJ GWAS. 
Previous studies provided minimal phenotype data, while the current study 
collected more detailed information regarding medical and dental history, in 
particular, ONJ onset time and event, which enabled extreme phenotyping and 
the discovery of a genome-wide significant SNP for ONJ development. 
6.4.2.3 Large and well-phenotyped replication cohort  
This is going to be the first replication cohort recruited by the same consortium 
under the same setting as the discovery cohort. This will facilitate comparison 
of results between the two cohorts in future.  
In replicating GWAS result from Sarasquete et al., 2008, four studied gene 
CYP2C8 and the largest study recruited only 46 ONJ cases (English et al., 
2010; Katz et al., 2011; Such et al., 2011; Balla et al., 2012). With a size of 
130 cases, and 70 more to be recruited, GENVABO’s replication cohort is 
going to be the largest amongst all reported ONJ pharmacogenetic studies. 
The same standardised CRF was used for the replication cases and they had 
also been thoroughly phenotyped. The two groups had also been rigorously 
compared using both descriptive and inferential statistics and were found 
largely phenotypically similar. In addition, it is favourable to have a larger 
proportion of non-surgery triggered cases in the replication cohort for extreme 
phenotyping in the ongoing replication.  
 
184 
 
6.4.3 Study limitations 
6.4.3.1 Population controls 
In GENVABO, population controls were analysed instead of BPs-exposed 
controls. If these healthy individuals were to be exposed to BPs, depending on 
the potency, some would have ONJ developed. This indicates that analysis 
with population controls may not be completely reliable. 
However, ONJ has a relatively low incidence; therefore, if exposed to BPs, 
there would only be a small number of potential ONJ cases amongst the 
population controls (Kühl et al., 2012). Second, analysis with population 
controls has been commonly practised in ADR GWAS. Three thousand six 
hundred and fifty five population controls were involved in a recent study on 
phenytoin-related severe cutaneous adverse reactions (Chung et al., 2014). 
There were also two GWAS on DILI with 3,001 and 532 population controls 
analysed respectively (Lucena et al., 2011; Urban et al., 2012). 
In short, analysis with population controls is considered appropriate for a 
discovery ADR GWAS. Nonetheless, at a later stage, BPs-exposed controls 
will also be analysed in GENVABO. At present, DNA extraction had been 
completed for all controls; genotyping and statistical analyses will soon follow. 
6.4.3.2 Genome coverage      
There are over 10 million SNPs in human (Wangkumhang et al., 2007). In 
GENVABO, only a million were covered. This is because these genotyped 
SNPs have the property of being proxies to the untyped SNPs within the same 
genomic region, known as linkage disequilibrium (LD) (Roses, 2000). In other 
words, through LD, these one million SNPs can help predict the rest of the 
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genome. Therefore, to date, GWAS remains commonly performed in search 
of genetic variants for ADR (Daly, 2010, 2012). Nevertheless, in future, follow-
up “fine-mapping” around the genome-wide significant SNP after its replication, 
so as to identify any previously untyped potential genetic risk factors may 
follow.       
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7.1 Conclusion 
The GENVABO study involves the largest and the most comprehensive 
GWAS to date, accompanied by robust case cohort validation in supporting 
the inclusion of the non-exposed ONJ cases into the GWAS analysis, novel 
BPs-exposed controls cohort validation and super-controls selection, followed 
by sophisticated clinical risk factor analyses. In total, 523 BPs-associated ONJ 
cases, 276 BPs-exposed controls and 2,554 ethnicity-matched population 
controls were analysed. 
For the first time, a genome-wide significant genetic factor was identified, and 
the GENVABO study also confirmed that BPs-associated ONJ is a 
multifactorial disease. The factors are rs12440268, a variant at gene TJP1, 
and clinical risk factors including advanced age, longer BPs duration, other 
cancers, mainly kidney and lung cancers as underlying diseases for BPs, and 
the use of steroids as concomitant medication. 
These findings are not only applicable to the mainstream exposed typed ONJ, 
but also the non-exposed variant, which was, for the first time, included into 
an ONJ GWAS after thorough case validation. One may argue that the 
inclusion of the non-exposed cases may increase the heterogeneity of the 
study cohort. However, in Chapter 3, they were found largely phenotypically 
similar to the exposed type in terms of demographics, medical and dental 
history. Furthermore, in Chapter 5, with novel risk factor analyses in different 
stratified cohorts, it was found that the all cases cohorts, i.e. with both exposed 
and non-exposed cases, shared exactly the same risk factors with the cohorts 
consisting of exposed cases only. In other words, the inclusion of the non-
188 
 
exposed cases into the all cases cohorts did not change the risk factor results. 
Having a larger cohort certainly increases the power of the current study and 
the current findings also confirm the importance of the recent revision of the 
2014 AAOMS ONJ definition in which the non-exposed variant was finally 
included.  
Time to onset amongst the ONJ cases and follow-up time of the controls were 
also studied. In general, in the current study, follow-up time was found shorter 
than time to onset, while onset time for  zoledronate cases was found shorter 
than those on alendronate, which can be explained by the higher potency of 
zoledronate.  
Through detailed comparison between time to onset and follow-up time, an 
original and novel control cohort validation was performed in Chapter 4. After 
careful consideration, the median onset times, 2.1 years for zoledronate and 
6.0 years for alendronate, were chosen as the cut-off in selecting super-
controls, i.e. those who had been more adequately reviewed and thus carry a 
lower risk of being “false-controls”. Out of a total of 203 zoledronate-exposed 
controls, 88 super-controls, who had been reviewed for 2.1 years or longer, 
were selected and had additional risk factor analysis in Chapter 5. Since the 
number of alendronate super-controls were small (N=8), additional analysis 
was not arranged due to statistical consideration. 
These super-controls were also found to have longer BPs duration than the 
rest of the controls. In their risk factor analysis in Chapter 5, BPs duration was 
not found a significant ONJ risk factor in this particular cohort with super-
controls, in contrast to most previous studies with no control cohort validation.  
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Following the investigation of the ONJ risk factors, for the first time, the 
interrelationship between the significant factors was also examined in the 
current post-hoc analysis in Chapter 5. Interestingly, there was a positive 
correlation between BPs duration and age, both identified as significant risk 
factors in the current study. In the super-control cohort, advanced age 
remained as a significant risk factor, however, BPs duration was no longer 
significant, as discussed above. This suggested that age was unlikely to be a 
confounder and may have direct association with ONJ. However, age was 
often matched between cases and controls, or adjusted in the statistical 
models in previous studies. The mechanism of how age relates to ONJ 
development is also largely unknown as this has never been formally studied. 
Meanwhile, the use of steroids was also found a risk factor amongst the 
alendronate users. However, this remains preliminary as it showed a wide 95% 
confidence interval, as well as a large standard error, due to the small number 
of steroid users. Similarly, other cancers as a risk factor also remains 
preliminary as there were also only a small number of individuals diagnosed 
with other cancers, hence its wide 95% confidence interval and large standard 
error. On the other hand, the following factors were not found significant in the 
current GENVABO study: gender, multiple myeloma and metastatic cancers, 
use of zoledronate, diabetes and smoking habit.  
Clinical features have also been helpful in extreme phenotyping in the current 
GWAS, which refers to focusing on individuals with more extreme disease 
behaviour and may help enhance the efficiency in identifying genetic variants. 
Amongst the 85 early onset cases, a genetic risk factor with large odds ratio 
was identified, though not genome-wide significant (OR=6.28, p=1.69E-07). 
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As for the said significant variant, rs12440268, it was found in the GWAS 
amongst 177 non-surgery triggered cases (OR=2.66, p=1.21E-08). Of note, 
the same SNP was not found significant in the overall cohort without extreme 
phenotyping. The two polymorphisms were related to gene TJP1 and BBS9, 
which may support the pathogenesis hypotheses of impaired wound healing 
and bone remodelling inhibition, as they are associated with oral mucosa 
epithelial stratification and integrity, and parathyroid hormone activity. 
Replication study is in progress to confirm the discovery GWAS results. The 
replication cases are largely phenotypically comparable to the discovery cases 
with regard to demographics and BPs history. There is also a large proportion 
of non-surgery triggered cases in the replication cohort, which is favourable to 
extreme phenotyping in the ongoing replication study.     
In conclusion, GENVABO has brought a new perspective to the challenging 
research into ONJ. The non-exposed variant, never included in a GWAS 
before GENVABO, was found largely similar to the exposed counterpart. The 
effect of BPs therapy duration, traditionally believed to increase the risk of ONJ, 
may have been overestimated due to the absence of control validation in 
previous studies. Yet, advanced age, a rarely investigated phenotype, was 
found a significant risk factor in the current study. Lastly, possibly due to small 
cohort sizes, no significant genetic polymorphisms had been identified in 
previous studies. GENVABO performed a large GWAS with extreme 
phenotyping, which has led to the discovery of the first genome-wide 
significant SNP in supporting the role of genetic predisposition in ONJ 
pathophysiology. Recruitment of replication cases is ongoing.  
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7.2 Future work 
The current study includes one of the early works on the comparison of the 
two ONJ types. As the non-exposed type was only recently incorporated into 
the official ONJ definition, it is expected that more non-exposed cases will be 
reported (Ruggiero et al., 2014).  This is considered favourable as the previous 
cohort sizes of the non-exposed type had been relatively small (Schiodt et al., 
2014; Fedele et al., 2015). Not only is this going to benefit ONJ type 
comparison studies, but also clinical and genetic risk factors analyses as there 
will be a larger cohort leading to more reliable results. 
There was also control validation through pioneering follow-up time 
assessment in GENVABO. At present, the super-controls, who had been 
reviewed longer, showed different clinical risk factor results from controls with 
no follow-up time screening. In future, there should also be genetic risk factor 
analyses with super-controls as they are less likely to be “false-controls” and 
is going to yield even more robust genetic variants. In the current study, the 
median time to ONJ onset was chosen as the cut-off in selecting super-
controls. Since this has been a first attempt, more studies in experimenting 
different cut-off thresholds are recommended.  
Following the discussion in Chapter 5, the recruitment of a larger cohort of 
osteoporosis and alendronate patients, the retrieval of missing data, and the 
inclusion of any unanalysed clinical risk factors would be desirable in future.  
It has also been suggested that ONJ development involves gene-environment 
interaction; therefore, clinical and genetic risk factors should be analysed hand 
in hand in future (Izzotti et al., 2013). Specifically, both clinical and genetic risk 
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factors will be entered together into a single regression model as explanatory 
variables, while ONJ case or control remains as outcome variable. It will then 
estimate the contribution of all the factors towards disease development, e.g. 
together, age, BPs duration and two genetic variants account for x% of ONJ 
occurrence (Sconce et al., 2005; Moreau et al., 2014). Statistical interaction 
between the clinical and genetic factors can also be investigated, and all these 
findings are going to be helpful in understanding ONJ pathogenesis.    
In addition to the replication study and GWAS with BPs-exposed controls 
discussed in Chapter 6, other potential future studies may include GWAS on 
ONJ in association with medications other than BPs and in ethnicity groups 
other than Caucasians. 
This is because in the majority of cases, ADR genetic variants are drug-
specific. For instance, both flucloxacillin and amoxicillin-clavulanate induce 
liver injury, but their genetic risk factors are different from each other (Daly et 
al., 2009; Lucena et al., 2011). Hence there may be different sets of genetic 
factors for bevacizumab- and sunitinib-associated ONJ, as well as with 
denosumab, another antiresorptive which can also causes ONJ (Epstein et al., 
2013; Sivolella et al., 2013).    
Similarly, ADR genetic variants are also population- or ethnicity-specific. For 
example, the Asians and Europeans are presented with different genetic 
polymorphisms for carbamazepine-induced skin reactions, the same 
phenotype (Chung et al., 2004; McCormack et al., 2011). Different results are 
therefore expected from ONJ pharmacogenetic studies on populations other 
than Caucasians.  
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In the long term, functional study, for instance with knockout mice technique, 
may also be considered to test how the culprit genes behave in relation to ONJ 
pathogenesis (Clarke et al., 2014). Lastly, a cost-effectiveness trial can test 
whether the saving on the cost of ONJ management, in particular jaw surgery 
and medications, and patients’ quality of life, can outweigh the cost of genetic 
screening prior to BPs prescription (Hughes et al., 2004). Once the replication 
is complete, the planning for these studies can follow, depending on the overall 
GWAS results and the availability of research funding. 
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